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Abstract
Specific or preferential expression of a gene in a particular tissue or organ is often
indicative of its importance in function or development. It would be beneficial to
discover novel genes with preferential expression to enhance understanding of the
tissue or organ in question. In this thesis, an in silico method was employed to find
novel genes preferentially expressed in the mouse eye.
The chosen in silico method was digital differential display (DDD), which utilises
the publicly available UniGene database as a resource. UniGene is composed of
expressed sequence tag (EST) sequences that are clustered by homology, such that
each cluster is considered to represent a gene. Crucially, ESTs in UniGene are
traceable to their library of origin. This allows DDD to statistically compare, for each
cluster, the proportional representation of ESTs in different user-defined pools of
libraries. Using an eye pool and a non-eye pool of libraries, DDD was performed on
the mouse, human and rat UniGene sets.
The DDD results used for further analysis comprised 292 mouse UniGene clusters
that were more highly represented in the eye pool than in the non-eye pool. Of the
154 clusters that represented known genes, 48% were known to be eye relevant.
Thirty-one of the 138 novel clusters were selected for expression studies. Ten of
these were later recognised as known genes, with five having eye relevance, that is,
previous evidence of preferential expression in the eye by in situ methods or
mutations associated with eye defects. Fifteen of the 31 novel clusters were
confirmed by RT-PCR to show preferential expression, with four appearing eye
specific. Four of the 15 genes are known (Aipll, Crygf,Gucalb and Otx2) and
another nine putative genes show expression in various regions of the eye. These
novel genes may well have a role in eye development or function and are candidates








List of figures ix
List of tables xi
Abbreviations xii
CHAPTER 1: Introduction 1
1.1 The mammalian eye 2
1.1.1 Gross eye structure 3
1.1.2 The cornea, iris and ciliary epithelium 5
1.1.3 The lens 6
1.1.4 The retina 8
1.1.5 Phototransduction and the visual cycle 10
1.2 Approaches to gene discovery 14
1.2.1 The advent of ESTs 15
1.2.2 Using ESTs to find novel genes 16
1.3 Differential expression 19
1.3.1 Northern blot analysis 19
1.3.2 RT-PCR 20
1.3.3 Sequencing ESTs from cDNA libraries 20
1.3.4 Subtractive hybridisation 21
1.3.5 In situ hybridisation 25
1.3.6 Differential display 25
1.3.7 SAGE 28
1.3.8 Arrays 30
1.3.9 In silico approaches 33
1.4 Progress in eye differential expression 34
1.4.1 EST sequencing to identify novel differentially expressed genes 35
1.4.2 Subtractive methods for assessing preferential expression and identifying novel differentially
expressed genes 36
1.4.3 A large scale in situ screen to identify differentially expressed genes 38
1.4.4 Using differential display to assess preferential expression and identify novel differentially
expressed genes 38
1.4.5 Using SAGE to assess preferential expression 40
1.4.6 Using arrays to assess preferential expression 41
IV
1.4.7 In silico approaches to assess preferential expression and identify novel differentially
expressed genes 43






CHAPTER 2: Materials and Methods 55
2.1 Bioinformatics 56
2.2 Manipulation of nucleic acids 57
2.2.1 Extraction of RNA from tissue 57
2.2.2 DNase treatment of RNA 57
2.2.3 Determining the concentration of RNA 58
2.2.4 Primer design 58
2.2.5 Polymerase chain reaction 59
2.2.6 Colony PCR 60
2.2.7 Reverse transcription polymerase chain reaction 61
2.2.8 Agarose gel electrophoresis and determining the concentration of DNA 62
2.2.9 DNA purification by the QIAquick PCR purification kit 63





2.2.15 Ethanol precipitation 68
2.2.16 Restriction 68
2.2.17 Blunt ending 69
2.2.18 Purification Using CHROMA SPIN Columns 69
2.3 In situ hybridisation techniques 70
2.3.1 Synthesis of DIG labelled riboprobes for in situ hybridisation 70
2.3.2 Synthesis of 35S labelled riboprobes for in situ hybridisation 71
2.3.3 Embryo treatment for wholemount in situ hybridisation 72
2.3.4 Tissue treatment for paraffin wax embedding and sectioning 73
2.3.5 Tissue treatment for OCT embedding and cryostat sectioning 75
2.3.6 Wholemount in situ hybridisation 76
2.3.7 Cryosection in situ hybridisations using DIG labelled riboprobes 80
2.3.8 Wax section in situ hybridisations using 35S labelled riboprobes 83
2.4 Microscopy 87
CHAPTER 3: Digital Differential Display 88
3.1 Introduction 89
v
3.2 Mouse Digital Differential Display: build 82 91
3.2.1 Composition of mouse build 82 91
3.2.2 Library pool construction for DDD on mouse build 82 94
3.2.3 Original results analysis for DDD on mouse build 82 94
3.2.4 Retrospective results analysis for DDD on mouse build 82 97
3.3 Mouse Digital Differential Display: build 100 99
3.3.1 Composition of mouse build 100 99
3.3.2 Library pool construction for DDD on mouse build 100 101
3.3.3 Original results analysis for DDD on mouse build 100 101
3.3.4 Retrospective results analysis for DDD on mouse build 100 103
3.4 Mouse Digital Differential Display: build 120 105
3.4.1 Composition of mouse build 120 105
3.4.2 Library pool construction for DDD on mouse build 120 107
3.4.3 Results analysis for DDD on mouse build 120 107
3.5 Human Digital Differential Display: build 160 109
3.5.1 Composition of human build 160 109
3.5.2 Library pool construction for DDD on human build 160 111
3.5.3 Results analysis of human build 160 DDD 111
3.5.4 Comparison of known genes from human and mouse build DDDs 113
3.6 Rat Digital Differential Display: build 119 116
3.6.1 Composition of rat build 119 116
3.6.2 Library pool construction for DDD on rat build 119 118
3.5.3 Results analysis ofrat build 119 DDD 118
3.7 Producing a set of clusters for further study 120
3.8 Discussion 122
CHAPTER 4: Analysis of novel preferentially expressed clusters.132
4.1 Introduction 133
4.2 Expression analysis using RT-PCR 136
4.3 Analysis and preferential expression 143
4.3.1 Control probes: Dct, Otx2 and Crygf 145
4.3.2 Mm.95741 151










CHAPTER 5: Discussion 202
5.1 Evaluation of the Digital Differential Display approach 203
5.2 Possible future investigation 204
5.2.1 Mm.95741 205
5.2.2 Tsd 206












As well as the written information provided in this thesis, a CD of HTML pages is
also provided. It contains additional information as well as a framework for easy
access to relevant webpages and data. To open the homepage from which other
information can be easily accessed, open the file "home.html". These pages are best
viewed using Microsoft Internet Explorer.
vm
List of figures
Figure 1.1 Structure of the human eye 4
Figure 1.2 Lens cellular structure 7
Figure 1.3 Cellular composition of the retina 9
Figure 1.4 The phototransduction cascade 11
Figure 1.5 The visual cycle 13
Figure 1.6 Schematic of cDNA library normalisation 18
Figure 1.7 Schematic of subtractive hybridisation 22
Figure 1.8 Schematic of suppression subtractive hybridisation 24
Figure 1.9 An example of differential dislay 27
Figure 1.10 Schematic of SAGE 29
Figure 1.11 Macroarray procedure 31
Figure 1.12 Microarray expression results 32
Figure 3.1 Cluster size distribution in mouse UniGene build 82 93
Figure 3.2 Cluster composition of mouse UniGene build 82 DDD results 96
Figure 3.3 Cluster composition of mouse UniGene build 82 DDD results after applying new
knowledge from build 120 98
Figure 3.4 Cluster size distribution in mouse UniGene build 100 100
Figure 3.5 Cluster composition of mouse UniGene build 100 DDD results 102
Figure 3.6 Cluster composition of mouse UniGene build 100 DDD results after applying new
knowledge from build 120 104
Figure 3.7 Cluster size distribution in mouse UniGene build 120 106
Figure 3.8 Cluster composition of mouse UniGene build 120 DDD results 108
Figure 3.9 Cluster size distribution in human UniGene build 160 110
Figure 3.10 Cluster composition of human UniGene build 160 DDD results 112
Figure 3.11 Proportions of eye relevant genes amongst subsets of known DDD genes 115
Figure 3.12 Cluster size distribution in rat UniGene build 119 117
Figure 3.13 Cluster composition of rat UniGene build 119 DDD results 119
Figure 4.1 Early eye development 134
Figure 4.2 RT-PCR panels of clusters showing eye specific expression 137
Figure 4.3 RT-PCR panels of clusters showing preferential expression in the eye 138
Figure 4.4 RT-PCR panels of clusters showing non-preferential expression in the eye 140
Figure 4.5 Dct wholemount in situ hybridisation 146
Figure 4.6 Dct in situ hybridisation 147
Figure 4.7 Otx2 wholemount in situ hybridisation at El 1.5 148
Figure 4.8 Otx2 wholemount in situ hybridisation at El2.5 149
Figure 4.9 Crygfwholemount in situ hybridisation 150
Figure 4.10 Mm.95741 wholemount in situ hybridisation 152
Figure 4.11 The mouse Mm.95741 region 153
Figure 4.12 Mm. 150838 in situ hybridisation 155
Figure 4.13 VISTA plot of the Mm.150838 region 156
Figure 4.14 Tsd wholemount in situ hybridisation 159
Figure 4.15 The human Tsd region 160
Figure 4.16 VISTA plot of the Tsd region 161
Figure 4.17 Trale wholemount in situ hybridisation at E9.5 and El0.5 164
Figure 4.18 Trale wholemount in situ hybridisation at Ell.5 165
Figure 4.19 Trale in situ hybridisation in the neonate 166
Figure 4.20 Tset wholemount in situ hybridisation 168
Figure 4.21 Phylogenetic tree of NAP proteins and TSET 170
Figure 4.22 Alignment of the TSET proteins and human TSPY 171
Figure 4.23 Bret in situ hybridisation 173
IX
Figure 4.24 Alignment of the BRET proteins 174
Figure 4.25 Phylogenetic tree of BTB/POZ proteins and BRET 175
Figure 4.26 Cln8l wholemount in situ hybridisation 178
Figure 4.27 Cln8l radioactive in situ hybridisation 179
Figure 4.28 Cln8l in situ hybridisation 180
Figure 4.29 Alignment of the CLN8L proteins 181
Figure 4.30 Phylogenetic tree ofTLC proteins and CLN8L 182
Figure 4.31 Sapan wholemount in situ hybridisation at E9.5 185
Figure 4.32 Sapan wholemount in situ hybridisation at E10.5 186
Figure 4.33 Sapan wholemount in situ hybridisation at El 1.5 187
Figure 4.34 Sections of Sapan wholemount in situ hybridisation 188
Figure 4.35 Phylogenetic tree of saposin domain proteins and SAPAN 190
Figure 4.36 Domain structure of saposin domain proteins 191
Figure 4.37 Alignment of SAP and SAPAN proteins 192
Figure 4.38 Duf676 in situ hybridisation 196
Figure 4.39 Alignment of the DUF676 proteins 197
x
List of tables
Table 3.1 The sequence composition of builds used in DDD 92
Table 3.2 The set of 31 clusters for further study 121
Table 4.1 Summary of RT-PCR results 142




AIPL1 aryl hydrocarbon receptor-interacting protein-like 1
Amp ampicillin
AMV avian myeoblastosis
BCIP 5 -bromo-4-chloro-3-indolyl phosphate
BLAST basic local alignment search tool
bp base pairs
BPAG1 bullous pemphigoid antigen 1
BRET BTB/POZ gene, retinal
BTB Broad-Complex, Tramtrack and Brie a brae
cDNA complementary DNA
CDS complete DNA sequence
CLN8 ceroid-lipofuscinosis, neuronal 8
CLN8L ceroid-lipofuscinosis, neuronal 8-like
CNS central nervous system
CRYGF gamma crystallin F
D15Ertd806e DNA segment, Chr 15, ERATO Doi 806, expressed





















EST expressed sequence tag
g gramme
GABT4 gamma-aminobutyric acid (GABA-A) transporter 4
GAPD glyceraldehyde-3-phosphate dehydrogenase
GCL ganglion cell layer
GRTP1 GH regulated TBC protein 1
GUCA1B guanylate cyclase activator IB
HISS heat-inactivated sheep serum
Hs Homo sapiens
HTC high throughput cDNA
IMAGE Integrated Molecular Analysis of Genomes and their Expression
INL inner nuclear layer
IPE iris pigment epithelium
IPL inner plexiform layer
IS inner segments
kb kilobase
LAG longevity assurance gene
LFC lens fibre cells
LGALS3BP lectin, galactosidase-binding, soluble, 3 binding protein
m milli
M molar
MGI Mouse Genome Informatics
Mm Mus musculus
mnd motor neuron disease mutation
mol moles
mRNA messenger ribonucleic acid
n nano
N,N-DMF N, N- dimethyl formamide
NAP nucleosome assembly protein
NBT nitroblue tetrazolium
NDR4 N-myc downstream regulated 4

































phosphate buffered saline with Tween
polymerase chain reaction
paraformaldehyde
pox virus and zinc finger

























serial analysis of gene expression
saposin A domain, novel
suppressor of variegation, enhancer of zeste and Trithorax
surfactant associated protein B
sine oculis-related homeobox 3 homologue (Drosophila)





TBE Tris, boric acid, EDTA




THC tentative human consensus
TIGR The Institute for Genomic Research
TLC TRAM, LAG, CLN8
TRALE transmembrane protein, retina and antisense lens expressed
TRAM translocating chain-associating membrane protein
tRNA transfer ribonucleic acid
Tsd antisense to Dst
TSET TSPY/SET related
TSPY testis-specific protein, y-encoded
U unit
UTR untranslated region





1.1 The mammalian eye
The complexity of the eye has made it a much discussed and studied organ. In 'The
Origin of Species', Darwin devoted a chapter to the proposal of theories that could
explain its evolution by natural selection. However, the differing morphology of
solutions to the light-sensing problem that are displayed by various organisms had
since been considered evidence for their separate origins. More recently, evidence for
the existence of a conserved genetic basis for development of the two very different
types of eye found in insects and vertebrates was discovered in the homology of
vertebrate Pax6 (paired box gene 6) with Drosophila eyeless (Quiring et al., 1994).
Subsequently, Pax6 was found to induce ectopic eye formation in Drosophila
(Haider et al., 1995), confirming its status as a master control gene and laying to rest
doubts surrounding the common ancestry of these two different solutions to sensing
light.
In addition to the interesting evolutionary aspect of the eye, the presence of many
genetic diseases affecting this organ make research more directly applicable to
human health. OMIM (Online Mendelian Inheritance in Man) has more than 200
diseases that include a form of retinal dystrophy (Sinha et al., 2000). In addition to
retinal disease, cataract is a major worldwide cause of blindness, with glaucoma and
corneal defects contributing to the diseases that cause visual impairment.
Although there are minor differences between the human and mouse eye, the mouse
serves as the best available model for human eye disease. This is supported by a
well-defined mouse genome that allows comparison to that of the human. Many
mouse models of human eye diseases exist and some have been used successfully to
locate the homologous human gene.
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1.1.1 Gross eye structure
The mammalian eye (Figure 1.1) is composed of highly differentiated tissues that
perform specialised functions, with light entering it being focused onto a layer of
light sensitive receptors which convert photons to nerve impulses that are relayed to
the brain and processed to form an image. At the core of the eye, there is a space
filled with a fluid known as vitreous humour that maintains intraocular pressure,
thereby supporting the shape of the eye. Three distinct layers surround this space, the
retina being the innermost, the sclera the outermost protective layer and the choroid
between the two, containing the vessels that supply the eye with blood. These layers
surround most of the eye surface, with the exception of the anterior. Here, the
transparent corneal layer covers an aperture, with aqueous humour filling the space
between them and performing the same shape maintenance function as vitreous
humour. Controlling the size of this gap, known as the pupil, is the iris, with the lens
















Figure 1.1 Structure of the human eye
The diagram presents a sagittal view of the human retina. The cornea acts as a protective
barrier to the eye. Aqueous humour is secreted by the ciliary body and is filtered through
Schlemm's canal before leaving the eye. The iris alters pupil size to control the amount of light
that enters the transparent lens and passes through the vitreous humour. Light is focused
onto the retina, containing a region known as the macula that is necessary for high visual
acuity. The choroid, delivering blood to the eye, and the sclera form the outer layers. Adapted
from an image taken from http://www.discoveryfund.org/anatomyoftheeye.html.
1.1.2 The cornea, iris and ciliary epithelium
The cornea consists of five layers, with the corneal epithelium as the most peripheral,
and the other layers, moving towards the central eye, are Bowman's membrane, the
stroma, Descemet's membrane and the endothelium. Corneal transparency allows
light to enter the eye and pass through the aqueous humour, a transparent fluid
contained in a chamber that lies behind the cornea.
Light that traverses the cornea and aqueous humour can then pass through the pupil.
This is an opening that has its size, and therefore the amount of light passing through
it, controlled by the iris. This pigmented structure, which also reduces glare in the
eye, is muscular, with contraction and relaxation altering pupil size. Roles in
controlling intraocular pressure (Chang et al., 1999) and regulating lens growth
(McAvoy et al., 1999) have also been postulated.
The ciliary epithelium is a continuation of the iris epithelium, with a bilayer of
pigmented and non-pigmented opposing cells (Raviola and Raviola, 1978). It
secretes aqueous humour and therefore contributes to the regulation of intraocular
pressure, as does the trabecular meshwork, a region through which the aqueous




Light passing through the pupil next encounters the lens (Figure 1.2). This structure
has attached suspensory ligaments that control lens thickness and therefore control
the refraction of light entering it, making it important for visual acuity. The lens is
composed of anterior lens cells and lens fibre cells (LFCs). The anterior epithelial
cells elongate and terminally differentiate into the LFCs, which are morphologically
distinct, losing their nuclei and organelles. Lens transparency is maintained by this
lack of internal structures, which would otherwise cause light to scatter, and also by
the structural arrangement of its proteins. The anterior cells continue to differentiate













Figure 1.2 Lens cellular structure
The lens is composed of anterior epithelial cells and lens fibre cells that extend from the
anterior cells to the posterior lens. Transparency is maintained by the lack of organelles present
in the light path. Adapted from an image taken from
http://www.eb.tuebingen.mpg.de/dept3/research_interests/eye_lens_dev.htmL
1.1.4 The retina
Light passing through the lens is focused on the retina. This complex sensory tissue
constitutes the innermost of three major layers on the outer surface of the eye. The
retina contains the photoreceptive cells and neurones that transmit signals to the
brain, which then produces an image.
The retina is in itself composed of multiple layers (Figure 1.3). Separating the retina
from the vitreous humour is the inner limiting membrane. Adjacent to this, the
innermost layers are the optic fibre layer (OFL) and the ganglion cell layer (GCL),
which contain ganglion cells and some amacrine cells. The next three layers are the
inner plexiform layer (IPL), the inner nuclear layer (INL) and the outer plexiform
layer (OPL). These layers incorporate ganglion, bipolar, horizontal and amacrine
neuronal cell types. Beyond these cells lie another fibre layer and the outer nuclear
layer (ONL). The inner and outer segments of the rod and cone photoreceptor cells
form the next two layers (IS and OS), while the outer limiting membrane (OLM)
separates these from the ONL. Miiller glial cells span the layers of the retina from the
OFL to the inner segments of the rods and cones. These layers of neuronal and glial
cells constitute the neural retina. The surface of the retina is not uniform in its
cellular composition. This is most obviously illustrated by the human fovea, a small
area of the neural retina diametrically opposite the cornea and pupil that contains
only cone cells. The fovea lies in the macula, 6mm in diameter in primate retinas,
which has a high proportion of cones, in contrast to the peripheral retina. Rods are
necessary for vision in dim light while cones are important in bright light conditions
and for colour vision and visual acuity. In the mouse, cones are much more sparse





Figure 1.3 Cellular composition of the retina
The multiple layers of the retina are shown alongside their corresponding cell types. The Muller
cells (not shown) span the layers from the OFL to the IS. Ganglion cells are also found in more
peripheral layers and amacrine cells are found in the GCL. As well as the retina, the choroid
is shown. The inner limiting membrane (not shown) marks the inner boundary of the retina,
separating the vitreous humour from the OFL. C, choroid; RPE, retinal pigment epithelium;
OS, outer segments; IS, inner segments; OLM, outer limiting membrane; ONL, outer nuclear
layer; FL, fibre layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform
layer; GCL ganglion cell layer; OFL, optic fibre layer. Adapted from an image taken from
http://thalamus.wustl.edu/course/eyeret.html.
The retinal pigment epithelium (RPE) is the outermost layer of the retina, separated
from the choroid by Bruch's membrane. It is pigmented, as the iris and ciliary
epithelia are, and is continuous with these tissues. The RPE contributes to the
maintenance of the neural retina, being involved in selective transport of nutrients
and ions, synthesis of the photoreceptor extracellular matrix, phagocytosis of shed
outer segments and maintenance of the blood/neural retina barrier (Bok, 1985; Bok,
1993). It also has a major role in the visual cycle (see section 1.1.5).
1.1.5 Phototransduction and the visual cycle
There are two phases involved in phototransduction. The excitation phase describes
the processes leading to hyperpolarisation and the production of a stimulus, while the
termination of transduction and recycling of its components occur in the recovery
phase.
Rhodopsin is the light sensitive pigment contained in rod photoreceptors.
Photoactivation of rhodopsin initiates the excitation phase of phototransduction
(Figure 1.4). This alters the conformation of transducin, a G protein, by converting
the GDP to which it is bound to a-GTP. The inhibitory y subunit of
phosphodiesterase (PDE) is removed by interaction with the transducin-bound a-
GTP. The subsequently active form of PDE hydrolyses cGMP present in the
cytoplasm. There are cGMP-gated channels in the membrane of the outer segments,
thus as the concentration of cGMP decreases intracellularly, the channels close.




Figure 1.4 The phototransduction cascade
Photoactivated rhodopsin alters the conformation of the bound G protein, transducin. The a-
GDP subunit is converted to an unbound a-GTP. This can then bind the y-PDE subunit, allowing
PDE activation. This activity converts cGMP, which gates calcium and sodium channels in the
cytoplasm, to GMP. Closed channels result in a decrease in intracellular ions and causes
hyperpolarisation. R* active rhodopsin; t, transducin; G, G protein; GMP, -DP, -TP, guanosine
-mono, -di, -triphosphate; PDE, phosphodiesterase. Taken from
http://www.howelaboratory.harvard.edu/vahomepage/research_arshavsky.htm.
The recovery phase sees the return of rhodopsin, transducin and PDE to their inactive
states. Rhodopsin is recovered using rhodopsin kinase and arrestin via the visual
cycle (described below), while a G protein mediates the hydrolysis of transducin-
associated GTP to GDP. In turn, GDP inactivates PDE. Activated guanylate cyclase
catalyses the increase of cGMP and the channels open.
The visual cycle (Figure 1.5) takes place in the RPE and regenerates photoreceptor
pigment. In its inactive state, rhodopsin is composed of opsin protein and 1 l-cz's
retinal. Photoactivation of rhodopsin changes the bound 11 -cis retinal to all-trans
retinal. The regeneration of inactive rhodopsin therefore necessitates the conversion
of all-trans retinal to 11 -cis retinal, which is the essence of the visual cycle. This
process is characterised by a series of chemical modifications, most of which take
place in the RPE, with an influx of the all-trans retinol component (an alcohol









Figure 1.5 The visual cycle
The visual cycle describes the regeneration of rhodopsin. Photoactivation of rhodopsin changes
the opsin-bound 11-c/s retinal to all-trans retinal, with the regeneration of rhodopsin brought
about by the conversion of all-trans retinal back to 11-c/s retinal. Initially, the released all-trans
retinal is reduced to all-trans retinol. This is transported out of the OS into the RPE, where
all-trans retinol, an alcohol derivative of vitamin A, can also be acquired from the bloodstream.
Esterification of all-trans retinol is followed by isomerisation. Hydrolysis and subsequent
oxidation result in 11-c/s retinal, which is transported from the RPE into the OS to bind with
opsin and reform active rhodopsin. OS, outer segment; RPE, retinal pigment epithelium; C,
choroid. Based on a figure taken from Rattner et al., 1999.
1.2 Approaches to gene discovery
Novel genes can be found through various methods. A top down approach may be
the investigation of an interesting phenotype to elucidate the gene or genes that may
be genotypically responsible. This would culminate in the mapping of a particular
mutation, which has historically been spontaneous. ENU (ethylnitrosonurea)
mutagenesis induces point mutations chemically and was first employed to screen for
specific mutations in the progeny of mutagenised mice in 1984 (Bode, 1984). Gene
trap methods have also been used and involve inserting a reporter gene into an
endogenous ES cell gene, which not only removes function of the gene of interest,
but also allows the visualisation of the expression domain of that gene through
transcription of the reporter gene by the endogenous promoter (Gridley et ah, 1987;
Jaenisch, 1988). These methods for gene discovery, like many others, are based on
the premise that the laboratory mouse is the best existing model for the human (Cox
and Brown, 2003).
The comparison of mouse and human is made more direct by the advent of well-
described genomes for these organisms. Related to this change is the possibility of
using bottom up approaches to gene discovery, by locating a novel gene and using
experimental techniques, such as expression studies and experimentally altering
genotype in model organisms to give a phenotypic effect that can be related to
function. Novel genes can now be located using features in the human genome such
as CpG islands, splice sites and open reading frames (ORFs) and the use of tools
such as BLAST allow orthologous and paralogous genes to be discovered (Cox and
Brown, 2003).
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1.2.1 The advent of ESTs
The potential for identifying genes from cDNA sequences was first realised in 1985,
with the publication of a novel gene found by shotgun sequencing (Putney et ah,
1983). The advent of fluorescent-based sequencing (Smith et al., 1986) allowed an
automated method to develop and be used in a more high throughput manner. The
term EST (expressed sequence tag) was coined by Venter's group in the early 90s
and describes a short sequence, usually between 200 and 400 bases in length, with
approximately 2% error, derived from a cDNA clone. These sequences were first
produced and used in a pilot study using brain cDNA libraries (Adams et al., 1991).
Adams et al. had recognised the potential of ESTs to identify genes and its relative
rapidity and low cost compared to sequencing the entire genome. Sequencing ESTs
has been described as the hare to the human genome project (HGP) tortoise (Gibbs,
1997), as while ESTs are a more efficient and direct approach to attain a complete set
of genes by targeting the coding 2% of the genome, the HGP provides the framework
on which to place these coding genes and the peripheral sequences that affect their
expression and function.
Given the advantages, EST sequencing was generally accepted as a good
complementary approach to genomic sequencing and therefore prompted the
production of thousands of ESTs by 1993. In order to provide these sequences in a
publicly accessible form, GenBank (Benson et al., 2003), the sequence submission
database, set up an EST arm known as dbEST (Boguski et al., 1993).
Large-scale studies of ESTs from the human genome were undertaken and have
contributed large amounts of data to dbEST. TTGR (The Institute for Genomic
Research) is an organisation that was set up for the purpose of sequence-based
research. The automated DNA sequencing and analysis equipment present at this
centre have enabled the high throughput sequencing that facilitates large-scale EST
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analysis. The initial result of this activity was the production of over 170,000 ESTs
from 300 cDNA libraries encompassing 37 different tissues and organs (Adams et
ah, 1995). Subsequent major EST producers have used human (Hillier et ah, 1996;
Houlgatte et ah, 1995) and mouse (Marra et ah, 1999) libraries.
IMAGE (Integrated Molecular Analysis of Genomes and their Expression) is a
consortium that was founded in an effort to pool cDNA libraries in a public database
and provide a single identifier for each, in order to provide expression data on a
single clone that may have been gathered by many different laboratories (Lennon et
ah, 1996).
ESTs are still the greatest source of new sequence data submitted to GenBank, with
human and mouse sequences constituting the largest numbers (Benson et ah, 2003).
1.2.2 Using ESTs to find novel genes
By 1994, ESTs were already fulfilling their predicted function as a tool for gene
discovery (Sikela and Auffray, 1993; Boguski et ah, 1994). However, the efficiency
of using ESTs to extract novel sequences was severely hampered by the large
variation in frequency for different mRNAs. This ranges from one copy per cell to an
average of 5,000 copies amongst those mRNAs contributing 40% to 45% of the total
population (Davidson and Britten, 1979; Bishop et ah, 1974). In order to reduce this
inherent problem, a normalisation technique was applied to the construction of a
brain cDNA library to allow representation to fall within a narrower range (Soares et
ah, 1994). This technique relies on reassocation kinetics, with rarer transcripts
annealing less rapidly than common ones, and bound sequences being removed in the
procedure (Figure 1.6). As well as allowing rare transcripts to be more readily
identified from cDNA libraries, the cost and time for sequencing ESTs was reduced
and has allowed the evolution of the large-scale analysis that is now carried out,
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including a recent "cDNA encyclopaedia" of the mouse that represents 70,000
transcriptional units (Carninci et ah, 2003).
A further advancement in EST studies was made through the presentation of ESTs
for analysis. Although dbEST serves the crucial purpose of allowing public access to
ESTs, there was an additional need for a more organised and structured EST
database, grouping ESTs from common transcripts and allowing more direct
comparison with the ongoing annotation of the human genome. Two similar but
distinct databases were set up, both providing a set of clusters containing ESTs that
had been grouped by homology. At TIGR, tentative human consensus (THC)
sequences were produced from homologous ESTs (Adams et al., 1995; Quackenbush
et al., 2000), while NCBI (National Center for Biotechnology Information) produced
the UniGene database (Schuler et al., 1996; Pontius et al., 2003; Wheeler et al.,
2003). UniGene comprises a set of clusters containing homologous ESTs and, in
cases where these have been derived from known genes, mRNA sequences.
ESTs provide a vast amount of sequence information that can be used to find novel
genes. Improved techniques, such as normalisation, and the provision of
organisational EST databases, UniGene and THCs being the prime examples, have



























Figure 1.6 Schematic of cDNA library normalisation
The normalisation procedure aims to equalise the abundance of different cDNA species from
a library in order to make sequencing more efficient and increase the likelihood of sequencing
rare cDNAs. The first step requires primer extension to produce complementary sequences
of cDNA clones of about 200 bases. The partial duplexes resulting from this are purified and
subsequently melted and reannealed. Rarer sequences anneal less rapidly than common
sequences, due to reassociation kinetics. The resulting duplexes, representing common
sequences, are extracted to leave unhybridised cDNAs that are used to construct the normalised
library. Adapted from a figure taken from Soares et al., 1994.
1.3 Differential expression
Expression analysis is used as a tool to discover genes involved in the development
or function of a particular tissue or cell type. This is based on an assumption that
differential expression of a gene implies an important role in that restricted group of
cells or tissues. Application of this technique to all cell types and tissues may
eventually lead to a "body map of expressed genes" (Okubo et al., 1992), an
additional level of complexity to the genome sequence.
There are many methods for assessing gene expression and discovering genes with
differential expression. This section describes these techniques, their strengths and
weaknesses and their previous application.
1.3.1 Northern blot analysis
Since the development of the Northern hybridisation technique (Alwine et al., 1977),
it has been used to assess gene expression. The simplest form of this technique is the
hybridisation of a radioactively labelled probe to RNA samples. The intensity of a
signal on radiographic film is indicative of the level of RNA present. Relative
concentrations can be deduced by using a dot blot technique, whereby multiple
samples are dotted on a filter before hybridisation (Kafatos et al., 1979). This
approach has many disadvantages compared to more recently developed techniques.
There are issues with the reproducibility of results and therefore quantification of
RNA can not be accurately assessed. It is also a technique that is unsuitable for large-
scale analysis, as only one gene can be assessed at a time and the amount of RNA
required for this type of approach is prohibitive to this type of study.
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1.3.2 RT-PCR
Following the publication of the polymerase chain reaction (PCR) (Mullis et al.,
1986), RT-PCR (reverse transcription-PCR) was soon developed and used to identify
a mouse mutation causing sparse fur (Veres et al., 1987). This technique amplifies
the relevant population of cDNAs derived from an RNA sample and therefore
presents a relatively simple method for assessing differential expression of a gene.
Various modifications of the basic technique have allowed quantification of cDNA,
either by assessing quantity once the reaction has been completed, or more accurately
by real-time PCR, monitoring the product as the reaction progresses (Freeman et al.,
1999). A major advantage of RT-PCR over using Northern analysis is the small
quantity of RNA that can be used for a reaction, as it much more sensitive.
Additionally, a large number of samples can be tested at the same time. However, as
with dot blots, the limiting factor is the number of genes that can be tested at one
time, with optimised conditions for quantitative RT-PCR being specific for each
primer set.
1.3.3 Sequencing ESTs from cDNA libraries
The generation of ESTs has already been discussed as a successful way of finding
novel genes. In addition to this function, ESTs have been used to quantify gene
representation in cDNA libraries that have not been normalised. Original studies
merely aimed to build a profile of genes expressed in a tissue, with the first such
study constructing a cDNA library from a liver cancer cell line (Okubo et al., 1992).
A follow up investigation sequenced ESTs from liver and lung cell libraries and
compared the expression profiles of these tissues with that deduced for the liver
cancer cell line in the first study in order to classify genes as tissue specific or non-
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specific (Matsubara and Okubo, 1993). This approach has since been applied to a
range of tissues and cell types.
As EST sequencing does not require prior knowledge of a sequence, it presents the
opportunity to discover novel genes with differential expression as well as establish
tissue specificity for known genes, unlike other techniques for assessing gene
representation. However, saturation of the transcript population of a cell can only be
achieved with extensive sequencing. As previously discussed, this is inefficient, with
common transcripts being sequenced repeatedly. However, inherent in the
normalisation procedure is the altered representation of transcripts. Thus, sequencing
from a single cDNA library constructed using the cells or tissue of interest has its
limitations.
1.3.4 Subtractive hybridisation
As sequencing cDNA libraries is an inefficient process for gaining transcriptional
profiles for cell or tissue types, subtraction is a method that can be employed to
produce a population of differentially expressed sequences (Figure 1.7). The
subtraction approach was first utilised to find T lymphocyte specific proteins by
using RNA derived from B lymphocytes to hybridise, and therefore remove, non¬
specific T lymphocyte cDNAs (Hedrick et al., 1984). This method produces
sequences that are preferentially expressed in one cell or tissue type (tester) and not















Figure 1.7 Schematic of subtractive hybridisation
Subtraction can be used to produce sequences that are preferentially expressed in a particular
tissue or cell type. The mRNA of these cells, known as the tester, is used to synthesise labelled
cDNA. Hybridisation between the tester cDNA population and the mRNA from a driver tissue
result in a mixed population of hybridised and non-hybridised sequences. The hybridised
sequences are removed to leave labelled sequences from the tester that represent cell or
tissue specific transcripts. Adapted from an image taken from
http://www.niaaa.nih.gov/gallery/genetics/outline.htm.
One of the disadvantages of subtraction is the high redundancy of clones. A
modification of the subtraction method, suppression subtractive hybridisation (SSH),
reduces this problem by combining subtraction and normalisation in one step
(Diatchenko et ah, 1996). SSH is based on suppression PCR, a technique for walking
in uncloned genomic DNA from gene specific sequences (Ma and Whitlock, Jr.,
1997). In SSH, tester cDNA is divided into two pools, each added to with distinct
adapter sequences (Figure 1.8). The first hybridisation is with the driver in each pool,
followed by a subsequent hybridisation of the two normalised tester pools with each
other. Only sequences with both adapters will be amplified exponentially by PCR
with adapter specific primers, so allowing the equalisation of cDNA representation
whilst removing sequences not expressed differentially.
Although SSH removes the redundancy that occurs in standard subtraction
hybridisation, there remains the disadvantage of only allowing the elucidation of
upregulated expression in one particular sample.
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Figure 1.8 Schematic of suppression subtractive hybridisation
Two pools of cDNA derived from the tissue of interest (the tester) are ligated with different
adapters. Each pool of sequences is hybridised to driver cDNA separately in the first hybridisation.
The second hybridisation uses both tester/driver pools. The ends of products are then filled
in and subjected to PCR using adapter specific primers. Only tester specific sequences that
have not hybridised within the same tester pool are amplified by PCR.
1.3.5 In situ hybridisation
Since the first publication of wholemount in situ hybridisation (Herrmann, 1991),
this technique has been widely used to visualise gene expression in a tissue or
embryo. In order to use this tool as an indicator of differential expression, large-scale
studies have been carried out to pinpoint differentially expressed genes, for example,
in Xenopus (Gawantka et al., 1998) and mouse embryo (Neidhardt et ah, 2000). In
these studies, 1,765 and 5,348 cDNAs were analysed in Xenopus and mouse embryo
respectively, yielding 273 and 317 differentially expressed genes. This approach can
be used with novel sequences and may give a more detailed view of differential
expression, as it can be seen in situ. However, it is a laborious method for screening
large numbers of unbiased cDNAs to discover those that are tissue specific.
1.3.6 Differential display
Differential display (DD) is a method that allows visualisation of differences
between expressed sequences across multiple RNA samples. Also known as DD-
PCR, this technique requires the use of non-specific primers, amplifying a variety of
sequences by PCR that can subsequently be separated by size electrophoretically.
The presence or absence of these bands, and in some cases the intensity of a band,
compared to the equivalent band in another sample can be used as an indication of
up- or down-regulation of a gene (Figure 1.9). This was first developed and used to
identify genes differentially expressed between a mammary epithelial cell line and a
breast cancer cell line, with four sequences characterised and three of these
confirmed as differentially expressed by Northern blotting (Liang and Pardee, 1992).
Another group independently developed an almost identical protocol at the same
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time and compared kidney to heart, characterising five sequences and confirming all
to be differentially expressed (Welsh et ah, 1992).
DD-PCR has since been a much used method for elucidating differentially expressed
genes and has the advantages of allowing the visualisation of relative amounts of
sequence representation across many samples, with no prior knowledge of sequences
required for their investigation. However, this technique is difficult to automate since
it requires visual comparison and removal of the relevant sequences for subsequent
cloning.
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Figure 1.9 An example of differential display
Differential display allows the visualisation of randomly primed PCR products between different
tissue or cell types. In this example, male (M) and female (F) rat lenses were either treated
with a growth factor associated with cataract susceptibility (+) or untreated (-) and samples
were run in duplicate. The arrow indicates a sequence that is differentially expressed between
male and female and also appears to be downregulated in treated lenses. Taken from Sun
etal.,2000.
1.3.7 SAGE
Serial Analysis of Gene Expression (SAGE) utilises a chain of biochemical steps to
produce a series of short DNA fragments, each representing an mRNA, and therefore
can produce sequences that represent the mRNA population of a given cell or tissue.
This provides an alternative to sequencing ESTs derived from a specific source,
which has been discussed previously (section 1.3.3). The SAGE technique (Figure
1.10) was first used in 1995 and describes the production and concatenation of these
short 9bp cDNA fragments that can be used to identify a specific sequence
(Velculescu et al., 1995). Thus, sequencing of these concatenations allows the
quantification of a particular mRNA in the cell or tissue of interest. In this initial
study, SAGE was applied to pancreas mRNA with success, as the ten most abundant
tags corresponded to gene transcripts with defined pancreatic functions. Since its
conception, SAGE has been used to compare expression profiles of various tissue
and cell types. The comparison of many samples and the possibility of discovering
novel genes are clear strengths of this approach. Additionally, the key advantage
over EST sequencing lies in its lower cost. However, automated sequencing is
required, as 30,000 to 100,000 tags need to be sequenced in order to make the results
statistically viable (Fryer et al., 2002) and the construction of a SAGE library
remains a costly and difficult procedure. SAGE is also limited to use in organisms
with well-defined genomes, as sequences derived from these techniques can only
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Figure 1.10 Schematic of SAGE
SAGE sequences and quantifies cDNA fragments representing transcripts from a particular
cell or tissue. The mRNA is used to synthesise double-stranded cDNA which is subsequently
anchored and restricted. Two pools are created and two different linkers are ligated to these.
A restriction endonuclease is used to cleave the sequence at a specific distance from its site
(TE), releasing sequences from their bound state. Ligation of these tags produces end-to-end
sequences that can be cleaved to produce ditags. These ditags are concatenated and
sequenced, with each tag identifying a specific sequence, allowing quantification of a transcript
in a SAGE library. Taken from Velculescu et a!., 1995.
1.3.8 Arrays
Array technology began with the use of what are now known as macroarrays (Zhao
et ah, 1995; Takahashi et ah, 1995; Nguyen et ah, 1995). This technique, also known
as the reverse Northern, robotically blots different cDNA sequences representing
genes onto a nylon membrane. These are referred to as the probes and the target used
is RNA, which is placed onto the array to allow hybridisation. Radioactivity is used
as the method of detection, with relative intensities used as indicators of the relative
abundance (Figure 1.11). In this way, a large number of genes can be tested using
one sample and the array can be used again with different RNA samples after
washing. In initial studies using this technique, Northern blotting was used to
validate the results.
Microarrays work on the same principle as macroarrays, using an array containing
probes and hybridising a target sample to this array to gain an indication of relative
abundance. However, microarrays have a larger number and higher density of probes
on a glass or plastic surface and they utilise fluorescence rather than radioactivity as
a measure of sequence abundance. An advantage of using fluorescence is the ability
to distinguish between different fluorescence types, therefore more than one sample
can be hybridised at one time due to competitive hybridisation (Figure 1.12). There
are two major types of microarray that are based on different probe synthesis
techniques; cDNA arrays and oligonucleotide arrays. The former consists of cDNAs
that are placed on the array surface and was first used to successfully identify
sequences differentially expressed between the root and leaf of Arabidopsis (Schena
et al., 1995). Oligonucleotide arrays require in situ synthesis of 25 base probes on a
silicon chip (Lipshutz et al., 1999). As the sequences are short, non-specific binding
is an inherent problem, which is reduced by using a control sequence with a
mismatch.
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Figure 1.11 Macroarray procedure
RNA samples are hybridised to a membrane spotted with cDNA sequences representative
of different genes. Multiple samples can be used for hybridisation to produce a visual display
indicating relative sequence abundance. Adapted from a figure from Freeman et al., 2000.
Figure 1.12 Microarray expression results
Microarrays can assess relative expression of two samples by using competitive hybridisation
and fluorescent tags. The presented example is taken from an analysis of human chromosome
22 exons undertaken in order to validate them and infer transcriptional units. Each row
represents an experiment using two samples to assess differential expression. The selected
regions below the main results display each represent a gene, with each column corresponding
to an exon. The region furthest to the right represents a novel transcript, with preferential
expression in the testis compared to pooled sequences indicated by the arrow. Taken from
Shoemaker et al., 2001.
Other forms of microarray continue to be developed, including microelectronic
arrays from Nanogen (Edman et al., 1997; Sosnowski et al., 1997), which use electric
fields to control hybridisation, Massive Parallel Signature Sequencing (MPSS) from
Lynx Therapeutics (Brenner et al., 2000), which utilises fluorescent signatures to
identify sequences, and fibre optic arrays from Gene Logic (Walt, 2000), which
transmit fluorescence from labelled sequences to a detection system.
The major strength of array technology lies in the magnitude of genes that can be
sampled at one time and microarrays allow analysis to be carried out on more than
one sample at a time. However, this approach will not find novel genes and has low
sensitivity, creating problems with reproducibility and necessitating a minimum two
fold difference between samples for statistical robustness (Fryer et al., 2002).
1.3.9 In silico approaches
Informatic techniques have become an essential part of research activities in
differential expression and the discovery of novel genes. This ranges from using the
BLAST tool to elucidate a single gene corresponding to an experimental sequence, to
complex programming that processes large amounts of data available from the public
databases. The applications of these bioinformatic techniques include the elucidation
and analysis of differentially expressed genes.
Various groups have designed computational methods for finding genes with tissue
specific or preferential expression. Many have used a computer-based approach to
analyse experimental data, whilst others have developed programs to mine public
databases. The provision of similar tools via the internet have allowed this kind of
analysis to become more accessible to a wide range of researchers. The two main
programs available for this use are Digital Differential Display (DDD) at NCBI and a
tool based on the gene indices at TIGR, which both facilitate identification of both
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known and putative genes that show differential expression in the EST databases.
These tools are described in more detail in a later chapter (section 3.1).
The TIGR method has been used successfully to identify testis specific genes
(Olesen et al., 2001) in an attempt to elucidate novel genes that may be implicated in
male infertility. This approach produced 131 novel testis specific sequences, with 14
being selected for RT-PCR analysis. Of these, four were specifically expressed, six
were differentially expressed and four were ubiquitously expressed in the adult, with
three of these being differentially expressed at the foetal stage.
A study aiming to identify genes important in cancer carried out a series of
comparisons with normal tissues and breast, colon, lung, ovary, pancreas and
prostate cancers using DDD (Scheurle et al., 2000). As well as producing known
cancer-associated genes, 500 novel sequences were also derived from the analysis.
Using RT-PCR, three of 12 known genes were shown to be specifically expressed, as
were two of 20 novel genes. An additional example of the success of DDD is found
in one of the recent studies showing the importance of Nanog as a factor defining ES
cell identity, as the Nanog sequence was derived from one of the 20 highest EST
clusters resulting from a DDD comparison of ES and somatic cells (Mitsui et al.,
2003).
1.4 Progress in eye differential expression
Differential expression is a valid route by which genes important in disease can be
found, either known or novel. This applies to ocular gene expression, as the majority
of single gene eye disorders are characterised by a mutation in a preferentially
expressed gene (Stohr et al., 2000). Many of the methods described earlier (section
1.3) have been applied to ocular sequences in order to assess the differential
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expression of known genes and, in some cases, elucidate novel genes displaying
preferential expression in eye tissue. This section describes results of investigations
utilising the most common methods. The majority of these studies focus on retinal
tissues, as this is the site of phototransduction and houses a variety of neuronal and
non-neuronal cells with specific functions.
1.4.1 EST sequencing to identify novel differentially expressed genes
Many studies sequencing eye-derived ESTs do so from retinal libraries. Genes have
been discovered in this manner, for example FZD2-RS1 (frizzled homologue 2,
related sequence 1, a homologue of Drosophila frizzled) (Wang et al., 1996) and
CLUL1 (clusterin-like 1) (Shimizu-Matsumoto et al., 1997), although these have as
yet unknown function.
More restricted retinal regions are also used for library construction, such as fovea
(Bernstein et al., 1996) and RPE (Paraoan et al., 2000; Buraczynska et al., 2002). In
the RPE study by Paraoan et al., CST3 (cystatin C), a protease inhibitor, was found to
be differentially expressed by its representation in the constructed library and also by
its representation in the databases, although this gene had no previous link with the
RPE. This differential expression was subsequently confirmed by Northern analysis
and RT-PCR. Another example of the discovery of preferential expression of a
known gene was found by sequencing ESTs from bovine ciliary epithelium and
using subsequent confirmational analysis to show that GST-k (glutathione S-
transferase class-7i), a member of a multifunctional enzyme family, was differentially
expressed between different eye tissues and within the ciliary epithelium (Hernando
et al., 1992). Other non-retinal EST sequencing efforts have produced novel genes,
including KRT12 (keratin 12), a structural protein differentially expressed in the
corneal epithelium (Nishida et al., 1996), and an uncharacterised novel gene from
human trabecular meshwork (Gonzalez et al., 2000a).
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A major recent contributor of eye-derived ESTs has been the NEIBank project
(Wistow, 2002). This project produced and sequenced thousands of ESTs from lens
(Wistow et ah, 2002c), iris (Wistow et al., 2002b), retina (Wistow et al., 2002d), and
RPE/choroid (Wistow et al., 2002a) cDNA libraries derived from adult human eyes.
These libraries were constructed to allow a resource of sequences representative of
the mRNA population of these tissues and consequently were not normalised,
although subsequent amplification and normalisation of the lens and iris libraries was
carried out to reduce highly abundant clones before another round of sequencing was
undertaken. Amongst the abundant ESTs found in this large-scale study were many
novel and highly represented genes, in addition to novel transcripts of previously
described genes. The sequences derived from these libraries will serve as a useful
tool for future microarray studies.
EST sequencing has produced novel genes, however, differential expression has been
deduced using further analysis on abundant sequences. Nevertheless, this technique
has had success for the initial provision of sequences that can be tested.
1.4.2 Subtractive methods for assessing preferential expression and
identifying novel differentially expressed genes
Subtraction has been employed on libraries derived from ocular tissues in order to
produce tissue specific genes that may relate to tissue function. A retinal study, using
Northern blotting to analyse expression of sequences from a subtracted library, found
that only five of 23 novel sequences were not expressed in the retina and, of the rest,
eight were expressed in the eye and less than four other tissues (Sinha et al., 2000).
In an investigation of preferentially expressed sequences in the RPE, 45 sequences
derived from a subtracted library were tested by Northern blot, with 29 preferentially
expressed in the RPE (11 of these were specific and a further 11 were expressed in
the RPE and retina only) and the remaining 16 showing retinal expression but no
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expression in the RPE (Sharma et al., 2002). This neural retina expression was
assumed to be caused by contamination of RPE tissue with neural retina prior to
RNA synthesis. Another RPE study utilising a subtracted library identified two
specific and one preferential sequence from seven novel sequences (Agarwal et al.,
1995).
A differing subtraction technique synthesises cDNA from RNA and carries out a
subtraction step before random priming from the remaining sequences (Rodriguez
and Chader, 1992). This technique, known as solid-phase subtraction, was employed
to find sequences preferentially expressed in the macula (Schoen et al., 1995). Of
100 sequenced clones, 63 were analysed by Northern analysis, 36% of which were
not detected and exactly half of the remaining sequences were macula-enriched.
The SSH method has been applied in a study on two eye libraries, one retinal and one
containing RPE and choroid (den Hollander et al., 1999). Of the 314 sequenced
retinal cDNAs, 86 were novel and 21 of the 126 RPE/choroid sequences were novel.
A semiquantitative RT-PCR method was used to assess the expression of 33 of these
novel genes, yielding 11 specifically expressed sequences, 13 expressed significantly
more in the expected tissues and nine expressed in the eye and in two or less other
tissues.
These methods show that although there is variability in the efficiency of these
techniques, they are successful at producing differentially expressed genes. Another
study, carried out on a ciliary body library, demonstrates the applicability of this
approach to questions about eye function (Escribano et al., 1995). From the 90
known genes corresponding to sequences derived from the human ciliary body
subtracted library, a group of plasma proteins were identified. This expression was
confirmed by Northern and in situ analysis and was a significant finding as it was
previously thought that aqueous humour plasma proteins were synthesised outwith
the eye.
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1.4.3 A large scale in situ screen to identify differentially expressed
genes
A high throughput in situ hybridisation procedure was utilised in an effort to gain
molecular markers for development of the anterior eye (Thut et al., 2001). Probes
were made from 1,035 ESTs, with each tested at six stages of mouse development.
From the results, 62 probes displayed distinct expression in the RPE, outer neural
retina, inner neural retina or the presumptive iris and ciliary body. These
developmentally expressed sequences were used as markers for inductive signals in
the anterior eye that may lead to lens induction and were tested in lens culture studies
by in situ hybridisation. This study represents a large-scale project that aims to
answer a specific developmental question and has succeeded in producing candidates
for factors involved in lens development.
1.4.4 Using differential display to assess preferential expression and
identify novel differentially expressed genes
The DD method has been used to identify differentially expressing eye genes,
particularly in the retina and lens. This method was used in a study aimed at finding
genes that were upregulated following severance of the optic nerve in rat, as they
hypothesised that the RGC cell death following this process is caused by the
induction of apoptotic genes (Levin and Geszvain, 1998). Using DD, upregulation of
ceruloplasmin, an antioxidant, was found in the retina after surgical optic crush. This
was confirmed by Northern blotting and RT-PCR showed differential expression in
normal retinas, with expression in the liver and, to a lesser extent, in the retina.
Immunofluorescence was used to show expression in the INL and RGCs.
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Ceruloplasmin therefore represents a candidate for inducing RGC cell death in the
retina.
A study on chick retina and choroid utilised DD to assess differential expression in
chick eyes that had been subjected to induced refractive error (Feldkaemper et al.,
2000). This was done by using lenses and fogged goggles to change the focus of the
lens and had previously been shown to induce the relevant change in cornea
thickness. After 6-24 hr of treatment, 12 retinal and five choroidal genes were seen to
be differentially expressed. Two genes, a cytochrome subunit and proglucagon, were
shown to be upregulated and these were confirmed by Northern blotting.
A study investigating differential expression between cultured and fresh RPE cells
highlights the alterations of gene expression in culture, but was used in the
investigation as an indicator of genes that may be important in a disease
characterised by the loss of epithelial nature of RPE cells (PVR, proliferative
vitreoretinopathy), as occurs in cultured tissue. A candidate gene, MAP1B
(microtubule-associated protein 1B), linked with roles in cell or subcellular structure
determination, was found using this method, as it was upregulated in culture
compared to fresh RPE and protein localisation showed it to be expressed in PVR,
but not in disease-free, RPE.
There has been evidence of differences between sexes in humans and in animal
models with relation to developing age-related cataract. DD has been used to assess
this difference in culture with male and female lenses and also with TGF-P
(transforming growth factor, beta), known to induce greater susceptibility to cataract
in male rats and females with removed ovaries (Sun et al., 2000). Two known genes
were highlighted in this study. Crygb (gamma crystallin B), a structural protein, was
found to be upregulated in males lenses and proteasome Z, a subunit of the small
peptide hydrolysing proteasome, was upregulated in TGF-P induced male lenses but
downregulated in ovariectomised female lenses and TGF-P female lenses compared
to normal lenses. These two genes found by DD represent candidates for sex-related
differences in the propensity for age-related cataract development. Another cataract
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study used DD to compare age-related cataract-affected lenses and with cataract-free
lenses and found three genes upregulated in the cataract, including METII
(metallothionein Ha), a detoxification protein induced by oxidative stress (Kantorow
et ah, 1998). One of the 12 genes found to be downregulated in cataract-affected
lenses was P2A-RS (protein phosphatase 2A regulatory subunit), a mitotic
suppressor.
In a study to find genes preferentially expressed in undifferentiated anterior lens
epithelium cells, DD was used to find differentially expressed genes between
untreated anterior cells in culture compared to those treated with the differentiation
factor bFGF (Cai et al., 1999). A novel gene was expressed preferentially in
undifferentiated cells and subsequent Northern analysis confirmed its presence in
anterior cells but only trace amounts in differentiated LFCs.
DD has allowed the direct comparison of two or more samples, showing upregulation
as well as downregulation, therefore presenting an ideal opportunity to study diseases
affecting the eye. These studies have mainly been focused on assessing differential
expression of characterised genes, but novel genes have also been found in this way.
1.4.5 Using SAGE to assess preferential expression
SAGE studies have been carried out on retinal and corneal tissues. A large SAGE
study constructed libraries for adult hypothalamus, retina at two day intervals
between El2.5 and P2.5, adult retina, adult ONL and postnatal retinas from normal
and homozygous mice for Crx, a homeobox gene expressed in developing
photoreceptors (Blackshaw et al., 2001). The SAGE libraries were compared to
deduce genes that may be important in photoreceptor development and function. Of
the 264 preferentially expressed sequences corresponding to novel genes, 86 mapped
to 37 uncloned retinal diseases. Another retinal SAGE study compared libraries
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constructed from human peripheral retina, macula and RPE (Sharon et ah, 2002).
Comparisons of these with non-ocular libraries from the public domain gave 89
genes that are preferentially expressed in the retina, 53 of which are RPE specific. In
comparisons between their SAGE libraries, genes encoding axon structural proteins
were upregulated in macula compared to the periphery. Tissues that were used for
SAGE libraries were taken from one 44 and one 88 year old, with genes expressing
iron metabolism and oxidative damage protection proteins upregulated in the latter.
The most recent reported ocular SAGE libraries reported were constructed in order to
assess differential expression between the normal human corneal endothelium and
that affected by Fuch's dystrophy, a condition characterised by cell irregularity and
areas of thickened Descemet's membrane (Gottsch et al., 2003). From a total of
19,136 sequenced tags, 18 sequences were deduced to be upregulated in Fuch's
dystrophy corneas and 36 were downregulated. Of these downregulated sequences,
seven showed no matches in the databases, three matched ESTs and the remaining 26
known downregulated genes have known antioxidant and toxic stress management
properties.
SAGE libraries have been used to show differential expression between libraries in
all three studies, but an important function of these libraries is for future mining and
for the production of novel sequences that may be candidates for ocular disease.
1.4.6 Using arrays to assess preferential expression
A large range of array types have been utilised in ocular research. One study used
this approach in order to gain insight into genes expressed in the human cornea by
using a corneal target on an array consisting of 5,600 human genes (Jun et al., 2001).
Differential hybridisation and macroarrays have also allowed the elucidation of novel
genes expressed in human photoreceptors (Swanson et al., 1997) and in chick
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(Hackam et al., 2003) and canine (Lin and Sargan, 2001) retina. However,
microarrays are designed to deduce differentially expressing sequences and therefore
this is their major use.
Microarray studies of retinal disorders have yielded candidate genes for disorders
and genes that may be involved in a disease phenotype. Retinal examples of this in
humans are SFRP2 (secreted frizzled-related protein-2), previously postulated to be
influential in retinal cell polarity and found to be upregulated in human retinitis
pigmentosa (a degenerative retinal disease) retinas (Jones et al., 2000a), a range of
genes upregulated in rats with induced diabetes suggesting an inflammatory
component to the response (Joussen et al., 2001) and upregulation of genes in ageing
(62 to 74yr) retina compared to young (13 to 14yr) retina (Yoshida et al., 2002). In
mouse, upregulation of a set of known genes was found in the rd/rd mouse (with a
mutation in the homologous gene to that involved in retinitis pigmentosa in human)
before its characteristic morphological retinal degeneration (Jones et al., 2000b) and
light-induced apoptosis in a mouse strain containing a sensitising mutation correlated
with downregulation of many photoreceptor specific genes and an increase in stress
response gene expression before morphological changes (Choi et al., 2001).
Corneal studies have also produced candidates for genes involved in human diseases
such as bullous keratopathy, a corneal disorder that commonly occurs after cataract
removal and leads to corneal opacity (Spirin et al., 1999), and keratoconus, a
condition that causes myopia and astigmatism and is characterised by corneal
thickening and an irregular epithelium (Nielsen et al., 2003). Glaucoma, associated
with an increased intraocular pressure, has been investigated using arrays to show
higher expression of a set of known genes (Gonzalez et al., 2000b).
As well as characterising ocular phenotypes further with gene expression analysis,
mouse strains with defects in eye genes can be used to investigate transcriptional
networks and developmentally expressed genes. Comparisons between mouse Crx'~
and Crx+I+ retinas (Livesey et al., 2000) and lenses from Pax6~'~ and Pax6^ ~ mice
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(Chauhan et al., 2002) have identified downstream targets of these genes in the
relevant tissues.
1.4.7 In silico approaches to assess preferential expression and identify
novel differentially expressed genes
The EST databases have been mined successfully in order to elucidate sequences
preferentially expressed in the eye or in specific eye tissues. One of these efforts was
based on the entire dbEST database, using an in house in silico subtraction technique
to derive 925 sequences preferentially expressed in the retina and providing
candidates for 49 of the 51 uncloned retinal diseases (Katsanis et al., 2002).
Two studies have utilised the TIGR database, with the first taking ESTs from retina
specific clusters and mapping 55 of 83 novel sequences to 14 candidate regions
(Malone et al., 1999). The second TIGR study focused on retinal and pineal gland
libraries, with the justification that pinealocytes are developmentally related to
photoreceptors and some genes, such as CRX, are expressed only in the retina and
pineal gland (Sohocki et al., 1999). On this basis, THCs with more than 10% EST
representation in pineal gland libraries were picked from TIGR and only those with
additional retinal transcripts but no representation in other tissues were extracted. Of
these 45 clusters, 22 were deemed to represent novel genes expressed only in the
retina and pineal gland.
Another two studies utilised UniGene rather than TIGR for this approach, although
neither used the DDD function but instead used techniques they developed. The first
based preferential expression on the ratio of retinal EST representation in a given
gene cluster compared to the total retinal EST population (Bortoluzzi et al., 2000), a
similar approach to that used by the UniGene utility, DDD (section 3.1). Using this
method, 536 retina specific clusters and 443 clusters preferentially expressed in the
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retina were hypothesised as representing the retinal transcriptome, as allowed by
available sequences in UniGene. The second study utilising UniGene extracted the
1,241 clusters with greater than 30% retinal EST composition, including 673 specific
clusters, and after in vitro analysis of 180, found 39 to be retina specific and another
30 preferentially expressed (Stohr et ah, 2000). Additional investigation of a cluster
characterised it as a novel gene displaying alternative splice forms.
Computational approaches present a relatively new method for assessing preferential
and specific expression in the eye and have led to the discovery of novel genes.
However, to date, there has been little characterisation of novel genes predicted to be
preferentially expressed in the eye by in silico methods. Therefore the potential for
gene discovery by this method has not yet been fully realised and presents the
opportunity for further research in this area.
1.5 Identification and expression of genes implicated in eye
disease
This section describes the isolation and characteristics of a number of genes that
underlie eye diseases. They each differ in their expression pattern, and are




Rho encodes rhodopsin, a protein expressed only in the retina, which was long
known to be involved in visual function and was an obvious candidate for a gene
underlying visual defects.
As discussed earlier (section 1.1.5), rhodopsin is an essential component of
phototransduction, activated by light to initiate the excitation phase. It was first
isolated as the pigment visual purple in 1878 (Garriga and Manyosa, 2002), which
was later named rhodopsin and shown to be composed of a protein, opsin, and a
chromophore. Opsin is a 40kDa apoprotein, encoded by the RHO gene, that is bound
to 11 -cis retinal (Elliott et al., 1990). RHO was sequenced in 1984 (Nathans et al.,
1986) with the mouse gene isolated in 1988 (Baehr et al., 1988).
Rhodopsin protein is found exclusively in rod photoreceptors of human and mouse,
with the Rho gene being specifically expressed in the eye. RHO is a member of the
G-protein coupled receptor (GPCR) superfamily of transmembrane proteins that bind
and activate a G-protein. Specifically, rhodopsin binds and activates transducin in the
rod OS, where it is associated with the flattened membranes, known as discs, within
the OS. As well as being a model of GPCRs, rhodopsin is also associated with retinal
disease.
There are two human retinal disorders associated with mutations in RHO: retinitis
pigmentosa (RP) and congenital stationary night blindness (CSNB). RP is
characterised by progressive degeneration of the retina, beginning with night-
blindness and a loss of peripheral vision and eventually loss of central vision. Both
rod and cone cells are lost through degeneration, probably through apoptosis (Jomary
et al., 2001, (Yang et al., 2001). Altogether, over 100 mutations in RHO have been
described and are associated with approximately 50% of all inherited RP in humans
(Chappie et al., 2001). The most common form of RP associated with rhodopsin is
autosomal dominant RP (ADRP), with 38 mutations reported in OMIM. The
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majority of these dominant mutations in RHO are thought to cause RP by causing
incorrect folding of opsin or through non-localisation to the OS discs with
consequent degeneration (Berson, 1996). Three null mutations described in OMIM
are associated with autosomal recessive RP. The difference between the dominant
and recessive forms of RP caused by RHO mutations is likely to be due to the type of
mutation. Mutations causing dominant RP produce abnormal RHO protein, which is
thought to lead to degeneration of photoreceptors. However, null mutations will not
produce RHO protein, therefore those heterozygous for the mutation may have a
reduced amount of rhodopsin but degeneration of rods may not be induced. Instead,
human carriers of putative null mutations have virtually normal vision before the
onset of significant photoreceptor death (Jacobson et al., 1996; Kajiwara et ah,
1993).
Only three dominant mutations in RHO have been associated with CSNB (Garriga
and Manyosa, 2002). These mutations have been associated with the disruption of
maintaining inactivity, therefore these mutations may cause constitutive activation of
rhodopsin (Garriga and Manyosa, 2002). It has been proposed that this inappropriate
stimulation of rod cells leads to their desensitisation (Jin et al., 2003).
Two mouse models with disrupted endogenous Rho have been generated. Both
homozygous knockouts displayed failure of rod OS formation, with complete
degeneration of photoreceptors within a few months after birth (Humphries et al.,
1997; Lem et al., 1999). Heterozygotes in one study developed OS, but with half of
the normal amount of rhodopsin present, with retinal degeneration occurring over a
much longer period of time (Lem et al., 1999). The other study produced
heterozygous mice that retained most of their photoreceptors, although the inner
segments (IS) and OS were structurally abnormal (Humphries et al., 1997).
As RHO is expressed specifically in the rod photoreceptors, diseases associated with
a mutation in this gene result specifically in the retinal diseases RP and CSNB.
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1.5.2 Pax6
Pax6 is an example of a gene that is involved in eye disease, but which is expressed
in both the developing eye and in the brain.
PAX6 (paired box gene 6) was first identified as a candidate for aniridia in humans
by positional cloning (Ton et al., 1991). This type of aniridia is characterised by a
range of ocular abnormalities that can include hypoplasia of the iris, fovea and optic
nerve, as well as cataracts and nystagmus, an oscillation of the eyeballs. Mouse Pax6
was subsequently identified as the gene containing the small eye mutation in mice
(Hill et al., 1991). This is a semidominant mutation, with heterozygotes having
smaller eyes than wild type and often displaying an optic fissure. Homozygotes have
no visible eyes and undeveloped nasal cavities and therefore die soon after birth.
Pax6 is expressed embryonically in a restricted set of tissues other than the eye; nasal
structures, brain and neural tube (Walther and Gruss, 1991; Grindley et al., 1995). In
the adult, it is expressed in the eye, cerebellum and pancreas (Ton et al., 1992;
Turque et al., 1994; Stoykova and Gruss, 1994). Its sequence is highly conserved
across invertebrates and vertebrates and contains a homeodomain as well as a paired
box domain, separated by a linker portion and followed by a PST domain (proline,
serine and threonine rich) that has functions in transcriptional activation (Glaser et
al., 1994). Within the eye, Pax6 is implicated in eye development through its
proposed regulation of several developmentally important genes. These include
transcription factors such as Six3, Proxl and basic helix-loop-helix transcription
factors that are important in cell determination and differentiation, keratins and
crystallins. Through these interactions, Pax6 is thought to be involved in cell cycle
regulation, cell determination and differentiation and apoptosis (Simpson and Price,
2002).
Many PAX6 mutations have been described, with the majority causing aniridia, a
disease with a population frequency of 1 in 60,000 to 1 in 100,000 (Prosser and van,
47
V, 1998). Although the majority of anridia cases have been shown to be caused by a
PAX6 mutation, there are also anirida patients with WAGR (Wilms tumour, Aniridia,
Genitourinary abnormalities, mental Retardation), a syndrome caused by deletions of
1 lpl3 including PAX6 (Fantes et al., 1992). The paired and homeodomains of PAX6
are the source of a large proportion mutations in PAX6 when considering their size
(Prosser and van, V, 1998). The vast majority of phenotypes resulting from PAX6
mutations appear to be caused by a loss of function, and cause predisposition to
aniridia. However, other eye abnormalities are seen, particularly in patients
displaying milder phenotypes, and may be caused by altered specificity of the
protein.
In contrast, there are fewer mutations in the PST domain, which is thought to be at
least partly due to lower detection caused by the milder effects on PAX6 activity
(Prosser and van, V, 1998). An example of this is a phenotype caused by compound
heterozygosity, with members of a family displaying congenital cataracts and late-
onset corneal dystrophy whilst others suffered from aniridia (Glaser et al., 1994).
This was associated with two distinct point mutations in the PST domain. There are
non-coding regions of the PAX6 gene that have conservation across species but, to
date, no mutations have been found in these regions.
There are two alternative transcripts produced by the PAX6 gene by either splicing in
or leaving out exon 5a (Azuma et al., 1999). These two forms differ in the paired
domain region, which consists of two DNA binding subdomains known as the N
terminal subdomain (NTS) and the C terminal subdomain (CTS). With exon 5a
included, there are 14 additional residues in the NTS, removing its binding activity
and allowing the binding activity of the CTS. This introduces an element of target
specificity by the PAX6 proteins. This extra exon is specific to vertebrates and a
mouse null for Pax6 exon 5a displayed iris hypoplasia as well as defects in the
cornea, lens and retina (Singh et al., 2002). This difference from the anopthalmic
phenotype, coupled with CNS abnormalities and subsequent lethality, suggests a
distinct function for this isoform in the development and function of a specific subset
of ocular structures.
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There are many mouse models of eye disease caused by Pax6 mutations such as the
original small eye mutation mentioned earlier. Some of these mutations have been
induced, including small eye Neuherburg (Hill et al., 1991), while others are
spontaneous, such as Dickie's small eye (Theiler et al., 1978). These are all
semidominant mutations and produce broadly similar phenotypes but with variable
severity.
1.5.3 Crystallins
Crystallins were first identified as major components of the lens. They are soluble
proteins that comprise two types of gene product; some crystallins are eye specific in
their expression whilst others are widely expressed but are more abundant in the eye.
As previously mentioned, lens thickness increases throughout life, with cells
proliferating continuously from the anterior lens cells and accumulating at the
periphery, leaving the oldest cells in the centre of the lens (section 1.1.3). Lens
transparency is required for clear vision to allow the passage of light without
scattering and this state must be maintained in the oldest cells as well as in the new.
This is achieved by the destruction of organelles within lens cells and also the highly
regular structure formed by lens proteins, a large proportion of which are crystallins.
The crystallins are soluble proteins that form the major structural components of the
lens and are important in lens transparency. This function is often recruited and a
phenomenon known as gene sharing, when crystallins carry out different functions in
other tissues, is common in the lens (Piatigorsky et al., 1988; Piatigorsky and
Wistow, 1989). In these cases, expression levels in other tissues are much lower than
they are in the lens. The most common functions for crystallins in non-lens tissues
are as chaperone proteins or metabolic enzymes (Wistow and Piatigorsky, 1988; de
Jong et al., 1989).
49
Not all crystallins have had expression detected in other tissues. Two subunits of
alpha crystallin, alpha A crystallin, encoded by CRYAA, and alpha B crystallin,
encoded by CRYAB, are examples of crystallins expressed in a restricted set of
tissues and more widely expressing crystallins. Alpha B crystallin has the more
widespread expression of the two, and is found in many tissues including heart,
kidney, skeletal muscle, retina, lung and brain, as well as lens (Bhat and Nagineni,
1989; Dubin et al., 1989).
Alpha crystallins appear to interact with lens cytoskeletal proteins phakinin and
filensin (Muchowski et ah, 1999). The exact role of alpha crystallins is unknown,
however their function as chaperone proteins in other tissues and their required
presence for correct folding of cytoskeletal proteins has led to hypothesised function
in cytoskeletal assembly (Carter et ah, 1995; Hess et ah, 1998). It is thought that
alpha crystallin selectively binds unfolded or denatured proteins, particularly
prevalent in the ageing central fibres in the lens, to suppress non-specific aggregation
which may follow and disrupt mammalian lens transparency (Wang and Spector,
1994; Boyle and Takemoto, 1994; Rao et ah, 1995; Carver et ah, 1996).
Cataract describes the opacification of the lens and reduces visual acuity and contrast
sensitivity. There are both age-related and congenital forms of cataract. Crystallin
genes are often associated with cataracts in the human population. Mutations in both
alpha A and alpha B crystallin have been discovered in humans with cataract
phenotypes.
Both dominant and recessive forms of cataract have been associated with mutations
in the CRYAA gene. One dominant form has a point mutation within a highly
conserved residue (Litt et ah, 1998). Using transfection studies with lens epithelial
cells, the protein was found to localise to the nucleus, which is abnormal, and these
cells were not protected from apoptosis as control cells were (Mackay et ah, 2003).
The recessive mutation in CRYAA, identified in an inbred Jewish Persian family, was
found to be a nonsense mutation (Pras et ah, 2000).
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The phenotypes associated with CRYAB mutations are more diverse than those with
mutations in CRYAA. The first mutation discovered in CRYAB was associated with
dominant desmin-related myopathy with cataract (Vicart et ah, 1998). Affected
members of the family in which this mutation was found had limb muscle weakness,
cardiomyopathy and cataract. Desmin is a type III intermediate filament protein and
muscle biopsies of family members with this disease displayed aggregates of desmin.
Transfection of muscle cells with this mutant CRYAB is associated with aggregation
of desmin and alpha B crystallin. Another mutation in CRYAB was shown to cause
autosomal dominant posterior pole cataract in a family, with the mutation causing a
frameshift and altering the final 35 residues (Berry et ah, 2001). The authors
speculated that this may occur through an increased tendency for the mutant protein
to aggregate or from a loss of chaperone activity.
Alpha A crystallin knockout mice develop cataract (Brady et ah, 1997). Further
investigation of the lenses of these mice indicate the formation of aggregates
predominantly containing alpha B crystallin but also composed of gamma crystallins.
It is hypothesised that the decrease of soluble gamma crystallin in alpha A crystallin
knockout mice may contribute to the cataract phenotype observed.
1.5.4 Rpgr
Mutations in the RPGR gene cause an eye disease, although the gene is expressed
ubiquitously.
RPGR (retinitis pigmentosa GTPase regulator) was first identified as harbouring loss
of function mutations in patients with RP3 (retinitis pigmentosa 3), an X-linked
disorder (Meindl et ah, 1996). In this study, two intragenic deletions, two nonsense
mutations and three missense mutations were found to be associated with RP3.
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The RPGR protein contains a series of tandem repeats, with eight potential
glycosylation sites and a consensus isoprenylation site at the C terminus, the latter
thought to be a potential region for membrane anchorage (Meindl et al., 1996).
Although RPGR is ubiquitously expressed, there are many alternative splice forms,
some of which are tissue specific, including an eye specific transcript containing
exonl5A that introduces a stop codon and truncates the resulting protein, including
the isoprenylation site (Kirschner et al., 1999). More exons have been discovered
since, including a conserved 3' terminal exon known as ORF15 (Vervoort et al.,
2000) that has since been shown to be mutated in 80% of X-linked retinitis
pigmentosa (XLRP) patients tested in Britain (Vervoort and Wright, 2002). This
exon is preferentially expressed in mouse and bovine retina and encodes 567
additional residues, including a glutamic acid rich repetitive domain. Due to the high
proportion of XLRP cases that can be attributed to this region, it is considered to be a
mutation hotspot.
In a study of 3 unrelated Japanese families with a mutation in ORF15 predicted to
cause truncation of the RPGR protein, affected males displayed RP whilst female
carriers were more varied in the severity of the phenotype (Yokoyama et al., 2001).
Some of these females had RP and most displayed myopia and astigmatism.
Further evidence of a wider range of phenotypes associated with RPGR mutations
was provided in a study describing males in a family where the underlying point
mutation was found in an intron and was thought to create a donor splice site
(Ayyagari et al., 2002). Ten males in this family displayed macular atrophy resulting
in a progressive loss of visual acuity but with only minimal peripheral visual
impairment, with cone and rod responses appearing normal in some of these family
members. However, one male showed more extensive macular degeneration and
peripheral loss of the RPE.
In a study that found 80 mutations in RPGR, 41 were novel (Sharon et al., 2003). Of
the 187 unrelated males with XLRP involved in the study, 66% had a mutation in
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0RF15. Further investigation revealed that the final dark-adapted vision became
lower, thereby being closer to normal, as the length of wild type ORF15 sequence
increased. Additionally, it was shown that the severity of the disease increased as the
abnormal sequence length following mutation in ORF15 increased. The ORF15
mutations were associated with milder forms of XLRP compared to mutations in
exons 1-14.
In RPGR knockout mice, cone opsins were localised incorrectly to the cell body and
synapses of the cone and rods contained a reduced level of rhodopsin (Hong et al.,
2000). Degeneration of rods and cones was observed. RPGR had previously been
localised to the rod OS in cow and human (Roepman et al., 2000) and also to cone
OS in humans (Mavlyutov et al., 2002). In the knockout study, RPGR was found to
normally localise specifically to the connecting cilia of rods and cones. For this
reason, it was hypothesised that RPGR is involved in maintaining the polarised
distribution of protein across the connecting cilium, either by directional transport or
by restricting redistribution.
1.6 Aims
This thesis describes a method to elucidate novel genes that may be influential in the
manifestation of eye diseases. As specific or preferential expression of a gene in a
particular tissue or organ is often indicative of its importance in function or
development, this basis was used to discover such genes. This approach may allow
the discovery of specifically or preferentially expressed genes, such as Rho, Pax6
and Cryaa, but will not be expected to highlight widely or ubiquitously expressed
genes, such as Cryab or Rpgr.
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An in silico approach was employed to produce a set ofpotential candidate genes for
disease relevance. Subsequently, further bioinformatic and in situ analyses were












Swiss-Prot and TrEMBL http://www.ebi.ac.uk/swissprot/
SMART http://smart.embl-heidelberg.de/





BLAST Altschul et al., 1990
ClustalW Thompson et al., 1994
Mega Kumar et al., 2001
VISTA Mayor et al., 2000
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2.2 Manipulation of nucleic acids
2.2.1 Extraction of RNA from tissue
The RNA was extracted from tissue by using RNA-Bee (Tel-Test). The procedure
was carried out according to the provided protocol with the following specifics:
• Following chloroform addition, samples were stored on ice for 5 min.
• Following isopropanol addition, samples were left at room temperature for 10
min.
• Centrifugation steps following isopropanol and 75% ethanol additions to the
sample were carried out at 4°C.
• RNA was resuspended in 25 pi DEPC dHFO.
• The amended protocol for small amounts of tissue was used for extracting RNA
from E14.5, E16.5, neonate and adult eyes and ovary.
2.2.2 DNase treatment of RNA
RNA samples were DNase treated using DNA-free (Ambion) according to protocol
with the following specifics:
• RNA samples were incubated at 95°C for 3 min before placing on ice briefly and
beginning the DNase treatment.
• 2.5 pi of 10 x DNase I buffer was added to the RNA sample.
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• 5 pi of DNase Inactivation Reagent was added to the sample following
incubation at 37°C.
• RNA was removed from the DNase Inactivation Reagent immediately after
centrifugation.
2.2.3 Determining the concentration of RNA
RNA samples were quantified by using the Genequantpro spectrophotometer with
samples diluted 1 in 100.
2.2.4 Primer design
Primers were designed using the Primer3 programme (see section 2.1) using default
settings, with the exception of stipulating an amplification length of 300bp to 350bp.
The following forward and reverse primer sequences were synthesised (MWG
Biotech) and used in the course ofproducing results seen in this thesis:
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2.2.5 Polymerase chain reaction
PCR reaction mixtures were made up for multiple reactions and then aliquoted, with





5 U/|il, Applied Biosystems
lOmMdNTPs 0.5
40 pi each of 25 pmol dA-, dC-, dG- and dTTP, (ABgene) plus 240 pi dH20
100 ng/pl forward primer 0.5
10 pi of lmg/ml synthesised primers in dH20 plus 90 pi dH20
100 ng/pi reverse primer 0.5
10 pi of lmg/ml synthesised primers in dH20 plus 90 pi dH20
MgCl2 1.5
25 mM, Applied Biosystems
10 x buffer 2.5
Applied Biosystems
dH20 18.3
Added 1 pi of template DNA, or dH20 for negative control, to each aliquot of PCR
mix to give a final reaction volume of 25 pi. The following programme was used on
a Peltier Thermal Cycler DNA Engine DYAD unless otherwise stated:








A picked colony was introduced to 20 pi dH20, which was then incubated at 100°C
for 5 min on a Peltier Thermal Cycler DNA Engine DYAD. This colony DNA was
used as the template for colony PCRs.
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2.2.7 Reverse transcription polymerase chain reaction
RT-PCR was carried out in two steps. The following component were mixed on ice
to set up the 20 pi reverse transcription reaction, with the RNA and DEPC dH20
volumes totalling 10.5 pi:
Component Volume (pi)
5 x AMV-RT buffer 4.0
Roche
lOmMdNTPs 2.0
40 pi each of 25 pmol dA-, dC-, dG- and dTTP plus 240 pi DEPC dH20




Reverse transcriptase, AMV 1.0
25 U/pl, Roche
1 pg/pl RNA X,
DEPC dH20 x2
For each of these reactions, another reaction was set up in which the reverse
transcriptase was replaced with an equal volume of DEPC dH20 to allow for a
negative control at the PCR stage. These reactions were all incubated at 42°C for 1 hr
followed by 8 min at 75°C to stop the reaction. PCR reaction mixtures were then
made up for multiple reactions and then aliquoted, with the following amounts of




100 ng/pl forward primer 0.50
100 ng/pl reverse primer 0.50
MgCl2 0.95
10 x buffer 2.00
dH20 13.45
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Each aliquot of PCR mix was added to by 2 pi of reverse transcription reactions as
template DNA, or dH20 for negative control, to give a final reaction volume of 20
pi. The following programme on a Peltier Thermal Cycler DNA Engine DYAD was
used:
2.2.8 Agarose gel electrophoresis and determining the concentration of
DNA
Agarose gels were prepared using the appropriate proportion of agarose ('Hi-Pure'
Low EEO Agarose, Biogene) in 1 x TBE for 0.8%, 1.0% or 1.5% gels as required,
with the following recipe per litre of 20 x TBE (by MRC Human Genetics Unit
technical staff):













TRIS base 216 g
Boric acid 110 g
0.5 M EDTA 80 ml
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The equivalent of 3 jj.1 ethidium bromide (BDH Laboratory Supplies) for every 50 ml
of gel volume was also added. 0.5 pi orange/blue 6 x loading dye (Promega) was
added to each 2.5 pi of nucleic acid to be run, to a maximum of 2 pi for a 10 pi
sample. The markers that were run alongside samples to determine their size were
lOObp DNA Ladder (Promega), lkb DNA Ladder (Invitrogen Life Technologies) or
bacteriophage lambda DNA digested with Hindlll (0.5 mg/ml, GIBCO BRL). The
marker used for determining size and concentration was High DNA Mass Ladder
(Invitrogen Life Technologies). All electrophoresis was carried out in 1 x TBE
buffer.
2.2.9 DNA purification by the QIAquick PCR purification kit
This method was used to purify RT-PCR products prior to ligation into a vector. This
was carried out according to the QIAquick PCR Purification Kit protocol with the
following specifics:
• The first and second centrifugation steps were carried out for 60 sec.
• The volume of Buffer EB used was 30 pi.
• The column was allowed to stand for 1 min before the final centrifugation step.
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2.2.10 DNA Purification by exonuclease I and shrimp alkaline
phosphatase treatment
This method was used to purify colony PCR products prior to sequencing. The
following volumes of components were mixed for each purification:
The samples were then incubated on a Peltier Thermal Cycler DNA Engine DYAD
at 37°C for 15 min, followed by 80°C for 15 min to stop the reaction.
2.2.11 Sequencing
This method was used to sequence colony PCR products. The following volumes of














Big Dye Terminator Cycle Sequencing Ready Reaction Mix 4
Applied Biosystems
Diluting buffer 4
200 mM TRIS pH9.0 + 5 mM MgCl2
3.2 pmol primer 1
diluted according to oligonucleotide length in dH20
The primers used were either for the T7 or the SP6 RNA polymerase promoter and
one of each was carried out for each product, to sequence the product in opposite
directions. Cycle sequencing was then carried out on a Peltier Thermal Cycler DNA
Engine DYAD using the following programme, with the reactions being kept on ice
and placed on the block once it had reached 96°C.
Temperature (°C) Time (min)
96 0.50 I
50 0.25 /
60 4.00 1 24 cycles
Ethanol precipitation was then carried out. Each product was added to 50 pi ethanol
and 2 pi 3M sodium acetate pH5.2 and incubated at room temperature for 1-8 hr.
They were centrifuged for 30 min at 13,000 rpm and the supernatant was
immediately removed. 200 pi of 70% ethanol was added and the products were
centrifuged for 15 min at 13,000 rpm. The supernatant was removed, followed by a
30 sec centrifugation at 13,000 rpm and further extraction of any remaining liquid.
After air-drying at room temperature for approximately 20 min, the samples were




Ligations were carried out according to the pGEM-T Easy Vector System protocol
with the following specifics:
• The volume of PCR product used was 3 pi in each standard reaction.
• No dELO was used in the standard reactions.
• Reactions were either incubated at 4°C overnight or for 1 hr at room temperature.
2.2.13 Transformation
Transformations were carried out according to the Subcloning Efficiency DH5a
Competent Cells protocol with the following specifics:
• Unused cells were replaced immediately at -70°C without using an intermediate
dry ice or ethanol bath stage.
• 2 pi of the DNA ligation was used in each transformation.
• L-broth was used for expression, with the following recipe per litre (by MRC










• L-agar+Amp plates were used for spreading the transformed bacteria, with the










• Each L-agar+Amp plate was spread with 20 pi of a 50 mg/ml solution of X-Gal
in N,N-DMF (Sigma), which was left to soak in for at least 1 hr before spreading
bacteria.
• One 100 pi plate and one 200 pi L-agar+Amp+X-Gal plate were spread for each
transformation.
2.2.14 Midiprepping
Midipreps were carried out according to the QIAGEN Plasmid Midi Protocol in the
QIAGEN Plasmid Purification Handbook with the following specifics:
• The starter culture was 2 ml of L broth, with 1 pg/ml of a 50 mg/ml solution of
ampicillin added, as with all L-broth+Amp media.
• The starter culture was diluted 1 in 500 by adding 50 pi to 25 ml L-broth+Amp
and cultured for 16 hr.
• All centrifugation was carried out in a Sorvall Super T21 centrifuge.
• Before applying to the QIAGEN-tip, the supernatant was filtered through pre-
soaked gauze.
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Ethanol precipitation was carried out to increase the concentration of a DNA sample.
A volume of 3 M sodium acetate pH5.2 equal to one tenth that of the sample was
added, followed by a volume of ice-cold ethanol equal to 2.5 times that of the
sample. This was mixed and kept at -70°C for 15 min. The sample was then
centrifuged for 5 min at 13,000 rpm and the supernatant removed. One ml room
temperature 70% ethanol was added and the sample was inverted. It was centrifuged
for 5 min at 13,000 rpm and the supernatant was removed. The sample was then air-
dried and an appropriate volume of dH20 was added for the required concentration.
2.2.16 Restriction
All restriction enzymes were from Roche or New England Biolabs. Digests were
carried out in a 40 pi volume for confirmation or quantification purposes and a 50 pi
volume to produce DNA for use in synthesising in situ hybridisation riboprobes. The
restriction enzyme was added at a concentration of 1-1.2 U/pl, with all restrictions
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being incubated overnight. Guidelines provided by the manufacturer were followed
to determine the correct buffer and incubation temperature for each enzyme.
2.2.17 Blunt ending
Due to the presence of an Ncol restriction site in the Mm.22913 primer amplified
insert, SacII was used in a plasmid restriction for probe synthesis. This enzyme
leaves a 3' overhang, therefore blunt ending was performed to allow correct probe
synthesis. This was done by adding 4 pi T4 polymerase (Roche) and 5 pi each of
25mM dATP, dCTP, dGTP and dTTP to the plasmid restriction. The DNA was then
incubated at 37°C for 15 min followed by incubation at 75°C for 10 min to stop the
reaction.
2.2.18 Purification Using CHROMA SPIN Columns
Purification using columns was used for restriction reaction products required for
synthesising in situ hybridisation riboprobes and, during the procedure for
synthesising 35S labelled riboprobes, for removal of unincorporated label. CHROMA
SPIN+DEPC H2O columns were used in the form of CHROMA SPIN-100 or
CHROMA SPIN-30. Purification was carried out according to the CHROMA SPIN
Columns User Manual with no alterations.
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2.3 In situ hybridisation techniques
2.3.1 Synthesis of DIG labelled riboprobes for in situ hybridisation
The following volumes of components were mixed for each labelling reaction, with a
total volume of 20 pi and DNA being derived from a column purified linearised
plasmid:
Component Volume (pi)
10 x transcription buffer 2
Roche
10 x DIG labelling mix 2
Roche
1 pg DNA X,





20 U/pl, T7 or SP6 as appropriate, Roche
The labelling reactions were incubated at 37°C for 1 hr after which 1 pi was removed
from each reaction to check by agarose gel electrophoresis, and 1 pi of the
appropriate RNA polymerase was added to each reaction. A further incubation at
37°C for 1 hr was completed and 1 pi of DNase 1(10 U/pl, Roche) was added to
each reaction. The reactions were incubated at 37°C for 15 min before the reaction




200 mM EDTA pH8 2.0
4 M lithium chloride 2.5
Ethanol 75.0
The reactions were stored at -20°C for 30 min, followed by centrifugation for 15 min
at 13,000 rpm. The supernatant was removed and 200 pi 70% ethanol (in DEPC
dH20) was added to each reaction. The reactions were centrifuged for 15 min at
13,000 rpm, the supernatant was removed and the product was resuspended in 40 pi
DEPC dH20.
2.3.2 Synthesis of 35S labelled riboprobes for in situ hybridisation
At least one full reaction was carried out for each antisense riboprobe and a half
reaction was carried out for each sense probe, with precisely half the volume of all
components being used. The following volumes of components were mixed for each
full labelling reaction, with a total volume of 11 pi and with DNA derived from a
column purified linearised plasmid:
Component Volume (pi)
10 x transcription buffer 3.0
10 mM dA,C,GTP 3.0
10 pi each of lOOmM dA-, dC- and dGTP plus 70 pi DEPC dH20
1MDTT 1.0
Melford
1 pg DNA X,




1 M DTT was made up by measuring out 7.7 g for each 50 ml required and making
up to final volume using DEPC dH^O.
10 pi of 35S rUTP (>1 pCi/100 pi, NEN) and 0.8 pi of the appropriate RNA
polymerase, either T7 or SP6 (20 U/pl, Roche), were added to each labelling
reaction. The reactions were incubated at 37°C for 25 min, after which 0.8 pi of the
appropriate RNA polymerase was added to each reaction. The reactions were
incubated at 37°C for another 25 min. One pi of DNase I (lOU/pl, Roche) was added
to each labelling reaction and they were incubated at 37°C for 10 min. The reactions
were stopped by adding 1 pi 200 mM EDTA. Unincorporated label was removed
using CHROMA SPIN-100 columns.
2.3.3 Embryo treatment for wholemount in situ hybridisation
After dissection, embryos required for wholemount in situ hybridisation were stored
in 4% PFA (Sigma) at 4°C overnight and dehydrated using the following washes
with shaking:
Each litre of PBST was made up by including 5 ml 10% Tween 20 (Sigma, made up
























The X value varies according to the embryo stage as follows:





2.3.4 Tissue treatment for paraffin wax embedding and sectioning
After dissection, embryos required for wholemount in situ hybridisation were stored
in 4% PFA at 4°C overnight. The following day, all tissue was dehydrated using the
following washes:






For all embryo stages other than E9.5, the tissue was removed from 50%
ethanol/PBS and stored in 70% ethanol. Further processing was carried out by a
Tissue-tek VIP, with all washes lasting 1 hr with the exception of the variable 70%
ethanol/PBS wash, before embedding in paraffin wax:
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For E9.5 embryos, the following washes were carried out by hand, with all washes
lasting 30 min, before embedding in paraffin wax:













Sectioning was carried out using a Reicheit-Jung Biocut 2030 microtome set at 7 pm,
with sections floated out in a 42°C waterbath before mounting on polysine or
Superfrost Plus slides (BDH Laboratory Supplies). Slides were incubated at 37°C
overnight before storing at room temperature.
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2.3.5 Tissue treatment for OCT embedding and cryostat sectioning
After dissection, all tissues were embedded in OCT (Sakura) immediately by placing
in a mould containing OCT, which was then placed in a weighing boat of isopentane
on dry ice. The samples were stored at -70°C until they were sectioned. A Jung
Frigocut Cryostat was used for sectioning, with the box temperature at -18°C and the
object temperature at -13°C. Ten pm sections were mounted on Superfrost Plus
slides and air dried for a minimum of 30 min before carrying out fixation, a
maximum of 4 hr after sectioning. The following washes were used in the fixation
process:
The slides were stored in 95% ethanol/ DEPC dH20 at 4°C until required.
Embryos for sectioning that had undergone wholemount in situ hybridisation were
washed in PBS, stored in 5% sucrose overnight and washed in PBS immediately















2.3.6 Wholemount in situ hybridisation
Embryos for wholemount in situ hybridisation were pre-treated by taking them
through the following washes:








30% H202 (Sigma) diluted in PBST
Proteinase K X
10 mg/ml stock diluted in PBST to 1 pg/ml
Glycine/PBST 5
Glycine from Sigma, made up to 2 mg/ml in PBST
PBST 10
PBST 10




The X value for proteinase K wash time varies according to the embryo stage as
follows:









Sigma, deionised by stirring with 5 g monobed resin per 2.51 for 4 hr and filtered







Melford Laboratories, 5 g in 50 ml DEPC dH20
0.2 M EDTA pH8.0














One litre of 20 x SSC contained 175.3 g NaCl and 88.24 g Tri-sodium citrate made
up in dH20.
The pre-treated embryos were sunk in 0.5 ml hybridisation mix contained in a 5 ml
cryotube. The hybridisation mix was removed and replaced with fresh mix and the
embryos were incubated at 65°C for 2 hr with shaking. DIG labelled riboprobes were
diluted 1:200 in hybridisation mix and denatured at 80°C for 7.5 min before placing
briefly on ice. Hybridisation mix was completely removed from the cryotubes
containing the embryos and replaced with hybridisation mix containing probe. The
embryos were incubated overnight at 65°C with shaking.
The following post-hybridisation washes were carried out on the embryos at 65°C
with shaking:
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Wash solution Time (min)
Solution A 2
Solution A 5
70% solution A 5
in DEPC dH20
30% solution A 5
2 x SSC/0.1% CHAPS 30
2 x SSC/0.1% CHAPS 30
0.2 x SSC/0.1% CHAPS 30
0.2 x SSC/0.1% CHAPS 30
Solution A was made up with the following volumes of components per 100 ml:
Component Volume (ml)





The following washes were carried out at room temperature with shaking:




10% HISS/TBST block 60
HISS from Diagnostics Scotland













1 M TRIS pH7.5 contained 12.1 g TRIS base (Sigma) in each 100 ml.
The 10% HISS/TBST block was removed from the embryos and replaced with anti-
DIG AP/HISS/TBST, which was made by diluting anti dig antibody (Roche) 1:2000
in 10% HISS/TBST. The embryos were incubated at 4°C overnight.
The following washes were carried out in the substrate reaction:






35 nl BCIP (Roche) and 45 pi NBT (Roche) added to 10 ml NBT
NTMT (alkaline phosphate buffer) was made up in DEPC dH20 with the following















X varied according to the time taken for an expression pattern to develop. The









STOP buffer was made up with 75 ml PBS and 25 ml 0.2 M EDTA for each 100 ml.
Embryos were stored in 4% PFA at 4°C.
2.3.7 Cryosection in situ hybridisations using DIG labelled riboprobes
Cryosection slides were removed from 4°C in 95% ethanol/DEPC dEI20 and the
following washes were carried out:
Wash solution Time (min)
70% ethanol/ DEPC dH20 2
50% ethanol/ DEPC dH20 2




10 mg/ml stock diluted in proteinase K buffer to 500 ng/ml
PBS 2
PBS 2
0.1 M TEA and acetic anhydride 5
625 pi acetic anhydride per 200 ml 0.1 M TEA
0.1 M TEA and acetic anhydride 5
1 x salts 2
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Proteinase K buffer was composed of 25 ml 1 M TRIS pH7.5 and 12.5 ml 0.2 M
EDTA made up in DEPC dH20 for each 500 ml. 0.1 M TEA pH8 was made by using
18.6 g TEA in DEPC dH20 for each litre. The 1 x salts was diluted from a 10 x salts
pH7.5 stock solution containing the following amounts of components:
Component Amount
NaCl 114 g




0.5 M EDTA 100 ml
Hybridisation mix was made up with the following amounts of components per ml:
Component Amount (pi)
Formamide (ultrapure) 500
50% dextran sulphate 200
Sigma, 500 |ig/ml in DEPC H20
50 x Denhardts 20
Sigma, 150 mg in 5 ml DEPC H20
1 M TRIS pH8 20
5 M NaCl 60
0.2 M EDTA 25
0.1 M NaP04 100
BDH Laboratory Supplies
10 pg/ml tRNA 50
DEPC dH20 25
DIG labelled riboprobes were diluted in hybridisation mix 1 in 200 and denatured at
80°C for 5 min. One hundred pi of the relevant hybridisation mix was overlaid on
each slide using Hybrislips (Surgipath). The slides were incubated at 55°C overnight
in a slide box humidified with 50% formamide/salts. After overnight hybridisation,
the following washes were carried out on the slides:
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Each 250 ml of solution A was composed of 12.5ml 20 x SSC, 125 ml formamide
and made up with dEEO before adding 250 pi 10% Tween 20.
The slides were incubated in 10% HISS/TBST at room temperature for more than an
hour followed by overnight incubation at 4°C with anti-DIG-AP in HISS/TBST. This
overnight incubation was carried out by either overlaying the slides with the antibody
using glass coverslips, placing the slides in a container humidified with TBST, or by
submerging the slides in the antibody. The following washes were carried out after
overnight incubation:
The X value varied according to the time taken for an expression pattern to develop.
The slides were washed twice in water and incubated in 4% PFA for a minimum of
20 min and overnight at the most. The slides were then washed twice in water before
staining with filtered Nuclear Fast Red (Vector), washing in water and carrying out
the following washes:















Wash solution Time (min)
30% ethanol/ dH20 0.5
50% ethanol/ dH20 0.5
70% ethanol/ dH20 0.5






The slides were then mounted using Histomount (National Diagnostics).
2.3.8 Wax section in situ hybridisations using 35S labelled riboprobes





100% ethanol 2 min
100% ethanol 2 min
100% ethanol 2 min
90% ethanol/ DEPC dH20 2 min
70% ethanol/ DEPC dH20 2 min
50% ethanol/ DEPC dH20 2 min
30% ethanol/ DEPC dH20 2 min
PBS 2 min
4% PFA 10 min
PBS 2 min
PBS 2 min
Proteinase K 7.5 min
10 mg/ml stock diluted in proteinase K buffer to 500 ng/ml
PBS 1 min
4% PFA 2 min
DEPC dH20 10 sec
0.1 M TEA 30 sec
0.1 M TEA and acetic anhydride 5 min
625 |il acetic anhydride per 200 ml 0.1 M TEA
0.1 M TEA and acetic anhydride 5 min
PBS 2 min
0.85% NaCl 2 min
Sigma
30% ethanol/ DEPC dH20 1 min
50% ethanol/ DEPC dH20 1 min
70% ethanol/ DEPC dH20 1 min
90% ethanol/ DEPC dH20 1 min
100% ethanol 5 min
100% ethanol 5 min
100% ethanol 5 min
Slides were air dried before hybridisation. Hybridisation mix was made up with the























A tenth of the final hybridisation mix consisted of the appropriate volume of probe to
give 7.2 pCi per slide, with DDT in DEPC H2O making up the difference. Probes
were denatured at 80°C for 2 min and 80 pi of the relevant hybridisation mix was
overlaid on each slide using Hybrislips. The slides were incubated at 55°C overnight
in a slide box humidified with 50% formamide/5 x SSC. After overnight
hybridisation, the following washes were carried out on the slides:
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Wash solution Time Temperature
5 x SSC 20 sec 55°C
5 x SSC/DTT 10 min 55°C
2.5 ml 1 M DTT and 62.5 ml 20 x SSC in 250 ml H20
High stringency wash 30 min 65°C
NTE 10 min 37°C
NTE 10 min 37°C
NTE 10 min 37°C
NTE/RNase A 30 min 37°C
1 ml of 10 mg/ml RNase A per 600 ml NTE
NTE 5 min 37°C
NTE 10 min 37°C
2 x SSC 15 min room temperature
2 x SSC 15 min room temperature
2 x SSC 15 min room temperature
2x SSC 15 min room temperature
0.1 x SSC 15 min room temperature
0.1 x SSC 15 min room temperature
0.1 x SSC 15 min room temperature
0.1 x SSC 15 min room temperature
30% ethanol and 3 M NH4OAC 1 min room temperature
200 ml ethanol mix and 20 ml NH4OAc
50% ethanol and 3 M NH4OAc 1 min room temperature
70% ethanol and 3 M NH4OAc 1 min room temperature
90% ethanol and 3 M NH4OAc 1 min room temperature
100% ethanol 5 min room temperature
100% ethanol 5 min room temperature
Slides were air dried and left on film (Kodak) for a week before developing the film
and dipping the slides in K5 emulsion (Ilford) under safe light conditions. Emulsion
was incubated at 42°C for 14 min before diluting in an equal volume of 1% glycerol
and incubating at 42°C for a further 2 min. The slides were then dipped and left to
dry in light tight containers overnight before boxing them and storing at 4°C for 4-10
weeks until ready to be developed. The slides were left at room temperature for at



















The slides were then counterstained with 1% methyl green and mounted using DePex
(BDH Laboratory Supplies).
2.4 Microscopy
Embryo imaging was performed with a Leica Stereo MZFLIII stereo fluorescence
microscope (Leica Microsystems) fitted with a fibre optic cold light source and
illuminated base for incident/transmission illumination. Image acquisition was with
a Photometries CoolSnap colour CCD camera (Roper Scientific) controlled by
scripts written for IPLab Spectrum (Scanalytics Inc).
Section imaging was performed with Zeiss Axioplan II fluorescence microscope
(Carl Zeiss Ltd) equipped with colour additive filters (Andover Corp) for sequential
colour imaging and a Photometries CoolSnap HQ monochrome CCD camera (Roper
Scientific). Image capture was by scripts written for IPLab Spectrum (Scanalytics
Inc) which controlled camera capture and filter selection via motorised filter wheels





The availability of publicly accessible data sets and bioinformatic tools for their
manipulation have made gene discovery a faster and easier process than was
previously possible. Differential expression analysis is a useful method to elucidate
genes that have an important input in the development or function of an organ, tissue
or cell type of interest. In this thesis, an in silico differential display approach was
taken to facilitate the discovery of novel genes that have enriched expression in the
eye compared with other organs and tissues. To this end, the UniGene database was
used with the accompanying programme Digital Differential Display (DDD).
UniGene is a database that contains sequences from a variety of species including
human and mouse (Boguski and Schuler, 1995). The majority of these sequences are
ESTs deposited in dbEST and deriving from specified cDNA libraries. In an effort to
reduce redundancy in the raw data set and allow its use to be effective, the ESTs
from a species are clustered, with the clusters representing putative genes and, in
some cases, known genes. The first step in the build procedure screens the ESTs and
ensures removal of repetitive, low complexity and contaminant sequences,
subsequently removing those less than lOObp in length. The set of mRNA sequences
from GenBank is clustered before creating initial links with ESTs. The links joining
mRNA clusters to each other are severed and the EST clusters are built up as
similarities between them are found. Clone-based edges are then used to cluster non-
overlapping 5' and 3' ESTs together, with stringency provided by the necessity of at
least two 5' ESTs from one cluster with at least two 3' clusters from the other before
they are merged. At this stage unanchored clusters, that is those without a sequence
containing a polyadenylation signal or tail, are eliminated. Unclustered ESTs are then
rechecked for similarity at a lower stringency than before and those meeting the
requirements are joined to the relevant cluster. A similar process is applied to
clusters with one EST, with comparisons being made with other clusters at lower
stringency than previously and mergers taking place if appropriate. Every new build
is compared with the last to provide continuity in annotation. Each cluster is given an
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identifier, although these are not permanent, as clusters and the sequences within
them can be removed or added to as more sequences are entered into UniGene.
(Pontius et al., 2003)
DDD (http://www.ncbi.nlm.nih.gov/UniGene/info_ddd.shtml) is able to measure the
number of sequences from a cluster that appear in a defined set of libraries. The
libraries available for use in DDD analysis are those with over 1,000 sequences in
UniGene, which provides a high enough number for statistical significance to be
shown for the frequency of gene representation. Within DDD, pools of two or more
libraries can be constructed by the user from these available libraries. For each
cluster within UniGene, the number of ESTs that have derived from each pool of
libraries is represented as a proportion of the total number of ESTs deriving from that
pool. The output of DDD consists of clusters with a statistically significant difference
between the EST representations of the two pools. It can therefore be utilised as a
resource for the identification of genes that may contribute to the identity of a
specific cell type, tissue or organ. (Pontius et al., 2003)
DDD was used in preference to utilising the search for tissue specific transcripts
available at TIGR (http://www.tigr.org/tdb/tgi/) to mine their Gene Index databases.
The Gene Index databases have similar content to the UniGene databases in that
there are clusters of ESTs, known as tentative consensuses (TCs) at TIGR. As
suggested by the name, these clusters are unlike those at UniGene, as the ESTs
within them must be overlapping by over 40 bases and have at least 95% percentage
identity in these regions. This implies a greater degree of redundancy in the Gene
Index databases than in UniGene, therefore UniGene will give a greater accuracy
with respect to clusters directly representing a gene (Schuler, 1997; Bouck et al.,
1999).
In this thesis, the DDD procedure was used multiple times. The initial DDD was
carried out on mouse build 82. The second DDD produced the results that formed the
basis for further experimental investigation and utilised mouse build 100. The third
and final DDD to be carried out on the mouse UniGene set was on build 120 and
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illustrates the current situation of UniGene. Human build 160 was used for a DDD to
allow comparison with the results derived from mouse and confirmation of the
preferential expression shown of mouse clusters by analysing their human
orthologues. Finally, a rat DDD on build 119 was carried out. This was also an
attempt to confirm preferential eye expression in orthologues of mouse clusters, but
instead demonstrated the effects of bias in tissue composition of pool libraries. As
well as analysing the output of DDD at the time of initiation, analysis has also been
carried out on the results in the light of current available information on the relevant
clusters in order to gain a more complete and accurate analysis. This serves to
highlight the shifting nature of the UniGene databases.
3.2 Mouse Digital Differential Display: build 82
3.2.1 Composition of mouse build 82
The first DDD was performed in October 2000 on mouse build 82. The sequence
composition of this build is shown (Table 3.1). The majority of sequences are 3'
ESTs (68%), with 5' ESTs making up most of the remaining total (29%).
Unclassified ESTs and mRNAs plus coding sequences are a minor contribution to
the build in numerical terms (2% and 1% respectively).
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Sequence type Number of sequences
Mm 82 Mm 100 Mm 120 Hs 160 Rn 119
mRNAs + gene CDSs 17,508 38,576 47,518 106,900 13,685
HTC - - 53,905 7,500 5
EST, 3' reads 980,395 1,254,576 1,575,035 1,451,825 261,813
EST, 5' reads 422,268 832,797 1,542,711 1,886,373 145,550
EST, other/unknown 26,806 104,901 223,213 682,624 5,059
Table 3.1 The sequence composition of builds used in DDD
The build organism and number are indicated. Mm, Mus musculus; Hs, Homo sapiens] Rn,
Rattus norvegicus] CDS, coding sequence; HTC, high-throughput cDNA.
There were 72,651 clusters in mouse build 82, with 6,979 (10%) containing at least
one known gene sequence, 71,954 (99%) including at least one EST and 6,282 (9%)
incorporating both types of sequence. The size of clusters ranges from one to more
than 4,097 sequences and the distribution of these is shown (Figure 3.1). There are
33,941 (47%) clusters in the build that can be described as singletons, in that they
consist of a single sequence. The remaining clusters take on a general trend of
decreasing frequency with increasing cluster size, with the exception of the 3-4
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3.2.2 Library pool construction for DDD on mouse build 82
DDD required the construction of two pools of libraries. The first was designated the
eye pool, containing the six available eye derived libraries (E9.5 optic vesicle; El 1.5
optic cup; E12 eyeball; neonate eyeball; adult eyeball; adult retina) and consisting of
26,029 EST sequences in total. The second target pool comprised all other available
libraries produced from normal tissues (those that are not cancerous or diseased) and
organs, thereby excluding cell lines, but also omitting those libraries that would
possess eye ESTs such as head and whole embryo libraries. This pool encompassed
222 libraries with 1,129,506 ESTs.
3.2.3 Original results analysis for DDD on mouse build 82
As DDD output consists of clusters with statistically significant differences, the
results included clusters with higher representation in the target pool than the eye
pool, that is, clusters that have lower expression in the eye than in other tissues and
organs. These were removed to give a set of clusters in which the EST composition
was significantly higher in the eye pool than in the target pool. The resulting clusters
were divided into known and unknown subsets, with the clusters containing a known
gene sequence, and thus being assigned that gene name, and the unknown subsets of
clusters representing putative novel genes. In order to gain an indication of the
proportion of false positives in the unknown set of clusters, the known clusters were
divided into those that are eye relevant and those that have unknown eye relevance.
Eye relevance was established by the presence of eye phenotypes incurred through
induced or existing mutations in the gene, previous evidence of elevated
representation of the gene in the eye by in situ expression analysis, a specific defined
function of the gene within the eye or a combination of these factors. A diagram
94
representing the results of this analysis is shown (Figure 3.2). There are 107 (65%)
clusters out of the total 165 that are unknown and may represent novel genes with
eye specific or eye enriched expression. Of the remaining 58 known clusters, 33
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3.2.4 Retrospective results analysis for DDD on mouse build 82
The current mouse build (120) was used to look at the results retrospectively, as
some unknown clusters may have subsequently been characterised. Alternatively,
unknown clusters may have been retired, with the majority of their sequences joining
those in a different cluster. Of the 107 unknown clusters from the first analysis, only
36 clusters remain unretired and unknown. Of the rest, 18 are now known, with six
of these being eye relevant. The remaining 53 clusters have been retired, with 22
disappearing completely and the other 31 adopted by other clusters. Six of these new
clusters are eye relevant, 10 are not known to be eye relevant and 15 are unknown.
Incorporating these changes, the new analysis of the results is shown (Figure 3.3).
The proportion of known genes is now higher at 64%. Of these, 45 (31% of the total;
49% of known) clusters are eye relevant. The number of eye relevant clusters and
their percentage of the total have increased from the original analysis, however the
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3.3 Mouse Digital Differential Display: build 100
3.3.1 Composition of mouse build 100
The second DDD was carried out in January 2002 on mouse build 100. The sequence
composition of this build is shown (Table 3.1). As in mouse build 82, the majority of
sequences are 3' ESTs (56%), with 5' ESTs remaining the second most represented
type of sequence (37%). The increase in percentage from mouse build 82 in number
of sequences is greatest for unclassified ESTs (from 2% to 5%), followed by mRNA
and coding sequences (from 1% and 2%), the two categories with the smallest
contributions to the total number of sequences.
The sequences in mouse build 100 were assembled into 85,049 clusters, with 16,994
(20%) including at least one gene sequence, 83,640 (98%) containing at least one
EST sequence and 15,585 (18%) clusters comprising both. The size of clusters
ranged from one to more than 8,193 sequences and the distribution of these is shown
(Figure 3.4). In this build, 35,935 (40%) clusters are singletons, which is a decrease
in percentage even though it is an increase in the number of clusters. As with build
82, the remaining clusters take on a general trend of decreasing frequency with
increasing cluster size, although there is more deviation from this pattern than there
was in build 82.
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3.3.2 Library pool construction for DDD on mouse build 100
The eye pool for the DDD on mouse build 100 consisted of seven libraries (El2
eyeball; E13.5 retina; E14.5 retina; neonate eyeball; adult eyeball; two adult retina)
containing 47,590 ESTs. The target pool encompassed 174 libraries with 1,433,821
ESTs.
3.3.3 Original results analysis for DDD on mouse build 100
The results were analysed in the same way as for the DDD on mouse build 82 and
this is shown (Figure 3.5). Of the 292 clusters with significantly higher
representation in the eye pool than in the target pool, 154 (53%) clusters are known,
which is higher than the 58 (35%) clusters from the mouse build 82 DDD results.
The ratio of eye relevant genes to genes with unknown eye relevance is
approximately equal, with the percentage of the total (25% and 28% respectively)
and the number of clusters (74 and 80 respectively) higher than in the previous DDD
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3.3.4 Retrospective results analysis for DDD on mouse build 100
New knowledge was applied to the results from mouse build 120, as was done with
those from mouse build 82. Of the 138 unknown clusters, 61 are now known, with 10
of these having eye relevance. Thirty-seven of the 138 unknown clusters were
retired, with just one being entirely removed and 36 being adopted by other clusters.
Of these 36, half are unknown and six of the 18 known clusters are eye relevant. The
new analysis is shown (Figure 3.6). As with the earlier DDD, the percentage of
known genes has increased since the previous used build, this time from 53% to
67%. The ratio of genes that are not known to be relevant to those that are is higher
in the new than in the original analysis, with just 30% of the total being eye relevant
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3.4 Mouse Digital Differential Display: build 120
3.4.1 Composition of mouse build 120
The third and final mouse DDD was carried out on mouse build 120 in April 2003.
The sequence composition of this build is shown (Table 3.1). Since mouse build 100,
there has been an introduction of high-throughput cDNA sequences (HTCs). These
sequences are longer than ESTs but may include UTRs and introns (Benson et al.,
2003). The vast majority of sequences in mouse build 120 are either 5' or 3' ESTs,
with these two types have an almost equal contribution (45% and 46% respectively)
in contrast to the domination by 3' ESTs in the previous mouse builds. Unclassified
ESTs provide a greater proportion (6%) than in the preceding builds, with the
minority classes of mRNA and HTCs (1% and 2% respectively) making up the
difference.
There are 90,444 clusters in this build, 16,177 (18%) with at least one mRNA
sequence, 30,021 (33%) containing at least one HTC sequence, 89,165 (99%)
including at least one EST and 15,063 (17%) incorporating both mRNA and EST
sequences. The size of clusters ranged from one to more than 8,193 sequences. The
cluster distribution amongst size classes is shown (Figure 3.7). The only classes with
a lower frequency than in build 100 are the singletons (28,139; 31%) and the 33 to 64
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3.4.2 Library pool construction for DDD on mouse build 120
The eye pool constructed for the DDD on mouse build 120 consisted of seven
libraries (El2 eyeball; E15, 16, 17, 18 eye; neonate eyeball; adult eyeball; neural
retina; two adult retina) with 78,722 ESTs in total. The target pool comprised 201
libraries containing 1,603,455 ESTs.
3.4.3 Results analysis for DDD on mouse build 120
The DDD results were analysed in the same manner as those of the previous two
mouse DDDs, the outcome of which is shown (Figure 3.8). There are a greater
number of clusters with significantly more representation in the eye pool than in the
previous two DDDs and this has led to a larger number of both known and unknown
clusters. The percentage of genes that are known (58%) is lower than the
retrospective analyses of the previous DDDs (64% and 67%). The percentages of eye
relevant clusters and clusters with no evidence of eye relevancy are both 29%, with
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3.5 Human Digital Differential Display: build 160
3.5.1 Composition of human build 160
The human DDD was executed on human build 160 in April 2003. The numbers of
sequence types contributing to this build is shown (Table 3.1). Unlike the situation in
the mouse, where 3' ESTs were either the dominant class or equally represented with
5' ESTs (mouse build 120), the largest class of sequence in the human build is 5'
EST reads (46%). Three prime ESTs still comprise a significant proportion of the
total (35%). There is a larger percentage of unclassified ESTs in the human build
(17%) than in mouse build 120 (6%).
The number of clusters present in human build 160 is 111,064, with 27,887 (25%)
possessing at least one mRNA sequence, 5,999 (5%) including at least one HTC
sequence, 109,660 (99%) containing at least one EST and 26,547 (24%)
incorporating both mRNAs and ESTs. Cluster size ranges from one to more than
16,385 sequences. The distribution of clusters amongst size classes is shown (Figure
3.9). As with the mouse builds, a lower number of clusters fall into the larger cluster
size categories, although classes 65-128 and 129-256 seem to have more occurrences
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3.5.2 Library pool construction for DDD on human build 160
The eye pool constructed for the human DDD comprised 26 libraries (iris; retinal
pigment epithelium (RPE); two foveal and macular retina; two foetal eye and adult
lens, eye anterior segment, optic nerve, retina, foveal and macular retina, RPE and
choroid; two eye anterior segment; two optic nerve; three lens; three RPE and
choroid; four foetal eye; six retina) containing a total of 105,143 ESTs. The target
pool consisted of 120 libraries, with 713,026 ESTs, chosen in the same way as the
mouse target libraries.
3.5.3 Results analysis of human build 160 DDD
Analysis of the DDD results is shown (Figure 3.10). The total number of clusters
showing preferential expression in the eye pool compared to the target pool was 299,
with 197 (66%) known. This is similar to the proportion in the first two mouse
builds, after applying new knowledge from the current mouse build, but more than
the proportion from the results from the current mouse build itself. The major
difference between human and mouse in terms of these categories is the lower
proportion of eye relevant clusters (27%) to those clusters that have not been found














Figure3.10Clustercompositionfhu anUniGenb ild16DDDresults Thetotalnumberfcl st rswi hsignificantlymorexpressionithypoolwa299.Tnumbcl ste sis wntboand percentageofthtalf reachcat goryisgiv nunderneath.Knowlust rsath sig edw hg nnam .Eyrele a tcl ersrt thathavebeenpreviouslyreport dsp c ficyex r ssionofuncti .
\
3.5.4 Comparison of known genes from human and mouse build DODs
A table listing the known genes that have significantly greater expression in eye than
in non-eye pools is provided (Appendix A). Their gene symbol and name are given
according to the accepted nomenclature, verified by MGI or HGNC, with the
exception of a few cases where this information could not be found. Their eye
relevance and their build identity, that is which build or builds they appeared in, are
also indicated. In some cases, the genes have been recorded as having two
occurrences in a particular build or one occurrence in a build and another in the new
analysis of a build. In these cases, the gene has been represented by more than one
cluster in that build. These clusters will have subsequently merged.
Of the total 414 genes, 145 (35%) are eye relevant, 268 are not known to be eye
relevant and one gene (mouse Osbp2 or human OSBP2) is eye relevant in the mouse
but not known to be in humans. It was removed from further comparisons between
eye relevant genes and those with unknown eye relevance, as it is unique in falling in
both classes.
To further elucidate any patterns in build identity that may be related to finding
genes that are preferentially expressed in the eye and have an eye relevant function,
the orthologous clusters were analysed in isolation. Of the 68 genes that are
orthologous, 49 (72%) are eye relevant, 18 (26%) have unknown eye relevance and
the remaining gene is Osbp2 or OSBP2, the gene that is relevant in mouse but not
known to be in human.
It is possible that the effectiveness of DDD producing eye relevant genes differs from
build to build or between mouse and human. In order to assess this, the proportions
of eye relevant genes and those with unknown eye relevance amongst the known set
have been compared between builds, both for the full set and also for the orthologous
subset, using histograms (Figure 3.11). There appears to be no significant difference
in proportion of eye relevant genes across the mouse builds in the full set of known
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genes, although the human percentage appears to be slightly lower. Amongst the
orthologous genes, there is a lower percentage of eye relevant genes in the mouse
build 82 DDD results compared to other builds, although the number of genes
deriving from this build are low and this is unlikely to be significant. Disregarding
this build, the histograms confirm that a higher percentage of the orthologous genes
are eye relevant compared with that of the full set ofknown genes.
The eye relevant orthologous genes in the list encompass different types of gene
products, such as structural proteins (crystallins), enzymes (phosphodiesterases) and
transcription factors (Rax; retina and anterior neural fold homeobox). There are eye
relevant orthologous genes that have a paralogue in the results that is also eye
relevant, for example there are many paralogous crystallin genes. However, there are
also a few crystallin genes, structural lens proteins, that do not have orthologues in
the DDD results such as Cryge and CRYAB, which are present in the mouse and
human results respectively, but not vice versa. In addition, there are examples in the
results of eye relevant orthologues having paralogues that are not known to be eye
relevant. For example, Fscnl and FSCN1, actin bundling proteins, are eye relevant
while the mouse paralogue in the results, Fscn2, is not known to have any eye
relevance. Conversely, there are orthologous genes with unknown eye relevance in
the results, such as Gnb3 and GNB3, signal transducer subunits, that have eye
relevant paralogues, in this case Gnbl. Eno2 and EN02, genes encoding enzymes
involved in glycolysis, are examples of orthologues with no known eye relevance in
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Figure 3.11 Proportions of eye relevant genes amongst subsets of known DDD genes
The percentages of eye relevant genes (blue) amongst all known DDD clusters are approximately
equal across all mouse builds, with a slightly lower proportion in the human build (a). Amongst
orthologous genes found in both mouse and human DDD clusters, mouse build 82 has a lower
percentage of eye relevant genes, although the number of clusters in this category are low (b). A
larger percentage of orthologous genes are eye relevant than in the entire known gene set.
3.6 Rat Digital Differential Display: build 119
3.6.1 Composition of rat build 119
The only rat DDD completed was based on rat build 119 in June 2003. The numbers
of sequence types contributing to this build is shown (Table 3.1). Unlike the recent
mouse and human builds, the majority of sequences in the rat build are 3' ESTs
(62%), with the 5' ESTs the second most prevalent sequence type (34%) and the
other types of sequence making up the remaining 4%. This is similar to the sequence
composition seen in the earlier mouse builds (82 and 100).
There are 54,012 clusters in the rat build, lower than the number in the mouse build
(90,444). This is probably a consequence of reduced saturation of the rat
transcriptome than of the mouse in the respective UniGene builds. Of the total
number of clusters, 5,424 (10%) contain at least one mRNA, with a much lower
proportion of the rat build clusters (less than 0.01%) than the recent mouse and
human build clusters containing at least one HTC. There were 53,395 (99%) clusters
with at least one EST and 4,807 (9%) clusters containing mRNAs and ESTs. These
proportions are the same as those seen in the first mouse build (82). Rat cluster sizes
range from one to more than 2,049 and their distribution amongst size classes is
shown (Figure 3.12). As with mouse and human build compositions, a decrease in
the number of clusters corresponds with an increase in their size, with singletons
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3.6.2 Library pool construction for DDD on rat build 119
There were two eye libraries available for the eye pool in the DDD analysis, both
corneal, containing 2,512 ESTs between them. The target pool comprised 17 libraries
with 67,587 ESTs.
3.5.3 Results analysis of rat build 119 DDD
The analysis of the rat DDD results is shown (Figure 3.13). Of the 46 clusters that
were represented significantly more in the eye pool than the target pool, 26 (57%)
were known genes. However, there are no eye relevant genes amongst the known
genes. A list of these known genes is provided (Appendix B).
None of these genes have orthologues in either the mouse or human build DDD
results. Many of the genes are related to the protective (C3; complement component
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3.7 Producing a set of clusters for further study
The results derived from the mouse build 100 DDD were used as a basis for
subsequent investigation. There were 138 unknown clusters produced from the DDD
results of this build, each potentially representing a novel gene expressed
preferentially in the eye. There was a necessity to refine and reduce the number of
clusters to consider by discarding clusters that may not have represented real genes
and improve the likelihood that these clusters would be specifically or preferentially
expressed in the eye. In lieu of this, only clusters meeting certain criteria were
studied further. The first three of the following four criteria were based on the
profiles of known eye relevant genes in the mouse build 100 results:
1. Clusters have a six-fold difference between eye pool and target pool
representation.
2. Clusters have a maximum of 0.006% representation in the target pool.
3. Clusters have a minimum of 0.01% representation in the eye pool.
4. Clusters contain a sequence annotated as full-length.
Of the 138 unknown genes, only 31 clusters met all four criteria and were therefore
used for further study. These clusters are summarised (Table 3.2), with their current
UniGene identifier, their representative sequence, which allows tracking of cluster
sequences should the cluster itself be retired, and a brief description based on
information discovered by carrying out BLAST on mouse Ensembl. These clusters
encompass a range of gene types, with possible transcription factors, structural
proteins, enzymes and signalling proteins. Through this process, three of these
clusters were determined as known genes (Mm. 134516, Otx2\ Mm.89477, Crygf,
Mm.95707, Aipll). These were subsequently confirmed by UniGene, with a further
seven clusters discovered as known genes (Mm.121647, Rdhl2\ Mm.44683, Gabt4;
Mm.29145, D15Ertd806e; Mm.29846, Ndr4; Mm.34901, Grtpl; Mm.37819,
D5Bwg0860e\ Mm.59151, Gucalb).
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UniGene Current Representative Description
cluster identifier sequence
Mm.103712 Mm.103712 AK014383 coils
Mm.121647 Mm.121647 BC016204 Rdh12
Mm. 134224 Mm. 134224 AK020935 -
Mm.134516 Mm. 134516 BC017609 Otx2
Mm.137178 Mm.44683 AK021402 Gabt4
Mm. 150838 Mm.150838 AK021382 -
Mm.151918 Mm.151918 AK018494 MCM domain
Mm.159861 Mm.159861 AK020813 -
Mm. 195923 Mm.89477 AK013953 Crygf
Mm.200734 Mm.29145 AK004048 D15Ertd806e
Mm.213208 Mm.213208 BC017153 bipartite nuclear localisation signal; thioredoxin domain 2
Mm.21485 Mm.21485 BC017540 nucleosome assembly protein domain
Mm.22913 Mm.22913 AK007745 -
Mm.23434 Mm.23434 AK005271 -
Mm.2965 Mm.218574 AK018181 -
Mm.29846 Mm.29846 BC006595 Ndr4
Mm.3124 Mm.3124 BC009660 protein kinase binding
Mm.34901 Mm.34901 AK017197 Grtpl
Mm.35511 Mm.35511 AK013554 homeobox and transmembrane domains
Mm.37819 Mm.37819 AK018184 D5Bwg0860e
Mm.38347 Mm.38347 AK005160 BTB/POZ domain
Mm.44242 Mm.44242 AK009408 related to prosaposin
Mm.44292 Mm.44292 AK019578 RNA recognition motif/pre-mRNA splicing
Mm.56565 Mm.268718 AK017115 Zn finger, C2H2 type; KRAB box
Mm.59151 Mm.59151 BC018258 Gucalb
Mm.62589 Mm.62589 AK016342 -
Mm.78118 Mm.78118 AK014852 beta-galactosidase/lactase
Mm.82341 Mm.82341 AK014271 rhodopsin-like GPCR/bipartite nuclear localisation signal
Mm.87130 Mm.87130 AK019549 immunoglobulin and bactericidal permeability motifs
Mm.95707 Mm.95707 AF296412 Aipll
Mm.95741 Mm.95741 AK020807 -
Table 3.2 The set of 31 clusters for further study
The cluster identifier and the representative sequence given at the time of mouse build 100
are shown along with a brief description based on Ensembl BLAST.
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3.8 Discussion
The ultimate aim for the UniGene database is to produce a set of clusters that
represent the transcriptome of a particular organism. The most recent mouse
UniGene build (120) has a total of over 90,000 clusters and the human equivalent
(build 160) has over 111,000 clusters. These are well over twice the number of the
current estimates of protein-coding genes, which range between 22,000 and 30,000
in mouse (Marra et al., 1999; Waterston et al., 2002) and between 23,000 and 40,000
in human (Lander et al., 2001; Venter et al., 2001; Waterston et al., 2002). The
estimate for total number of genes, including those not translated, is of course much
greater than that for protein-coding genes, and in mouse is estimated to be
approximately 63,000 (Carninci et al., 2003). This is still well below the 90,000
clusters in the current UniGene build. Although the sequences are screened for
contaminants before build construction, it is probable that many are not removed, as
evidenced by the removal of many sequences from UniGene builds over time.
However, this cannot be the only cause of the discrepancy between Carninci et al's
estimate and the number of clusters in UniGene. Another factor is redundancy, which
may be a true redundancy, where more than one cluster represents the same
transcript, or it may be that multiple clusters represent the same gene, but each one
has sequences that define separate alternative gene transcripts. As part of Lander et
al's human genome sequence publication, it was declared that for each human gene
on chromosome 22, an average of 2.6 splice variants were detected and for
chromosome 19 this average was 3.2 (Lander et al., 2001). With 70% of splice
variants predicted to affect coding sequence (Lander et al., 2001) and 40% of human
genes being alternatively spliced (Brett et al., 2000), this may have an effect in the
UniGene builds in terms of number, as well as on the complexity of the species'
proteomes.
The high number of singleton clusters in the UniGene build may be another
indication that there is a high level of redundancy in both the mouse and human
builds. The alternatives are a low saturation of gene representation by ESTs or that
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singleton sequences may be genomic contamination. The number of singletons alone
exceeds current gene number estimates in both the mouse and human, making low
saturation of the transcriptome unlikely to be a major factor. The percentage of
singleton clusters has decreased from build to build, from 47% in mouse build 82 to
40% in mouse build 100 and finally 31% in build 120, similar to the 36% of
singletons in the human build. The decrease from build 100 to 120 is accompanied
by a decrease in the actual number of singleton clusters, even though the total
number of clusters has increased. This decrease in singletons could be symptomatic
of a decrease in redundancy or a more effective removal of contaminating sequences.
However, as the proportion of singletons in the builds is, at its lowest, over a third of
the total, the implication is that many singletons represent real mRNAs. Estimates of
polyadenylation signal frequency in a recent large-scale sequencing project indicated
that, in their data, this proportion was a half (Carninci et al., 2003). As the clusters
chosen from DDD results for further analysis were full length, this effect should not
influence this subset.
The number of clusters showing significantly different levels of expression between
the eye and target pools has increased from the earlier to the later mouse builds,
probably due to an increase in the total number of clusters from build to build. When
applying current build knowledge to all mouse builds, the proportion of known genes
is higher than the unknown genes. This was not true of the original analysis of the
build 82 DDD results, but a number of clusters have been removed since, presumably
due to contaminating sequences. An additional factor is gene discovery, with the
number, as well as the proportion, of known genes increasing. The proportion of eye
relevant genes is consistently between 29% and 31% when applying new knowledge
to all mouse builds. However, the proportion of genes that are not eye relevant lies
between 29% and 37% which is higher than the eye relevant proportion in the first
two builds but equal to the recent mouse build. The proportion of known genes from
DDD results that are eye relevant, given the current knowledge of the genes
involved, is between 45% and 50%. If this is applied to the mouse build 100 DDD
unknown genes, 72 to 80 of the 159 clusters will be eye relevant genes. However,
this is likely to be an overestimate of the true number. There will be clusters in the
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DDD results containing ESTs not representative of a true mouse gene, either due to
genomic DNA or the products of illegitimate transcription, for example, promoter
activity from Alu sequences, which remain untranslated. In addition, redundancy is
more likely to occur in the unknown cluster set as there are clusters without full-
length sequences and, as a consequence, a greater chance that ESTs deriving from
the same transcriptional unit will not be clustered.
For the human build DDD results, the proportion of eye relevant genes in the known
gene set is slightly lower than those in the recent mouse build DDDs, but there is also
a lower number of clusters (80 compared to 110 clusters in the recent mouse build
120 DDD results). This may reflect a difference in the libraries available for use in
the mouse and human DDDs. It is also possible that this may relate to the differences
in the way these two organisms are studied rather than an intrinsic difference in the
phenotypic consequences between the two genomes. A large proportion of mouse
phenotypes derive from induced mutation and can be studied more invasively and in
larger numbers. However, since human mutations are existing rather than induced,
they are present in smaller numbers and the phenotypes are not as fully described and
studied as those of mice.
The presence of orthologous genes, found in the mouse and human DDD results,
gives greater confidence in the eye relevancy of that gene, shown by the higher
proportion of eye relevant genes amongst the orthologues than across the whole list.
However, this still leaves 19 genes that are not known to be eye relevant in the
mouse but have orthologues amongst the human results. This may be part of the error
in the DDD process, or these may be genes that have an as yet undiscovered eye
relevant function. The same is true for the paralogues that are present in the DDD
results.
One of the orthologues that is not known to be eye relevant in the mouse is Osbp2
(oxysterol binding protein 2) and is unique amongst the orthologues in having a
splice variant with reported high and specific expression in human retina (Moreira et
al., 2001), but no known eye relevant role in mice. This difference could either be
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due to a real difference between mouse and human in gene expression, or it may be
an indication that the eye expression of Osbp2 has not yet been revealed in mice. The
latter is likely to be true, since mouse studies have commented on the possible eye
relevant role of Osbp2 (Anniss et al., 2002), but have not as yet demonstrated a link.
The genes deriving from DDD have been described as eye relevant or not known to
be eye relevant. It is almost impossible to declare any gene to be known not to have a
particular function, as new functions for genes are being continuously described, thus
the known functions of a gene cannot be presumed to be the only ones. It is therefore
possible that some of the genes not known to be eye relevant may have an
undescribed optic function. This is more likely when orthologous genes have been
produced in the results. The orthologous genes Gnb3 and GNB3 (guanine nucleotide
binding protein, beta 3), as well as Gnb5 and GNB5 (guanine nucleotide binding
protein 5), are not known to be eye relevant. However, their paralogue Gnbl
(guanine nucleotide binding protein, beta 1), also identified by DDD, has an eye
specific function as part of the beta subunit of retinal transducin (Danciger et ah,
1990). Gnb3 and GNB3 form the beta subunit of transducins, however GNB3 has
been found to be ubiquitously expressed (Levine et ah, 1990). Gnb5 is
predominantly expressed in brain (Watson et ah, 1994) while GNB5 is expressed in
brain, pancreas, kidney and heart (Jones et ah, 1998). Another pair of orthologous
genes in the results that are not known to be eye relevant are Eno2 and EN02
(enolase 2, gamma neuronal), with their non-relevant paralogue, Enol (enolase 1,
alpha non-neuron), also produced in the results. Enolases are glycolytic enzymes,
with Eno2 specific to neurons and Enol ubiquitously expressed (Lebioda and Stec,
1991). Of possible relevance is the fact that tau crystallin, a type found in reptiles,
birds and lamprey, has been identified as an enolase, with a much higher abundance
in the lens than required for its enzymatic activity in other tissues (Wistow et ah,
1988). It is possible that some or all of these orthologous genes with unknown eye
relevance may have an eye specific alternative transcript, as with OSBP2, or an
undiscovered eye specific function.
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A number of the known genes with unkown eye relevance in the results have been
implied, through differential expression but not by the criteria required for eye
relevance described earlier (section 3.2.3), to have an eye relevant role in previous
studies. In a study to identify genes differentially expressed in cow RPE and retina,
the bovine homologue of Wdr6 (WD repeat domain 6), with unknown function, was
found to be upregulated (Sharma et al., 2002) and the canine homologues of Dnm
(dynamin, involved in endocytosis) and Ubc (ubiquitin C, associated with protein
degradation) were found to be differentially expressed in retina, with elevated
expression (Lin and Sargan, 2001). CPE (carboxypeptidase E, involved in hormone
synthesis), and C4A (complement component 4A, associated with immunological
defence) were identified as genes upregulated in the human ciliary epithelium (Coca-
Prados et al., 1999). Other genes displaying differential expression in eye domains
have also been found to have other eye relevant connections. For example, TF
(transferrin, iron transporter) and ALDOC (aldolase C, fructose-biphosphate, a
glycolytic enzyme) have been extracted from an enriched human retina library (Sinha
et al., 2000) and been found to be photoreceptor specific in a separate study
(Swanson et al., 1997). Further to these studies, 7Fhas been found to be upregulated
in the retinal periphery compared to the macula (Sharon et al., 2002) and ALDOC, as
well as LOX (lysyl oxidase, a crosslinking enzyme) and SLPI (secretory leukocyte
protease inhibitor), was discovered to be upregulated in corneal epithelium derived
from individuals with the human corneal disease, keratoconus, when compared to
normal cornea. IGFBP5 (insulin-like growth factor-binding protein 5) has been
extracted from an enriched human retinal library (den Hollander et al., 1999) and the
rat homologue has also been found, together with Aldol (aldolase 1), to be
upregulated in the retina of a diabetes-inducible strain after chemical administration,
compared to pre-treatment levels (Joussen et al., 2001). Four genes from the known
gene list (CLU, clusterin; CD74, CD74 antigen; EEF1A1, eukaryotic translation
elongation factor 1, alpha-\\SERPINA3, a protease inhibitor) are upregulated in the
peripheral retina of an older eye compared to that of a younger eye (Sharon et al.,
2002). In the same study, Ndr4 (N-myc downstream regulated 4) shows higher
expression levels in retinal periphery than macula, while Nefl (neurofilament, light
polypeptide) and Tubal (tubulin, alpha 1) have higher expression in the macula.
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Tubal is also upregulated in human trabecular meshwork, through which the outflow
of aqueous humour passes, in response to an induction of raised intraocular pressure,
a situation that is associated with glaucoma, and Scg2 (secretogranin II), also shows
this trend (Gonzalez et al., 2000b). Thirdly, Tubal has also been found to be more
highly expressed in Crx ~ mice (mice without the expression of this transcription
factor in developing photoreceptors) than in normal mice, along with Tuba2, Nedd4
(neural precursor cell expressed, developmentally down-regulated gene 4), Rpll3
(ribosomal protein L13) and Rplla (ribosomal protein L7a) (Blackshaw et al., 2001).
In this analysis, Sast (syntrophin associated serine/threonine kinase), Gpil (glucose
phosphate isomerase), Eno2 and Tubb5 (tubulin beta 5) are shown to be
downregulated in crxv" mice. Along with Ddrl (discoidin domain receptor family
member 1, a receptor tyrosine kinase), Tubb5 also has lower expression in the
transgenic mouse lenses overexpressing PAX6 than in haplosufficient PAX6 mouse
lenses (Chauhan et al., 2002). KRT5 (keratin 5) has been seen to be downregulated in
the corneal endothelium of individuals with Fuch's dystrophy, a progressive corneal
disorder, compared to control corneal epithelium (Gottsch et al., 2003) and, finally,
Crabpl (cellular retinoic acid binding protein 1) has elevated expression in the
ventral, compared to the dorsal, side of the developing mouse retina (Diaz et al.,
2003). Taken together, these studies have shown differential expression in eye tissue,
or in certain domains of normal, diseased or experimentally challenged eye tissue,
for 31 of the 267 non-relevant genes deriving from DDD, with five of these
mentioned in more than one study. This further indicates that there are genes that do
not display an obvious eye relevant role but may nevertheless be differentially
expressed and thus important in eye development and function.
It was expected that there would be a number of genes that have eye relevance, in
terms of association with an eye disease, that would not appear in the list. These
include Rpgr, discussed earlier (section 1.5.4), which is ubiquitously expressed. As
hypothesised, this gene is not produced in the mouse DDD results, as is the case with
its human homologue in the human DDD results. In contrast, the specifically
expressed Rho and preferentially expressed Pax6 are both produced in the mouse
results along with their human counterparts in the human DDD results. The alpha
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crystallin genes, Cryaa and Cryab, also discussed earlier (section 1.5.3), differed;
Cryaa was specifically expressed, while Cryab was more widely expressed, but still
with significant expression levels in the eye compared with other tissues. Cryaa and
CRYAA were present in the mouse and human DDD results respectively, as would be
expected. However, although CRYAB was present in the human DDD results, Cryab
was not produced in those of the mouse. This may represent a real difference in the
expression between mouse and human. Alternatively, it may be that the larger
number of transcripts in the human has produced the expected, and perhaps more
accurate, result of preferential eye expression.
The rat DDD was initiated with the expectation of producing more eye relevant
genes, some of which may have been orthologues of genes from the mouse and
human DDD results. However, the lower number of gene sequences and ESTs
available for the rat than for the current mouse build has led to a sequence
composition comparable to the earliest mouse build (82) and there is a lower number
of libraries and a skew in their composition. With no eye relevant genes produced,
this was an unsuccessful attempt to confirm mouse genes by producing their rat
orthologues. It demonstrates the effect that the eye libraries have, and it may be that
the composition of the eye pools in the mouse and human builds are skewed in
favour of certain eye domains. In terms of the number of libraries, this may have
been the case in mouse build 100, when four of the seven libraries were retinal, and
in human build 160, which had 15 of 22 specific eye domain libraries (26 libraries in
total) having a retinal component. However, it is the number of sequences
contributed by the different eye domains that will influence the results and there is no
way of judging what the 'correct' representation of each of these domains should be,
nor is this a factor that could, or may need to be, easily controlled. Indeed, any retinal
favour in the pool that there may be is not excluding genes important in structure and
function of other eye domains, such as crystallins (lens) and keratocan (cornea). This
does not preclude the possibility that genes expressed at lower levels in these tissues
may not be represented in the eye pool sufficiently to be discovered in this way. As
well as the organ or tissue domain composition of the library pools, other features of
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the libraries' identities could have an influence on the results, such as sex, which has
been previously shown to have a differential effect (Sun et ah, 2000).
Ten of the 31 clusters that were chosen for further study have turned out to represent
known genes. Three of these were determined to be such at the time of DDD
initiation and were later annotated as genes in the UniGene build. The first of these,
Otx2 (orthodenticle homologue 2), is a homeodomain protein related to the
orthodenticle gene in Drosophila that is important in head development (Simeone et
ah, 1992) and essential for eye morphogenesis, with Otx2~'~ mice having severe eye
defects (Matsuo et ah, 1995). The second known gene, Crygf (crystallin gamma F) is
one of many crystallin genes that encode structural proteins in the lens (Goring et ah,
1992). However, unlike the other crystallins, gamma crystallins are expressed in the
elongating central nuclear fibres of the adult lens as well as the secondary fibre cells
(Van Leen et ah, 1987). The Crygfop mouse, recovered from a mutagenesis screen,
has a dominant cataract phenotype (Graw et ah, 2002). Of these three known genes,
Crygf is the only one not to have a human homologue in the human DDD results.
The third known gene is Aipll (aryl hydrocarbon receptor-interacting protein like-1),
the human homologue of which is AIPL1. Mutations within AIPL1 have been found
to be associated with a severe, early-onset form of LCA (Leber congenital
amaurosis), an autosomal recessive retinal degeneration disorder (Sohocki et ah,
2000). Although the function of AIPL1 is not known, in the adult human retina it has
been found to be expressed specifically in the rod photoreceptors (van der Spuy et
ah, 2002).
In addition to these three clusters that represented genes known at the time, an
additional seven clusters represent genes that have been annotated as known genes in
the current mouse UniGene build (120), with six of these seven representing genes
that have been described recently. Rdhl2 (retinal dehydrogenase 12) was first
isolated from human retina. Retinal sections showed it to be specifically expressed in
monkey and mouse photoreceptors, although it is expressed in other tissues
(Haeseleer et ah, 2002). Gabt4 (gamma-aminobutyric acid (GABA-A) transporter 4)
encodes one of four transporters for the GABA neurotransmitter and is specific to
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neural tissue in mouse (Liu et al., 1993) and shows particularly strong expression in
the rodent spinal cord embryonically (Jursky and Nelson, 1999). Ndr4 (N-Myc
downstream regulated 1) is the fourth member of a family and in humans NDR1,
NDR2 and NDR3 are ubiquitously expressed but in contrast NDR4 is specifically
expressed in brain and heart (Zhou et al., 2001). Rat NDR4 has been implicated in
having a role in neurite outgrowth (Ohki et al., 2002). Grtpl (GH regulated TBC
protein 1) was identified from a microarray analysis of GH-responsive cells in vitro
and expression analysis showed it to be expressed highly in testis, with lower levels
in intestine, kidney, liver and lung (Lu et al., 2001). Gucalb (guanylate cyclase
activator IB) was originally studied as a gene that encoded a ligand of guanylate
cyclase-C, an intestinal receptor (Currie et al., 1992) and was found to be highly
expressed in the proximal small intestine of mice (Whitaker et al., 1997). However, it
is also expressed in the mouse retina, predominantly the rod photoreceptors, as well
as in the amacrine and ganglion cells (Howes et al., 1998), where it is thought to
activate guanylate cyclase during phototransduction (Mendez et al., 2001). The final
two genes were discovered as part of large-scale studies, with D5Bwg0860e being
mapped as a gene on chromosome 5 by SSCP (Brady et al., 1997) and D15Ertd806e
was mapped as a gene on chromosome 15 and derived from the two cell stage of an
embryo (Ko et al., 2000).
UniGene statistics and DDD results have shown that the most recent builds are best
for analysis, with a greater number of clusters but an implied reduction of
redundancy. It may therefore be useful to check older DDD results with those from
the most recent build. Another effective method to validate genes deriving from a
mouse DDD would involve comparison with the human equivalent, as a higher
proportion of orthologous genes are eye relevant. These methods were not employed
for selecting clusters for more investigation in this study. However, five (Otx2,
Crygf, Aipll, Rdhl2 and Gucalb) of the 10 known genes amongst the 31 clusters
chosen using other criteria for further investigation are associated with important
roles in eye development or function. Thus their discovery serves as a vindication of
the DDD method utilised to discover novel genes with eye relevant roles. The next
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two chapters describe expression analysis of the novel clusters to confirm
preferential expression in the eye experimentally.
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CHAPTER 4
Analysis of novel preferentially expressed
clusters
4.1 Introduction
In order to make an initial assessment of the success of DDD in extracting novel
clusters that are preferentially expressed, further analysis was carried out on the 31
clusters derived from the UniGene build 100 DDD output. This entailed carrying out
an RT-PCR screen to select clusters appropriate for further investigation.
Subsequently, expression studies were carried out using in situ hybridisation during
developmental stages as well as in the neonate and adult.
Mouse eye development begins at E7.5, with the lens and cornea deriving from
surface ectoderm, neural ectoderm giving rise to the retinal layers, ciliary body and
iris and neural crest creating Descemet's membrane, the sclera and the pigment
layers in the iris, ciliary body and retina. By E9.5, the optic vesicle has matured to
form the optic cup, or secondary optic vesicle, and the optic stalk (Figure 4.1). The
presumptive neural and pigment layers of the retina derive from the inner and outer
layers of the optic cup respectively and begin to develop at E10, with the pigment
layer differentiated by Ell. Meanwhile, at approximately E10, the lens placode
invaginates to give rise to the lens pit, which eventually buds off to form the circular
lens vesicle by E10.5. The choroid has differentiated by El 1 and the lens fibre cells
begin to form between El 1.5 and E12.5, as the posterior cells of the lens vesicle
elongate in the vesicle. At El 1.5, the corneal epithelium begins to develop from the
surface ectoderm that lies adjacent to the lens vesicle. By El2.5 the optic nerve and
the choroid, deriving from the optic stalk, have formed, the lens, sclera, cornea and
pigment layer are undergoing maturation and the neural layer of the retina is
differentiating.
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The lens vesicle becomes the lens capsule at about E12.5, when the lens fibre cells
have elongated to obliterate the vesicle cavity. After this time, the nuclei of the lens
fibres migrate away from the periphery to a central position within the cell and the
lens capsule, with the cells becoming more transparent from El7.5 to birth. After
birth, the lens enlarges through the genesis of additional secondary lens fibre cells
from the equator and is visibly mature at P12 to PI4. Meanwhile, the choroidal layer
undergoes development, with its capillary network developing from El2.5 and its
neural crest-derived pigment cells differentiating at E12.5. The sclera differentiates
at El5.5 and the corneal endothelium and Descemet's membrane begin to
differentiate at approximately El6, with the cornea undergoing development until
after birth. Retinal development also continues after birth. The ciliary body and iris
are formed at E16.5 from the peripheral neural retina. Simultaneously, the retinal
layers begin to differentiate visibly at approximately E16.5 or E17.5. Initially, there
are three layers: the outer nuclear layer, consisting of horizontal cells and the nuclei
of photoreceptors; the transient intermediate layer; and the inner nuclear layer,
containing supporting cells and ganglion cells, which later form axons to the optic
stalk. The cell layers forming the adult mouse retina (ganglion cell layer, inner
nuclear layer, outer nuclear layer and the retinal pigment epithelium) are not
recognisable until several days after birth.
Bearing in mind the processes taking place at various developmental stages, the
expression patterns of clusters expressed preferentially in the eye, along with their
bioinformatic investigation, have been used as a basis for hypothesising the possible
functions of these clusters.
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4.2 Expression analysis using RT-PCR
In order to validate the preferential expression of clusters, RT-PCR was utilised to
assess expression in CD1 mouse eyes taken at four stages (E14.5, E16.5, neonate
(PI) and adult) as well as in a panel of seven other adult CD1 tissues (brain, heart,
kidney, liver, lung, ovary and testis). The primer pair for each cluster was designed
to amplify its representative sequence, as given by UniGene, and a Gapd primer pair
was also used as a control to confirm that RNA used from samples had
approximately equal quantities and were not degraded.
On the basis of the results, the clusters were classified as displaying eye specific
expression, preferential eye expression (expressed in three or less non-eye tissues) or
non-preferential eye expression (ubiquitous expression, no eye expression or
undetectable expression). The results of the four eye specific, 11 preferentially eye
expressed and 13 non-preferentially expressed clusters are shown (Figures 4.2, 4.3
and 4.4 respectively). Three clusters did not produce detectable expression in these
tissues by RT-PCR (Mm.44292, Mm.62589 and Mm.78118). The RT-PCR results of
tested clusters are summarised (Table 4.1).
Of the four eye specific clusters, three are known genes (Mm. 195923, Crygf,
Mm.95707, Aipll; Mm.59151, Gucalb). The remaining clusters are therefore
potentially novel genes, with Mm. 150838 showing expression in the eye at every
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Expression UniGene Represented E14.5 E16.5 Neonate Adult Other
classification cluster gene eye eye eye eye expression
Mm.150838 - • • • O -
Eye specific
Mm. 195923 Crygf • • • • -
Mm.59151 Gucalb • O • -
Mm.95707 AipH O • -
Mm.134224 - • • • • Li
Mm.134516 Otx2 • • • • B
Mm.159861 - • • • • B
Mm.23434 - • • • • B
Preferentially
expressed
Mm.95741 - • B
Mm.22913 - • • • • B,T
Mm.38347 - • • • • B.T
Mm.44242 - • • • • B,0
Mm.21485 - • • • • B,0,T
Mm.56565 - • • • • B.T
Mm.87130 - • • • • B.H.T
Mm.103712 - T
Mm.121647 Rdh12 • • • • B,H,K.O,T
Mm.200734 D15Ertd806e • • • • B,H,Li,Lu,T
Mm.213208 - • • • • B.H.K.O.T
Mm.29846 Ndr4 • • • B,H,K,Lu,0,T
Non- Mm.3124 - • • • B,H,K,Lu,0
preferentially Mm.137178 Gabt4 • • • • A
expressed Mm.151918 - • • • • A
Mm.2965 - • • • • A
Mm.34901 Grtpl • • • • A
Mm.35511 - • • • • A
Mm.37819 D5Bwg0860e • • • • A
Mm.82341 - • • • • A
No detected
Mm.44292 - O O o o -
expression
Mm.62589 - O O o o -
Mm.78118 - o o o o -
Table 4.1 Summary of RT-PCR results
RT-PCR results are shown for all clusters tested and are categorised according to this
outcome. Gene names are given for those clusters that were subsequently identified as
representative of known genes. Filled circles represent a positive result with RT-PCR while
unfilled circles represent a negative result. Expression in other tissues is also represented.
B, brain; H, heart; K, kidney; Li, liver; Lu, lung; O, ovary; T, testis; A, all tissues.
The fifth and last known gene (Mm. 134516, Otx2) is preferentially eye expressed
and is one of five of these clusters that display expression in just one non-eye tissue.
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For four of these five (Otx2, Mm. 159861, Mm.23434 and Mm.95741), this tissue is
the brain, with the other cluster (Mm. 134224) being expressed in the liver.
Interestingly, amongst the preferentially expressing clusters, ten are expressed in the
brain, with Mm. 134224 being the only exception. Ovary and testis also appear to
express many of these clusters.
The three clusters not displaying expression in any of the tested tissues are
Mm.44292, Mm.62589 and Mm.78118. Of the remaining 13 non-preferentially
expressed genes, only Mm.103712 shows no eye expression, while seven are
expressed in all tissues.
The results of this analysis have further refined the number of studied clusters, with
15 of 31 (48%) clusters shown to be specifically or preferentially expressed in the
mouse eye and used as a basis for further investigation.
4.3 Analysis and preferential expression
In order to gain expression information at stages earlier than had been tested using
RT-PCR, wholemount in situ hybridisation was performed on four embryonic stages
(E9.5, E10.5, El 1.5 and E12.5) using the 12 novel clusters chosen for further
analysis. In situ hybridisation was also performed on cryosections at later stages
(E14.5 and E16.5 CD1 embryos and neonate and adult CD1 eyes) in an effort to
elucidate cell locations and types that express the novel clusters discussed in this
thesis, as well as to confirm RT-PCR expression of these clusters. A DOPAchrome
tautomerase (Oct) specific probe was employed as a positive control for eye
expression. Two of the known clusters (Mm. 134516, Otx2; Mm. 195923, Crygf) also
had their early embryonic expression assessed as an indication of the desired activity
of probes designed and synthesised using the methods described in this thesis. All
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sense and antisense probes were synthesised from the same plasmid, in which inserts
were cloned in either direction. The restriction enzymes used to linearise the
plasmids were Spel and Ncol, with the exception of the plasmid containing the
Mm.22913 insert, when SacII was used due to the presence of an Ncol site in the
insert. In situ analysis carried out on the novel clusters detected expression for nine
of the 12 tested.
In order to elucidate possible roles for these eye-expressing genes, a bioinformatic
approach was taken. This was initiated by BLAST searches against the mouse
genome using the Ensembl interface (www.ensembl.org). Predicted protein
information was used as a basis for further investigation in some cases.
The mouse regions and the homologous human regions for the nine novel clusters
described in this chapter are shown (Table 4.2). There are no existing gene traps of










Mm.150838 - 17E4 2p21 -
Mm.159861 Tsd 1B 6p12.1 autosomal dominant congenital
Mm.21485 Tset 10B1 6q22.1 -
Mm.22913 Trale 15E3 22q13.31 -
Mm.23434 Cln8l 7F4 16p11.2 -
Mm.38347 Bret 11E2 17q25.1 age-related maculopathy
Mm.44242 Sapan 5B1 4p16.1 -
Mm.87130 Duf676 1A5 6q13 macular dystrophies
Mm.95741 - 2A2 10p12.31 -
Table 4.2 Regions and mapped diseases of novel clusters
The UniGene cluster, proposed gene name, mouse region and homologous human region
are shown along with relevant diseases mapped to these regions. Tsd, antisense to Dsf;
Tset, Tspy/Set related; Trale, transmembrane, retina and antisense lens expression; Cln8l,
Cln8-\\ke\ Bret, BTB/POZ domain, retinal; Sapan, saposin A domain, novel; Duf676, DUF676
domain.
The twelve clusters discussed here describe a sequence with no clear orthologues
(Mm.95741), a sequence upstream of Six3 with retinal expression (Mm.150838), a
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sequence that lies antisense to an exon in a known gene (Tsd), a novel gene
displaying antisense expression (Trale) and five novel genes with interesting
expression patterns and predicted protein domains with known functions (Tset, Bret,
Cln8l, Sapan and Duf676).
4.3.1 Control probes: Dct, Otx2 and Crygf
The Dct antisense riboprobe was synthesised from the p5A7 plasmid and the sense
probe was transcribed from the p5A3 plasmid. These probes have been previously
used to detect Dct expression in the developing eye (Steel et al., 1992). Expression is
shown in the RPE at E12.5 as expected (Figure 4.5) with no expression in the sense
control. Expression can also be seen in melanoblasts and the telencephalon. CD1
(albino) embryos were used in all in situ hybridisation experiments so that
pigmentation did not mask a retinal signal. Expression of Dct is also shown at El 4.5,
El6.5 and neonate stages (Figure 4.6). Signal is seen in the RPE at all stages and in
the IPE and ciliary epithelium in the neonate as expected. Expression can also be
seen in melanoblasts at E14.5. Retinal detachment has taken place in the E16.5
section, and in many of the later sections, as a consequence of tissue processing.
The Otx2 probe shows expression in the retina of the developing eye at El 1.5 (Figure
4.7) and E12.5 (Figure 4.8). Expression is also seen in the brain at both stages. This
was expected, as vertebrate expression of Otx2 has previously been reported in the
telencephalon, diencephalon and mesencephalon (Simeone et al., 1992) and eye
expression at El 1.5 and E12.5 is known to be restricted to the RPE (Bovolenta et al.,
1997).
As Crygf is expressed in the lens, it presents the opportunity to assay expression in a
non-retinal region of the eye. This is shown at El 0.5, El 1.5 and E12.5 (Figure 4.9).
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Figure 4.5 Dct wholemount in situ hybridisation
In situ hybridisation at E12.5 using Dct antisense probe shows expression in the RPE and
melanoblasts (a). The sense control is also shown (b). Scale bars, 800 pm.
Figure 4.6 Dct in situ hybridisation
In situ hybridisation on sagittal sections. At E14.5, expression can be seen in melanoblasts
and in the RPE and IPE of the eye (a). At E16.5, expression is visible in the RPE, although it
is detached from the neural retina due to sectioning procedures (b). The cilary body, IPE and
RPE are all expressing in the neonate (P1) eye (c) and the RPE is shown at higher magnification
(d). High magnification images show the choroid/lens axis from the bottom to the top of the
image. RPE, retinal pigment epithelium; IPE, iris pigment epithelium. Scale bars, 20 |xm (d);
50 urn (b); 500 (im (a,d).
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Figure 4.9 Crygf wholemount in situ hybridisation
In situ hybridisations at E10.5 (a, experimental; b, control), E11.5 (c, experimental; d, control)
and E12.5 (e, experimental; d, control) show expression in the developing lens (indicated by
arrows). Scale bars, 800 ^m.
4.3.2 Mm.95741
RT-PCR results suggest that Mm.95741 is only expressed in the adult eye and not in
the late embryo at E14.5, E16.5 or in the neonate. Wholemount in situ hybridisations
reveal that Mm.95741 is expressed in the early embryo. At E9.5 expression is
restricted to the optic and otic vesicles and the brain and at El0.5 less pronounced
signal is seen in the retina, otic vesicle and brain (Figure 4.10). However, in situ
hybridisation at stages El 1.5 and E12.5 showed no expression. This was also the
case with in situ analysis at E14.5, E16.5 and in the neonate eye as well as in the
adult eye, which is contrary to the earlier RT-PCR data (section 4.2).
The representative sequence of Mm.95741 is AK020807, which aligns to the last
exon of a Genscan predicted mouse gene (Figure 4.11). This prediction links a single
exon gene (2810030E01Rik) to the Mm.95741 sequence, as they align with
consecutive predicted Genscan exons. The 2810030E01Rik gene has homologues in
human (Q8N3C3), rat (novel), zebrafish (novel) and fugu (Q9CSH2), but has no
distinguishing domains or features. Mm.95741 aligns with a region downstream of
the human and rat genes as well as the mouse prediction, however it is only in
zebrafish that there is an EST in the corresponding region.
Although there are no ESTs seen in the human or rat regions, the sequence
representing Mm.95741 lies downstream of a gene that has orthologues in other
vertebrates. Mm.95741 may represent a conserved region syntenic to this gene or it
may be its 3' UTR. However, there is no evidence to suggest that this gene is
preferentially expressed in the eye, thus Mm.95741 could be an alternative 3' UTR,
preferential to the developing eye, ear and brain, and possibly adult eye and brain
according to RT-PCR data.
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Figure 4.10 Mm.95741 wholemount in situ hybridisation
The lateral view of Mm.95741 in situ hybridisation at E9.5 shows expression in the optic and
otic vesicles and the brain (a, experimental; c, control). Brain and otic vesicle expression can
also be seen in the dorsal view (b, experimental; d, control). At E10.5, expression remains
visible in the brain and to a lesser extent in the otic vesicle (e, experimental; f, control). Within
the developing eye, signal is restricted to the retina (indicated by arrow). OPV, optic vesicle;
OTV, otic vesicle. Scale bars, 400 urn (a, b, c, d); 800 urn (e, f).
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4.3.3 Mm.150838
RT-PCR results for Mm.150838 indicate specific eye expression in the tissues used.
Expression is only seen in the eye while it is undergoing development (E14.5, E16.5
and neonate) but not in the adult. Expression of Mm.150838 in the neonate eye is
confirmed by section in situ hybridisation (Figure 4.12). The retinal cells display
signal, with the inner nuclear layer and discrete cells, lying in a particular retinal
layer on the peripheral side of the central retinal region, showing the strongest
expression. High expression is also detected in a layer of cells that may correspond to
the innermost choroidal layer or the RPE and also in the RGCs. Although in situ
hybridisation was carried out at all stages, no expression was seen at stages E9.5,
E10.5, El 1.5, E12.5 or in the adult. Expression was also absent from the eye at
stages E14.5 and E16.5, contradicting the RT-PCR results.
In both mouse and human, AK021382, the representative sequence for Mm.150838,
aligns with the exon of an EST sequence within a group of ESTs that lie 7kb
upstream of, and in the opposite sense to, Six3. In order to assess the homology
between human and mouse in this region, VISTA analysis was performed (Figure
4.13). The exonic similarity to Mm. 150838 is from the second and final exon of
ENSESTT00000601866, which shows between 50% and 75% homology between
the two organisms, whilst the other two exons that are part of the same cDNA
sequence (in ENSESTT00000601864) display over 75% homology. In addition,
there are regions of over 75% homology between the 5' regions of Six3 and these
ESTs. However, Mm. 150838 has no ORF.
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Figure4.12Mm.150838insituhybridisation
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The expression of Mm. 150838 in neonate retina is widespread, with signal
throughout the retina and also in a single layer that may correspond to a layer of the
choroid or RPE. The retinal cells with more intense Mm. 150838 staining are those in
the INL (bipolar cells) and the line of dispersed cells that show a similar expression
pattern to that of Proxl in differentiating horizontal cells at the same stage (Dyer et
ah, 2003). Therefore, Mm. 150838 may be important in retinal development or
function, either indirectly or directly. As the representative sequence of Mm. 150838
has no ORF, it may represent an untranslated part of a transcript in this region, as
suggested by the existence of ESTs located here. The presence of conserved regions
between the Mm. 150838 gene and SIX3 suggests a regulatory role for these regions
on the two genes' expression. The non-exonic conserved region immediately
upstream of SIX3 (surrounding 25kb in Figure 4.13) has been previously identified as
a possible promoter region (Lengler and Graw, 2001), whilst other regions have not
been reported in the literature. Clustering of tissue specific genes has been reported
in the literature as occurring more often than would be expected by chance (Megy et
ah, 2003). If this is a genuine phenomenon, with implications for shared regulation of
gene expression at some level, Mm. 150838 and Six3 may be subject to the same
influences. This hypothesised relationship is supported by the role and expression of
Six3. Mutations in the human orthologues cause holoprosencephaly type 2 (Wallis et
al., 1999) as it is a homeodomain protein required for eye formation (Lagutin et ah,
2001). In the neonate mouse retina (Zhu et ah, 2002) and human retina at 20 weeks
gestation (Granadino et ah, 1999), SIX3 is expressed in RGCs and the INL in the
neonate, a subset of the expression seen with Mm. 150838.
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4.3.4 Tsd
RT-PCR detects expression of Tsd in the eye at all tested stages (E14.5, E16.5,
neonate and adult) as well as in the brain. In situ hybridisation at earlier stages of
development detected expression of Tsd at E9.5 and E10.5 (Figure 4.14). At E9.5,
there appears to be widespread expression, including expression in the optic cup.
However, at El0.5, both the antisense and sense probe appear to show expression in
the retina of the optic cup. The experimental probe also detects possible expression
in the brain, whilst the control probe detects expression exclusively in the optic cup.
Although eye expression was seen at all stages tested by RT-PCR (E14.5, E16.5,
neonate and adult), the in situ results at these stages showed no expression.
Expression was also absent from in situ analysis at El 1.5 and E12.5. The brain
expression indicated by adult brain RT-PCR has not been shown to be present at
embryonic stages.
In both human and mouse, AK020813, the representative sequence of Mm. 159861, is
located antisense to dystonin (Dst; bullous pemphigoid antigen 1 (BPAG1) in
human). In the human genome, it comprises two exons, the first of which overlaps
the second of two exons of an EST (ENSESTT00002995780) (Figure 4.15).
Therefore, taken together, these sequences probably represent a transcript deriving
from three exons. If this is the case, the third exon is the only one not to have a
corresponding antisense BPAG1 exon. A vista plot of the relevant region shows that
whilst the first two exons show homology between human and mouse, the third exon,
the second of AK020813, does not (Figure 4.16). Additionally, the protein sequence
predicted for the human EST has no domains or features and the representative
sequence of Mm.159861 has no significant ORF. In zebrafish, the sequence aligns




Figure 4.14 Tsd wholemount in situ hybridisation
At E9.5, expression is ubiquitous, including the optic vesicle, with the experimental probe (a),
while the control probe shows relatively little expression (b). At E10.5, both the experimental
(c) and the control (e) probes show expression in the developing retina (indicated by arrows),
with the sense also showing brain signal. Higher magnification images display the eye nasal
to temporal from bottom left to top right of the image (d, experimental; f, control). Scale bars,
200 urn (f); 400 p.m (b, d); 800 urn (a, e); 1.6 mm (c).
ENSESTT00002995780
BPAG1
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BPAG1 has many isoforms, all producing spectroplakin proteins, which are
cytoskeletal crosslinkers. A mutation in BPAG1 is responsible for causing bullous
pemphigoid, a human autoimmune disease (Minoshima et al., 1991) and spontaneous
mutations in BPAG1 are associated with dystonia musculorum (Duchen et ah, 1964;
Brown et ah, 1995), a disease characterised by degeneration of sensory neurons
(Bernier et ah, 1995; Dowling et ah, 1997). The in situ hybridisation riboprobes for
Tsd are complementary to the second exon of the representative sequence and do not
correspond to a known BPAG1 exon on the opposite strand. It is possible that Tsd
may be antisense to an undiscovered exon. However, the lack of conservation
specifically in this region between mouse and human makes this less likely. As the
representative sequence of Tsd is homologous to a region in zebrafish that is
antisense to the exon of an unannotated gene, it is possible that the function of Tsd
has been conserved and that the novel zebrafish gene is the Dst homologue. The
predicted exonic region corresponding to Mm. 159861 may be the 3' UTR of the EST
gene, which would explain the lack of conservation in this region specifically. This
gene may have a regulatory function and so influence the transcription, elongation,
processing, splicing, localisation, stability, translation, transport or mRNAi mediated
degradation ofDst transcripts. Interestingly, a different antisense transcript to Dst has
recently been discovered further upstream (Kiyosawa et al., 2003). The phenomenon
of antisense expression is discussed further elsewhere (section 4.4).
An autosomal dominant form of the disorder congenital nystagmus maps to the
homologous human region on 6p 12 in a region spanning 28Mb and including over 90
known genes (Kerrison et al., 1996). Congenital nystagmus has onset at infancy with
a reduced visual acuity due to slippage of images across the fovea as a result of
ocular oscillations. However, the physiological basis of this has not yet been
determined and there has been no evidence of an underlying visual sensory disorder,




RT-PCR data for Trale (section 4.2) indicates expression at all tested eye stages
(E14.5, E16.5, neonate and adult) and also in brain and testis. In wholemount in situ
hybridisations, expression is seen in both sense and antisense directions, as was the
case with Tsd. At E9.5 and E10.5, strong expression seems to be restricted to the otic
vesicle in the antisense direction (Figure 4.17). However, at El 1.5, expression is
detected in the eye in both directions (Figure 4.18). In the sense direction, expression
appears to be in the retina. In the antisense direction, there is no retinal expression
but instead it is present in the lens vesicle. Section in situ hybridisations display
signal in the neonate retina, but not at E14.5, E16.5 or in the adult as suggested by
the RT-PCR results. Additionally, there is no expression at E12.5. In the neonate eye,
signal can be seen with the experimental probe, but not with the control probe, in
discrete points distributed throughout the retina (Figure 4.19). This may represent a
background effect and not real expression, however if this is the case, it is specific to
certain riboprobes, since the sense controls show no signal. This is possible, as signal
at the periphery of sections, a phenomenon known as edge effect, also seems to be
specific to particular riboprobes (not shown), however edge effect has been observed
with both sense and antisense riboprobes whilst the non-specific signal has only
occurred with antisense riboprobes.
In Ensembl, the representative sequence of Mm.22913 (AK007745) aligns to a
Genscan mouse gene prediction that includes a novel mouse gene
(ENSMUSG00000036118). The protein deriving from this novel gene is predicted to
have a transmembrane domain but no other recognisable domains. There are
homologues of this gene in human (Q9BYB5), rat (novel ENSRNOGOOOOOOl 1788),
zebrafish (novel ENSDARG00000005569) and fugu (Q9BYB5). With the exception
of the fugu homologue, which is only predicted to have a signal peptide, all of these
genes have a predicted transmembrane domain. In Ensembl, none of these transcripts
have antisense genes.
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Figure 4.17 Trale whoiemount in situ hybridisation at E9.5 and E10.5
At both E9.5 (a, experimental; b, control) and E10.5 (c, experimental; d, control) strong
antisense expression is seen in the otic vesicle (indicated by arrows). Scale bars, 800 rim (b,
d); 1.6 mm (a, c).
Figure 4.18 Trale in situ hybridisation at E11.5
In situ hybridisation of Trale shows sense expression to be widespread but strong signal can
be seen in the retina (a, indicated by arrow). This can be seen more clearly at higher
magnification, with the nasal/temporal axis from the left to the right side of the image (b).
Antisense expression also seems to be widespread, but particularly strong in the lens (c,
indicated by arrow). Lens expression is shown at higher magnification, with the nasal/temporal
axis from left to right (d). Scale bars, 100 urn (d), 400 ^im (b), 800 ^m (c) and 1.6 mm (a).
Figure 4.19 Trale in situ hybridisation in the neonate
In situ hybridisation on sagittal sections of the neonate (P1) eye shows signal in small, discrete
points within the retina (a, experimental; c, control). Signal is also shown at higher magnification
(b, experimental; d, control). All images show the choroid/lens axis from left to right. Scale
bars, 20 pm (b, d); 50 pm (a, c).
Although signal seen in the neonate retina may not represent true expression, the
early expression of Trale in the otic vesicle at E9.5 and El0.5 and its sense/antisense
expression in the eye (retina and lens vesicle respectively) may be important in early
development. The complementary domains of expression shown by the experimental
and control probes could be indicative of co-regulation of gene expression. For
example, expression from one strand in the lens may restrict expression of the
opposing gene in the lens but not in the retina.
4.3.6 Tset
Expression of Tset is detected by RT-PCR (section 4.2) in the eye at E14.5 and E16.5
and in the neonate and adult. Expression was also seen in the brain, ovary and testis.
Wholemount in situ hybridisations show expression of Tset at E10.5 (Figure 4.20) in
the retina, but this is not observed at any of the other stages (E9.5, El 1.5, E12.5,
E14.5, El6.5, neonate or adult), despite previous indications by RT-PCR of eye
expression at later stages of eye development as well as in the adult eye. There may
also be brain expression. However, signal is also seen in the control, which may be
indicative ofbackground signal that is often associated with this organ.
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Figure 4.20 Tset wholemount in situ hybridisation
In situ hybridisation of Tset at E10.5 shows expression in the retina (a, experimental, indicated
by arrow; c, control). Retinal expression can be seen more clearly at higher magnification, with
the nasal to temporal axis from bottom left to top right (b). Scale bars, 200 ^im (b); 800 urn (a,
c).
The representative sequence of Mm.21485, BC017540, aligns to a gene encoding a
novel protein with a nucleosome assembly protein (NAP) domain. This is true in
mouse (NM_133745), rat (novel ENSRNOG00000000547) and human
(NM_021648). These proteins belong to the testis specific Y encoded protein
(TSPY) family. The relationship between NAP domain-containing proteins was
assessed by constructing a phylogenetic tree (Figure 4.21), with sequences derived
from Swiss-Prot (www.ebi.ac.uk/swissprot). It suggests that human TSPY is the
most closely related to the novel NAP domain proteins identified here, followed by
the SET translocation (SET) proteins. An alignment of the TSET, TSPY and SET
proteins shows that the NAP domain region corresponds to the region of most
homology between the proteins, with the N terminal end still showing similarity
amongst the TSET proteins (Figure 4.22).
TSPY, the most closely related protein to Tset, was one of the first described genes
on the human Y chromosome (Arnemann et ah, 1991). As the name suggests, it has
been shown to be specifically expressed in testis and testicular tumours (Arnemann
et ah, 1991; Zhang et ah, 1992; Schnieders et ah, 1996; Lau and Zhang, 2000; Dasari
et ah, 2001). Multiple copies exist in human (Vogel and Schmidtke, 1998) but it is a
pseudogene in mice (Vogel et ah, 1998) and its postulated role in spermatogenesis
(Arnemann et ah, 1991; Zhang et ah, 1992) is yet to be confirmed. However, the
domains of the TSPY/NAP/SET family suggests that it plays a role in gene
regulation or in controlling replication or chromatin structure (Schnieders et ah,





























Figure 4.21 Phylogenetic tree of NAP proteins and TSET
TSET is more closely related to the human TSPY protein than to the other NAP domain-
containing proteins. The neighbour-joining method was used to produce this tree and a
cut-off value of 93 was applied to node confidence.
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4.3.7 Bret
Earlier RT-PCR results suggest that Bret is expressed at all tested stages in the eye
(E14.5, El6.5, neonate and adult) as well as in the brain and testis (section 4.2).
Using in situ hybridisation on cryosections, signal is seen throughout a central band
in the neonate retina (Figure 4.23). This is similar to the pattern shown with Trale,
however the signal is more intense, covers a more restricted region of the retina and
each separate area of signal is larger. No expression was seen in the early embryo,
neither was there any indication of signal at E14.5, E16.5 or in the adult, contrary to
RT-PCR data.
In mouse, the representative sequence of Mm.38347, AK005160, aligns with all
three exons of a gene (1500005102Rik) with a BTB/POZ domain and a signal peptide
sequence. In rat, the same is true (novel gene ENSRNOG00000003109), except for
the presence of an additional, and seemingly untranslated, fourth exon. The fugu
homologue, Q9DB72, also containing the BTB/POZ domain, aligns with the
sequence. A Genscan prediction (AC103809.2.1.198764.8602.13713) and three
ESTs are homologous to Bret in human. An alignment of these Bret predicted and
novel proteins is shown (Figure 4.24). The predicted BTB/POZ domain is highly
conserved across all proteins, but this conservation is maintained from this domain
until the C terminus, with the exception of the fugu sequence, in which the final 96
residues are not included. A phylogenetic tree of the BRET proteins and BTB/POZ
domain-containing proteins shows that BRET is most closely related to the mouse
PPICAP protein and its human homologue LGALS3BP (Figure 4.25).
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Figure4.23Bretinsituhybridisation
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Figure 4.25 Phylogenetic tree of BTB/POZ proteins and BRET
BRET is more closely related to PPICAP and its human homologue LGALS3BP than to
the other BTB/POZ domain-containing proteins. The neighbour-joining method was used
to produce this tree and a cut-off value of 98 was applied to node confidence.
The high conservation of the BRET proteins across mouse, rat, human and fugu
suggests an important conserved function across these species. The BTB/POZ
domain was identified by two groups, hence the dual name encompassing BTB
(Zollman et ah, 1994) and POZ (Bardwell and Treisman, 1994). It has been shown to
allow hetero- and homodimerisation of its member proteins (Bardwell and Treisman,
1994) and has been associated with transcriptional repression, through interaction
with histone deacetylase co-repressor complexes (Deweindt et ah, 1995; Wong and
Privalsky, 1998; Huynh and Bardwell, 1998). The closely related PPICAP protein
(peptidylprolyl isomerase C-associated protein) has been characterised as a
cyclophilin C binding protein (Friedman et ah, 1993). The physiological functions of
both the cyclophilins and their binding proteins are as yet unknown. In human,
LGALS3BP (lectin, galactose-binding, soluble, 3 binding protein) has been found to
be upregulated in the serum of cancer patients (Iacobelli et ah, 1986; Iacobelli et ah,
1988; Iacobelli et ah, 1993). Elevated protein levels were also observed in patients
with AIDS and it was shown to stimulate host defense systems in vitro, prompting
the authors to hypothesise a role in the immune system (Ullrich et ah, 1994). The
presence of a cysteine rich domain in both the human (Koths et ah, 1993) and mouse
(Friedman et ah, 1993) proteins that is also found in MSR1 (macrophage scavenger
receptor) supports this hypothesis. The BRET proteins, however, are not predicted to
contain this domain, therefore it is less likely to have a closely related immune
system function.
With respect to the Bret region, a locus associated with susceptibility to age-related
maculopathy has been found in human at 17q25 in a genome scan that identified two
significant associated loci (Weeks et ah, 2001). However, this region is large




Using RT-PCR, Cln8l has shown expression in all tested stages of eye development
(E14.5, E16.5, neonate and adult) and in adult brain (section 4.2). From wholemount
in situ hybridisations, a low level of Cln8l expression can be seen in the optic cup at
E9.5 and in the retina at El 0.5 (Figure 4.26). The higher sensitivity of radioactive in
situ hybridisation was used to examine more precisely the weak signal of Cln8l
found in the eye at E10.5. Expression was found in the developing brain at E10.5
(Figure 4.27). This includes a region of expression extending from the telencephalon
to the optic stalk. Although RT-PCR expression was seen at all stages, only E16.5
and adult in situ hybridisation sections produced visible signal. At these stages,
expression is seen in the RPE (Figure 4.28). Morphology is poor in the adult eye due
to sectioning procedures. No expression was seen at El 1.5 or El2.5.
The representative sequence of Mm.23434 (AK005271) aligns with the entire five
exon length of the novel mouse gene 1500016010Rik, which has homologues in
human (NM_031478), rat (novel ENSRNOG00000019914), zebrafish (novel
ENSDARG00000015685) and fugu (SINFRUG00000136300). The rat gene is
predicted to have a signal peptide sequence and the human and zebrafish genes are
both predicted to have four transmembrane domains. Using a search against the
SMART database (http://smart.embl-heidelberg.de/) for conserved protein domains,
it was found that the mouse gene has a transmembrane domain and a TLC domain.
An alignment of the genes from mouse, rat, human, fugu and zebrafish shows the
position of these signal peptide, transmembrane and TLC domains (Figure 4.29). The
TLC domain region is conserved across all genes. A phylogenetic tree was
constructed to assess which of the known TLC domain-containing proteins Cln8l is
more closely related to. The Cln8l proteins as well as other proteins with this domain
are included, with sequences taken from Swiss-Prot (Figure 4.30). According to this,
the CLN8 proteins are more closely related to Cln8l than the LAG and TRAM
proteins.
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Figure 4.26 Cln8l wholemount in situ hybridisation
At E9.5 low signal can be seen in the optic vesicle (a, experimental, indicated by arrow; b,
control). At E10.5, sense signal is also feint, but present in the retina (c, experimental, indicated
by arrow; e, control). Retinal signal can be seen more clearly at higher magnification, with the
nasal/temporal axis from left to right of the image (d). Scale bars, 100 |xm (d); 400 |im (a, b);
800 urn (c, e).
Figure 4.27 Cln8l radioactive in situ hybridisation
At E10.5 signal can be seen in the brain and in a region extending from the optic stalk to the
telencephalon (a, experimental; b, control). T, telencephalon; OS, optic stalk. Scale bars, 500
p,m.
Figure 4.28 Cln8l in situ hybridisation
In situ hybridisation on sagittal sections of E16.5 embryo shows expression in the RPE, with
the choroid/lens axis from top to bottom of the image (a, experimental; b, control). RPE
expression is also seen in adult eye sagittal sections, with the choroid/lens axis from right to
left of the image (c, experimental; d, control). Scale bars, 50 ^m.
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Figure 4.30 Phylogenetic tree of TLC proteins and CLN8L
CLN8L is more closely related to the CLN8 proteins than to the other TLC domain-
containing proteins. The neighbour-joining method was used to produce this tree and a
cut-off value of 97 was applied to node confidence.
The TLC domain contained within the CLN8L proteins is named after its
commonality amongst the TRAM, Laglp and CLN8 proteins (Winter and Ponting,
2002). The roles of these three types of protein have prompted the authors who gave
the name to this domain to hypothesise roles for its members in lipid metabolism.
Possible functions include activating lipid synthesis, protecting proteins from
proteolysis, lipid transport or lipid sensing. Of the three types of protein that gave
their name to this domain, CLN8 proteins seem to be most closely related to CLN8L
proteins. CLN8 has a missense mutation in patients with progressive epilepsy with
mental retardation (EPMR), although it is in a non-conserved N terminal region and
not in the TLC region (Ranta et al., 1999). In the same publication, the mndlmnd
mouse was reported to contain an insertion, within the TLC domain of Cln8, that is
predicted to cause protein truncation. These mice display early-onset retinal
degeneration and progressive adult-onset motor system degeneration, leading to
premature death (Messer and Flaherty, 1986). Hence, it is not unreasonable to
suggest that the function of CLN8L may be similar to other TLC proteins and that, as
it is most closely related to CLN8, in addition to the fact that late expression of Cln8l
is seen in the RPE, this protein may have an influence in maintenance of the retina.
Signal in the brain and, more relevantly, between the telencephalon and the optic
stalk, may suggest a possible role in the formation, function or maintenance of nerve
fibres connecting the eye and the brain. However, the principal sensory association
of the mature telencephalon is olfaction, with vision being the domain of the
diencephalon. The expression data is not sufficient to indicate whether there are also
connections between the optic stalk and the diencephalon at this stage. However,
wholemount in situ hybridisation shows expression in the retina and, given later
expression in the RPE, this could be expression in the presumptive RPE.
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4.3.9 Sapan
In terms of RT-PCR data, Sapan shows expression in the eye at all tested stages
(E14.5, E16.5, neonate and adult) as well as in the adult brain and ovary. At earlier
stages of development, Sapan gives a striking expression pattern in wholemount in
situ hybridisations. Signal is restricted to the developing eye, ear and brain and the
dorsal neural tube at E9.5 (Figure 4.31), E10.5 (Figure 4.32) and El 1.5 (Figure 4.33),
but no expression is seen at E12.5. In the developing eye, expression appears to be in
the optic vesicle at E9.5, in addition to the lens vesicle, which remains as an oval
region without signal in cases where expression is restricted to the optic vesicle. At
El0.5 and El 1.5 signal is restricted to the lens vesicle. Sections of an El 1.5 embryo
that had undergone wholemount in situ hybridisation show expression in the central
region of the lens vesicle (Figure 4.34). There is also signal in the cells lining the
interior of the neural tube at this stage, known as the ependymal layer. Although RT-
PCR data indicates that Sapan is expressed in the eye at all tested stages (E14.5,
E16.5, neonate and adult), the in situ hybridisations carried out did not display
specific signal at any of these stages.
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Figure 4.34 Sections of Sapan wholemount in situ hybridisation
E11.5 wholemount tansverse sections confirm that signal is present in the eye and in the
developing neural tube. Eye signal is within the lens vesicle specifically, with the nasal/temporal
axis from bottom to top (a; b, high magnification). Expression in the neural tube appears to
be in the innermost cells, the ependymal layer, with the ventral/dorsal axis from top to bottom
of the image (c; d, high magnification). LV, lens vesicle; NT, neural tube. Scale bars, 10 pm
(d); 20 pm (b); 50 pm (a, c).
The representative sequence of Mm.44242, AK009408, aligns to a mouse protein
containing two saposin A and two saposin B domains, encoded by a novel gene
(ENSMUSG00000043430) that has homologues in both human (Q8N7T4) and rat
(ENSRNOG00000006845). The only known proteins in mice to contain saposin
domains are prosaposin (PSAP) and surfactant associated protein B (SFTPB). A
phylogenetic tree was constructed to show the relationship of the novel proteins
found here, using a saposin-related protein in fruitfly as an outlier (Figure 4.35). It
shows that in terms of protein sequence, SAPAN is no more related to either of the
two proteins. However, in terms of domain structure, the SAPAN proteins are more
similar to PSAP (Figure 4.36). An alignment of these proteins, indicating the
individual saposins that human prosaposin is cleaved into (Rorman et al., 1992) is
shown (Figure 4.37). The region comprising the second saposin is largely absent in
the SFTPB proteins, while there is homology between SAPAN and PSAP.
Additionally, the regions outwith the saposins tend to be more similar to PSAP than
to SFTPB, with the exception of the C terminal regions. This may imply that its
function is more related to PSAP than to SFTPB. The novel gene aligning to the
Mm.44242 representative sequence is located within an intron of, and in the opposite
direction to, the Sorcs2 gene in mouse, its provisionally named homologue, SOR2, in
















Figure 4.35 Phylogenetic tree of saposin domain proteins and SAPAN
SAPAN is no more related to the PSAP proteins than to the PSPB proteins. Additionally,
the PSAP proteins appear to have diverged from each other at the same time as diverging
from PSPB and the SAPAN proteins. The neighbour-joining method was used to produce
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Figure 4.37 Alignment of SAP and SAPAN proteins
Areas boxed in red represent the individual saposins cleaved from the human prosaposin
protein. Saposin C (3rd saposin) and the N terminal end of saposin D (4th saposin) show
greatest conservation. More homology exists with PSAP in regions outside the saposins
and also in saposin B (2nd saposin) which seems to be a largely missing region in SFTPB.
Mm, Mus musculus; Rn, Rattus norvegicus; Hs, Homo sapiens; Gg, Gallus gallus; Dr,
Danio rerio; Bt, Bos taurus; Oc, Oryctolagus cuniculus.
S0RCS2 was recently identified as a member of the VPS 10 domain-containing
receptor family. It is expressed predominantly in the developing mouse brain, but
also in the floor plate of the developing spinal cord, embryonic lung and heart and
transiently in smooth and skeletal muscle and cartilaginous and connective tissue
(Rezgaoui et al., 2001). Sapan is located antisense to Sorcs2, however, unlike Tsd,
there is no expression in the antisense direction and it is located in an intronic region.
This makes it unlikely that expression of either gene affects the other, but does not
preclude the possibility. What might be the function of Sapan.? Phylogeny suggests
that Sapan is no more related to Psap than to SFTPB and that these genes diverged
simultaneously. However, the protein structure of PSAP in terms of domain
composition is the same as that predicted for SAPAN. Psap displays differential
expression mediated by upstream regulatory regions (Sun et al., 2003), with high
levels in the CNS, including the retina and ciliary body of the eye (Sun et al., 1994).
The protein has a role in neurite outgrowth in mouse cells (Campana et al., 1996;
O'Brien et al., 1994; O'Brien et al., 1995). PSAP has additional roles when it is
proteolytically cleaved into four saposins, or sphingolipid activator proteins, that
promote intracellular degradation of sphingolipids by specific hydrolases (O'Brien
and Kishimoto, 1991). As a consequence, mutations in this gene are associated with
glycosphingolipid storage diseases caused by its deficiency in humans (Paton et al.,
1992; Hulkova et al., 2001; Rafi et al., 1993; Holtschmidt et al., 1991) and in its
mouse homologue (Fujita et al., 1996; Matsuda et al., 2001). A patent (US6271196)
filed by O'Brien in 2001 includes the DNA sequence corresponding to residues 318
to 339 of human PSAP. It describes a method for alleviating or preventing
neuropathic pain by administration of an effective amount of this active fragment,
although there is no evidence that these properties have been proved. Sapan, like
Psap, is expressed in the CNS, however, in contrast to Psap, its eye expression is
restricted to the lens and not the retina and ciliary body. Interestingly, a recent
publication shows the similarity of J3-crystallin, one of three crystallins in
cubomedusan jellyfish, to vertebrate saposins (Piatigorsky et al., 2001). As discussed
in Chapter 1 (section 1.5.3), gene sharing in the lens is a common phenomenon, with
crystallins carrying out different roles and being expressed at lower levels in other
tissues (Piatigorsky et al., 1988; Piatigorsky and Wistow, 1989). These roles are
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often as chaperone proteins or metabolic enzymes (Wistow and Piatigorsky, 1988; de
Jong et al., 1989) and the roles of saposins mean that J3 crystallin fits the theory of
enzyme recruitment for lens crystallins. It is not unreasonable to suggest that Sapan,
showing differential expression in the developing mouse lens, may act as a crystallin.
If this is the case, it is probable that it is a product of proteolytic cleavage, as there is
evidence to suggest that J3 crystallin is cleaved from a precursor (Piatigorsky et al.,
2001). Sapan expression in the brain, neural tube and the otic vesicle suggests it has
a role in the development or function of these regions of the CNS. Expression in the
otic vesicle is most prominent at E9.5, the stage at which the otic vesicle has just
developed from the otic pit. Between E9.5 and El 1.5, the otic vesicle changes shape
and the endolymphatic appendage and semicircular canals, later involved in
vestibular function, begin to develop. In the middle ear, the external pinna and
Meckel's and Reichert's cartilage, from which the three auditory ossicles derive,
have begun to develop. In spinal cord development, the dorsal half of the neural tube,
known as the alar plate, eventually gives rise to the sensory region of the grey matter.
The ependymal layer, in which expression of Sapan is seen at El 1.5, is the innermost
of three concentric layers that have differentiated by E10.5. The cells in this layer
have a major role in the production and resorption of the cerebrospinal fluid. Sapan
may therefore have roles in function or development in the eye, ear, brain and spinal
cord, additional to eye and brain functions in the adult suggested by RT-PCR.
4.3.10 Duf676
RT-PCR results identified expression of Duf676 in all tested stages of eye
development (E14.5, El6.5, neonate and adult) and additionally in the brain, heart
and testis. Although morphology is poor due to sectioning procedures, in situ
hybridisation shows expression in either the choroid or the RPE in the adult eye
(Figure 4.38). No Duf676 expression was seen at early stages of embryo
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development (E9.5, E10.5, El 1.5 and E12.5), or at other stages at which RT-PCR
results in the eye were positive (E14.5, El 6.5 and neonate).
The representative sequence of Mm.87130 (AK019549) aligns with all eight exons
of a mouse gene (4921533L14Rik) and a rat gene (ENSRNOG00000013587) with
the DUF676 domain. These are also homologous to genes in human (NM_020819)
and zebrafish (ENSDARG00000010247), with a longer but otherwise identical
sequence to NM_020819 in human (Q9P2D6) and DUE676 domains as part of one
alternative transcript in both organisms. An alignment of these predicted and novel
proteins shows the high degree of homology in the domain region at the C termini of
the proteins, however a much lower level of homology exists outside this domain
(Figure 4.39).
The role of Duf676 may be related to the function of the choroid or RPE cells in
which it is expressed. In either case, Duf676 may be associated with RPE
maintenance and function. The novel DUF676 domain has wide taxonomical
representation, which implies an important conserved function. However, the domain
itself appears to be rare, with only 16 examples described in TrEMBL, and its
function is unknown.
Duf676 lies within the region associated with North Carolina macular dystrophy
(MCDR1) (Small et al., 1992). MCDR1 is a slowly progressive disorder with
variable severity (Lefler et al., 1971; Small et al., 1992). However, the MCDR1
region is unrefined, spanning 24.7Mb from 6ql4 to 6ql6.2.
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Figure 4.38 Duf676 in situ hybridisation
In situ hybridisation on sagittal sections of adult eye shows expression in either the RPE or
choroid (a, experimental; b, control). Images show the periphery of the eye, with the choroid/lens
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Figure 4.39 Alignment of the DUF676 proteins
The DUF676 domain region shows high conservation (boxed in red) and there is also
conservation through the rest of the protein, although to a lesser extent. M_musculus,
mouse; R_norvegic, rat; H_sapiens, human; D„rerio, zebrafish.
4.4 Discussion
Previously in this investigation, the success rate of DDD in producing eye relevant
genes has been deduced to lie between 45% and 50% based on known genes. If this
is the case for novel clusters as well as those representing known genes, 14 to 16 of
the 31 genes that were chosen for further expression analysis would be expected to
be eye relevant. As 15 of these clusters are preferentially expressed in the eye, and
assuming this is an indication of their relevance in the development and function of
the eye specifically, it would appear that this is indeed the case. However, this
assumes that non-preferential eye expression is indicative of no specific eye
relevance and this may not always be the case. Nevertheless, 50% seems to be a good
approximate success rate for this method on the basis of RT-PCR data.
Amongst the clusters displaying preferential expression in the eye, all except one of
those showing transcription in another tissue exhibited brain expression. This is not
unusual, as the retina can be thought of as an extension of the brain, with its
development ensuing from the neuroepithelial layer of the cephalic neural folds, the
neuronal cell types present in the retina and its obvious sensory function. Otx2, for
example, is important in early head development and is therefore important in brain
and eye function (Matsuo et ah, 1995). Perhaps more surprising is the number of
preferentially expressed clusters that display ovary and, particularly, testis
expression. As all RNA samples were quantified, and a GAPD control was employed
to ensure no bias in expression, this appears to be a real phenomenon, however there
is no obvious reason for this to be the case.
Five of the 11 novel clusters were negative in wholemount in situ experiments. This
may have been due to a combination of factors. It is possible that some of these
clusters have derived from ESTs that are the result of spurious transcription, resulting
in little or no expression and certainly no expression detectable by this method.
There may also be functional clusters that have low expression that can not be
detected in this way. A third alternative is that the probe designed was ineffective in
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these hybridisation experiments. However, Dct represents a good positive control,
with expression shown in the RPE. The Otx2 and Crygf in situ hybridisations,
showing expression in the RPE and lens respectively, validate the methods used for
the design and production of probes for the 11 novel clusters.
Of the 11 novel clusters with which preferential eye expression at El4.5, El6.5,
neonate or adult stages was detected by RT-PCR, only five have been confirmed by
in situ hybridisation. The use ofDct as a positive control suggests it is unlikely for in
situ experiments to have failed due to experimental procedures during in situ
hybridisation. However, whilst the known clusters representing Aipll, Crygf and
Otx2 were used as controls for experimental procedure using the same probe
synthesis techniques during the wholemount in situ hybridisations, this was not done
with in situ hybridisations carried out on sections. Therefore, the nature of individual
riboprobes may have had an effect or, alternatively, if these clusters are expressed at
low levels, expression detected by RT-PCR may not be detectable using the in situ
hybridisation technique employed. This implies that although the success rate of
between 45% and 50% for eye specificity amongst known genes seems to apply to
RT-PCR data of novel genes, this does not necessarily translate to detectable in situ
expression. As in situ techniques are less sensitive than RT-PCR, discrepancies
between RT-PCR and in situ results in this study may be caused by this difference.
Although this is possible, for many of the clusters some positive RT-PCR results
were confirmed by in situ analysis whilst others were not. As RT-PCR was not
quantitative, there may be an underlying difference in levels of expression that in situ
is sensitive to. This could be addressed by using quantitative RT-PCR techniques.
The E14.5 and E16.5 stages are under-represented amongst the results, with no
clusters expressing at E14.5 and just one cluster showing expression at E16.5. This
could be a consequence of lower expression at these stages or the experimental
procedure used. However, the Dct control did not appear less convincing at these
stages than at the neonate stage, which is the stage that has shown expression with
most clusters and the procedure itself was not changed.
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Surprisingly, two of the six early expressing novel clusters display sense and
antisense transcription (Tsd and Trale). Recent studies have found 2,481 and 1,600
pairs of sense/antisense transcripts in mouse (Kiyosawa et al., 2003) and human
(Yelin et al., 2003), respectively. This indicates that at least 17% of the mouse and
8% of the human genes have antisense transcripts. The true number may be higher,
as the non-coding nature of many antisense transcripts result in difficulty in their
discovery when using bioinformatic methods. Many antisense transcripts are
discovered experimentally through investigation of the sense RNA. Such examples
include developmentally important genes such as Hoxd3 and antisense Dxoh3 in
mouse (Bedford et al., 1995), FGF2 and antisense gfg in Xenopus (Kimelman and
Kirschner, 1989), rat (Murphy and Knee, 1994; Li and Murphy, 2000) and human
(Murphy and Knee, 1994; Knee et al., 1994) and Msxl and its antisense transcript
(Blin-Wakkach et al., 2001). In both cases presented in this thesis, expression is seen
in the eye in both sense and antisense directions, with one gene showing expression
within the same domain of the eye in both directions. It has recently been reported
that sense and antisense transcripts tend to be isolated from the same cDNA libraries
(Kiyosawa et al., 2003). Although this is not proof that the transcripts will be
expressed in the same cell, this coincident library expression is associated more with
antisense transcripts than with bi-directional transcripts that are antisense to the
intronic region of another gene. The antisense expression seen with Tsd and Trale
could be verified by using specific amplification of the antisense sequence by RT-
PCR, as a positive result would show that transcription is taking place in the
antisense direction.
For Mm. 150838 and Duf676, there is uncertainty about the identity of positive cells
in the periphery of eye sections. These could be choroidal or RPE cells as the nature
of the sections make it impossible to be certain. Better quality sections may resolve
this ambiguity. Colocalisation with a specific antibody to either of these cell types or
in situ hybridisation with two probes, one for the cluster and one for a gene known to
be specifically expressed in one or the other of these cell types, could definitively
identify the cell types expressed by Mm. 150838 and Duf676. In addition, with the
exception of Mm.150838, all clusters tested by in situ hybridisation were shown to
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be expressed in the adult brain by RT-PCR. It would therefore be useful to carry out
in situ analysis on adult brain in order to identify expressing cell types which may
then be related to cells in the eye expressing these sequences.
Of the 11 novel clusters that have confirmed preferential eye expression, nine display
preferential expression by in situ hybridisation. Domains of expression and
bioinformatic investigation have allowed the postulation of a variety of roles for
these novel proteins: controlling expression of opposite strand transcripts;
determining cell fates by their positional identity in the retina; developing and
maintaining neuronal connections between the retina and the brain; maintaining lens
structure and function; development and function of the CNS; regulation of gene
expression or mitosis; lipid metabolism; RPE maintenance; horizontal cell
proliferation and/or maturation; retinal development and/or differentiation. These
represent interesting novel genes that may be important in eye development and
function. Further studies of these genes and their homologues may lead to a greater




5.1 Evaluation of the Digital Differential Display approach
A Digital Differential Display (DDD) approach was taken to identify novel
differentially expressed genes and was successful for this purpose, with the discovery
of a number of novel genes that have been shown to be preferentially expressed by
RT-PCR, and in some cases by in situ hybridisation at embryonic stages.
RT-PCR showed eye specific expression for four of the 28 sequences that were
successfully amplified and a further 11 were confirmed to be preferentially
expressed, with representation in the eye and three or less other tissues. Only one
sequence was not expressed in the eye at any tested stage, showing that the presence
of ESTs is a reasonable indicator of expression detectable by RT-PCR. Twelve
sequences are expressed more widely, therefore the occurrence of false positives for
differential expression is less than half. The DDD success rate lies within the range
seen using subtractive techniques to elucidate novel genes preferentially expressed in
the eye and is generally better than that seen in large scale in situ hybridisation
analysis and in other in silico analysis. Previously, DDD has been used to find
differentially expressed genes with respect to different cancer types and comparing
cancerous to normal tissue, with only a tenth of tested novel genes showing
specificity, compared to four of 15 (27%) in this study (Scheurle et al., 2000). If
sequences that were later found to represent known genes are removed from this
comparison, two of 12 are still shown to be specifically expressed, therefore the
success of DDD has enabled the discovery of tissue specific novel genes, as well as
those that are preferentially expressed. However, this RT-PCR analysis has been
carried out with a limited number of tissues, as with most confirmational techniques,
and can not definitively prove tissue specificity.
For the possible reasons discussed earlier (sections 4.4 and 5.3), several in situ
hybridisations failed to give a result. Despite this, the results presented here show eye
expression at a minimum of one stage for nine of 11 novel sequences analysed using
this approach. The process of DDD, applying conditions to novel clusters for further
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investigation and subsequent RT-PCR confirmation was vindicated. Of the nine eye
expressing clusters, six describe novel genes, while the remaining three have no
ORF. However, it is possible that these are UTRs of novel genes.
The importance of a gene in tissue development or function where preferential
expression is seen is based on the assumption that RNA levels are indicative of
functional protein levels. Although this is irrelevant where genes are specifically
expressed, preferential expression relies on this quantitative relationship between
RNA and protein and this may not be an accurate evaluation for all genes.
Nevertheless, RNA levels are reasonable indicators of novel protein levels and
subsequent protein assays can be used to confirm this relationship.
5.2 Possible future investigation
As detailed earlier (chapter 3), the number of sequences in UniGene are increasing
and this allows build construction to become more accurate. Future use of the DDD
tool will therefore give more accurate results. Also, a more direct approach to finding
novel genes that may be implicated in human eye development and function would
be to use DDD results from the human UniGene build, although this would require
the identification of mouse orthologues for subsequent in depth analysis. As well as a
build that is likely to be more accurate, the process of analysing DDD output can be
automated using a recent tool, known as Digital Extractor, which is freely available
from the developers (Madden et al., 2003).
The information gained through the DDD approach and experimental analysis of
expression has provided a basis for more investigation of the expressed sequences
discovered. Further expression analysis of these sequences could provide more
information about the temporal as well as the spatial aspect of expression,
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particularly as RT-PCR expression was not always confirmed by in situ
hybridisation. Additionally, an obvious next step would be downregulation or
elimination of expression. This could either be carried out on the whole organism
level, invoking a phenotype that may indicate gene function, or at the cellular level,
using analysis of differential expression to assess the effect of downregulation on
gene expression.
As well as general steps that can be taken with the set of sequences already
identified, there are specific questions that can be asked of each. These are discussed
here.
5.2.1 Mm.95741
Although this sequence displays eye expression, it has no ORF. However, it is part of
a Genscan prediction and may therefore be an untranslated part of a gene. The
general approaches of further in situ hybridisation could be applied to this sequence,
particularly in the adult eye, as expression was seen at this stage by RT-PCR.
However very little information about the nature of this gene is forthcoming,
preventing a more detailed investigation.
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5.2.2 Tsd
The Mm. 159861 sequence could represent part of a transcript lying antisense to Dst,
however it has no ORF. It may be interesting to investigate the impact of
downregulating Tsd to assess the effect, if any, on Dst expression.
5.2.3 Mm.150838
The expression of Mm. 150838 in the neonate retina is widespread, yet signal appears
to be strong within certain individual cells. The horizontal cells may be one of these
strongly expressing cell types. This possibility could be investigated by using
colocalisation of Mm. 150838 in situ signal with an antibody to a horizontal cell
protein such as calbindin. Although there is no ORF, this may be an untranslated
region of a gene. Further in situ hybridisation at different stages may provide more
information about the nature of this differential expression within the retina.
5.2.4 Trale
Trale codes for a membrane protein. The interesting aspect of this gene is the signal
seen with the control probe in a contrasting domain, with Trale expressing in the
retina and antisense expression in the lens. In situ hybridisation between El 1.5 and
the neonate would be useful to further define these expression patterns temporally.
As well as inferring function, a knockdown or knockout approach could be used to
evaluate the impact on antisense expression under these conditions.
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5.2.5 Bret
Further in situ hybridisation is required to assess the cellular nature of Bret
expression. In particular, colocalisation experiments using the Bret probes and
antibodies to proteins found in specific cells within the developing neural retina
could be carried out to identify expressing cells. Similar analysis of adult brain, in
which RT-PCR indicates there is expression, could also elucidate the cells that
express Bret. Following this, a mouse knockout approach would be valuable to infer
function from phenotype. As the BTB/POZ domain that this predicted protein
contains has been implicated in transcriptional repression in other proteins, it may
also be interesting to carry out differential expression analysis between normal and
knockout in an effort to discover genes that may be repressed by the functional
protein.
5.2.6 Duf676
Colocalisation of Duf676 with a choroidal or RPE marker would be the next step in
its analysis, to more precisely determine cell types exhibiting expression in existing
in situ data. As RT-PCR results have indicated expression in the heart, if expression
is within the the choroid, it would not be unreasonable to suggest this is blood-related
expression that may not be connected to eye specific function. However RT-PCR
data is preferential to the eye, brain, heart and testis and the expressing cells may be
located in the RPE instead of the choroid, suggesting that this is not necessarily the
case. Of added interest is the presence of a rare but conserved domain with unknown
function. In order to gain clues about the function of this protein, a reasonable




Further in situ analysis would be required to analyse the expressing cells. In situ
hybridisation on sections of early embryo and at later stages of development as well
as in the adult brain could be performed to achieve this. The NAP domain predicted
for this protein suggests a regulatory role in gene expression, providing the ideal
opportunity for downregulation to gain insight into genes that may be affected by its
function. Once expressing cells have been identified, the cell type in question could
be cultured. Using RNAi specific to Tset, this gene could be downregulated and
experimental and control cells could be subjected to microarray analysis to find
genes whose expression correlates with the downregulation of Tset. It would be
expected that genes lying downstream of Tset would be amongst this set of genes.
This could be complemented by a mouse knockout approach to provide a phenotype.
At a cellular level, the TSET protein could be localised to assess the possibility that it
may function as a transcriptional regulator. TSET produced in Escherichia coli could
be used to raise antibodies in rabbit or sheep, which should prove useful in assessing
whether TSET is localised to the nucleus, consistent with its potential role as a
repressor.
5.2.8 Cln8l
The expression of Cln8l ranging from E9.5 to adult suggests an important role in eye
development and function, specifically in the RPE where signal was detected at
E16.5 and in the adult, with signal in the developing retina at E10.5 being
hypothesised as presumptive RPE expression. Expression is also seen in the brain,
both embryonically by in situ analysis and in the adult by RT-PCR. Analysis of Cln8l
could therefore be carried out in brain by in situ in an effort to identify expressing
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cell types. RPE expression could be confirmed by colocalisation experiments with
Cln8l and an antibody to an RPE specific protein such as rhodopsin. A mouse
knockout or morpholino knockdown in zebrafish may be utilised to assess the impact
on RPE development or function. It is possible that if an eye phenotype is observed,
it may be comparable to the mnd/mnd mouse, which has a CLN8 truncation and
displays retinal degeneration. As CLN8 is thought to play a role in lipid metabolism,
CLN8L may have a similar function. If this is the case, it may be localised in the
endoplasmic reticulum, therefore localisation of CLN8L in the cell could ascertain
whether this is a possibility. CLN8L antibodies would be raised as described for
TSET antibodies.
5.2.9 Sapan
The expression of Sapan implies that it represents a protein important in early
nervous system development. Additionally, expression in the lens and the previous
identification of a jellyfish crystallin as a saposin homologue suggest that this may be
a novel crystallin. Further in situ hybridisations, particularly using adult lens, are
required to assess lens expression at more stages than those already provided. Further
analysis of otic vesicle and developing neural tube expression are also necessary to
identify expressing cells in these developing regions. As the jellyfish crystallin is
homologous to saposins, rather than prosaposin, it would suggest that SAPAN is
cleaved to produce individual saposin-like proteins if it is indeed a novel crystallin.
In order to assess this possibility, the lens-expressed protein could be isolated using
antibodies to the saposin structures implied in SAPAN. This would be done as
previously described for TSET. The antibody could localise SAPAN derived
proteins. This would allow the cellular localisation of SAPAN to be determined, as
well as permitting the isolation of the proteins in lens cells. Once isolated,
crystallography of the products would elucidate the size of the proteins, indicating
whether cleavage of SAPAN has occurred. A mouse knockout would serve to
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provide clues to protein function by analysis of a possible phenotype. As Sapan is
located in the opposite direction and in an intron of Sorcs2, it is possible that there is
a co-regulation of expression between the two genes, although this would be more
likely if they were antisense to each other. Differential expression analysis may be
utilised to check the effect, if any, on Sorcs2 expression, using RNAi to
downregulate one gene and quantitative PCR to assess the effect on the other.
5.3 Conclusions
This thesis has shown that a relatively simple in silico approach followed by
experimental expression analysis is effective at identifying interesting novel genes
that are preferentially expressed in the eye. Resulting from this method are several
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retinaandnteriorneu lfolhom ob x retinolbindingprote n3.interstitia
RAX RBP3
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Slc6a9
solutecarrierfamily6(neurotransmittertransporter,glyc n )emb9
SLC6A13 SLC12A4 SLC12A5 SLC21A12 SLC22A8





iptutecarrierfandfr16(moneoarta^teaddtr nspo rs),m mb6 solutecarrierfamily21(organ cniontransport r),emb12
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Tubb5 Tulpl Tyr Tml Ubb Ubc Unci19h Usp11 Vamp2
tubulin,betaS tubbylikeprot in1 tyrosinase

































Na,K-ATPasealpha1isoformhom log(S lmos l r)
:










































meningiomaexpressedant gen5(hy lu onid se)
Mmp12
matrixetalloproteinase12
Muc4
mucin4
RT1Aw2
RT1classlbgene
S100a9
S100calcium-bindingproteinA9(calgranuliB)
Sdc4
syndecan4
Slpi
secretoryleuko ytepr teasinhibitor
unr
unrprotein
Zfp361l
Zfp3611
-
MHCclassantigenRT1.B-1bet -chai
-
MHCclassIIRT.u-D-alphah in
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